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Abstract
Precision oncology aims to tailor clinical decisions specifically to patients with the objective of improving treatment outcomes. This can
be achieved by leveraging omics information for accurate molecular characterization of tumors. Tumor tissue biopsies are currently the
main source of information formolecular profiling.However, biopsies are invasive and limited in resolving spatiotemporal heterogeneity
in tumor tissues. Alternative non-invasive liquid biopsies can exploit patient’s body fluids to access multiple layers of tumor-specific
biological information (genomes, epigenomes, transcriptomes, proteomes, metabolomes, circulating tumor cells, and exosomes).
Analysis and integration of these large and diverse datasets using statistical and machine learning approaches can yield important
insights into tumor biology and lead to discovery of new diagnostic, predictive, and prognostic biomarkers. Translation of these new
diagnostic tools into standard clinical practice could transform oncology, as demonstrated by a number of liquid biopsy assays already
entering clinical use. In this review,we highlight successes and challenges facing the rapidly evolving field of cancer biomarker research.
Lay Summary
Precision oncology aims to tailor clinical decisions specifically to patients with the objective of improving treatment outcomes.
The discovery of biomarkers for precision oncology has been accelerated by high-throughput experimental and computational
methods, which can inform fine-grained characterization of tumors for clinical decision-making. Moreover, advances in the
liquid biopsy field allow non-invasive sampling of patient’s body fluids with the aim of analyzing circulating biomarkers,
obviating the need for invasive tumor tissue biopsies. In this review, we highlight successes and challenges facing the rapidly
evolving field of liquid biopsy cancer biomarker research.
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Introduction
Cancer is a class of complex diseases characterized by abnor-
mal cellular growth and the potential to invade healthy tissues
and organs. The incidence of cancer and cancer-related death
rates has been on the rise globally [1]. With more than 18
million new cases, and more than 9 million deaths per year,
cancer is the first or the second cause of death before the age of
70 in 91 out of 172 countries [1].
Cancer survival rates vary substantially between differ-
ent types of cancer, where diagnosis at late stage worsens
prognosis even for treatable cancers. Metastatic spread to
distal sites, which is the definition of late-stage cancer,
accounts for 90% of cancer-related deaths [2]. There is a
case to be made that population-wide screening and early
cancer detection might have a substantial positive impact
on cancer morbidity and mortality [3]. Despite this need
for earlier detection of cancer, screening tests with proven
clinical utility are uncommon. The advent of high-
throughput technologies and computational tools is likely
to facilitate early diagnosis in years to come. However,
adoption of new biomarkers for early cancer diagnosis
requires careful consideration of available evidence for
associated benefits, costs, and potential harms [4].
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For cancers in which early diagnosis is possible and treat-
ment options exist, favorable outcomes are often impeded by
our limited understanding of patient stratification to guide treat-
ment decisions. The current clinical practice for diagnosis and
treatment decisions is commonly based on methods like tissue
biopsy, imaging techniques (CT, MRI, or PET), and cytology.
The information gained from these approaches is coarse-
grained, because they provide little detail at the molecular level
about the underlying cancer. This can complicate treatment
decisions, because the interpatient tumor heterogeneity often
dictates the response to the available therapies [5, 6].
Rapid advances in omics technologies, such as genomics,
transcriptomics, epigenomics, proteomics, and metabolomics,
can be used to profile biopsied tumor samples at great detail,
enabling precision oncology [7, 8]. However, even such de-
tailed analyses render only static snapshots of the tumor tissue.
Rather than being homogeneous, tumors exhibit spatial het-
erogeneity and undergo Darwinian evolution [9–12], which
can confound prognosis or render treatment decisions ineffec-
tive. Unfortunately, solid tumors can only be repeatedly
biopsied with invasive procedures, necessitating alternative
non-invasive diagnostic strategies.
Precision oncology is turning towards liquid biopsy as an
approach for non-invasive and risk-free detection and moni-
toring of cancer. Liquid biopsy relies on deriving diagnostic
information about cancer by detecting and measuring tumor-
related biomarkers in non-solid biological tissues (most com-
monly blood, urine, and stool) [13–16]. Liquid biopsy can
target diverse classes of biomarkers, such as circulating tumor
cells (CTC), circulating free and tumor DNA (cfDNA and
ctDNA, respectively), RNA, exosomes with their correspond-
ing biological cargo, circulating proteins, or metabolites
[16–18]. Integration of these omics technologies enables in-
terrogation of clinical samples for early diagnosis, prediction
of therapy response for patient stratification [18], and longitu-
dinal monitoring in cancer patients. For cancers which can be
treated, precise localization, burden quantification, and
knowledge of molecular signatures can be used to longitudi-
nally tailor treatments. Furthermore, accurate cancer profiling
can readily identify non-aggressive cancers and help patients
avoid overtreatment.
Biomarkers are defined as a “characteristic that is measured
as an indicator of normal biological processes, pathogenic
processes, or a response to an exposure or intervention”
[19]. Therefore, effective implementation of personalized
medicine depends on identifying substances, patterns, or ac-
tivities which can be reliably assayed as indicators for differ-
ential diagnosis (diagnostic), classifying tumors based on the
probable outcome in the absence of treatment (prognostic) or
assessing the probability that a patient will respond positively
to a particular treatment (predictive). The goal of the cancer
biomarker research is to develop robust, sensitive, specific,
and cost-effective strategies for these clinical uses.
A survey of cancer biomarker literature shows a steady
increase of interest in the field (Fig. 1). However, only a frac-
tion of putative cancer biomarkers has made it to clinical trials,
and only precious few validated in clinical trials (Fig. 1). This
discrepancy has been a topic of several reviews [20, 21] and
will be discussed in later sections. Briefly, in order to have
clinical utility, performance of cancer biomarkers should con-
form to a set of analytical and clinical requirements [22].
Analytical requirements, such as precision, trueness, limit of
detection and quantitation, linearity range, and specificity,
while necessary, are not sufficient evidence of clinical validity
or utility. Clinical validity of a biomarker is the ability of the
biomarker to accurately identify patients with the targeted
pathological state [23], while the utility measures the benefit
(such as reduced mortality) of using a biomarker in clinical
settings [24]. Evaluating the clinical performance [24]
(intended use, clinical specificity and sensitivity, ROC analy-
sis, positive and negative predictive values, cost-effectives,
fast turn-around) of a biomarker requires carefully designed
studies with large cohorts. Adopting biomarkers into standard
clinical use without evidence of their clinical utility can be
highly problematic. For example, population-wide screening
based on biomarkers with poor specificity or low positive
predictive values can translate into large numbers of patients
undergoing unnecessary, expensive, and potentially harmful
procedures. However, validation and utility studies are
lengthy and expensive, and often out of reach for most labo-
ratories conducting basic research. On the other hand, invest-
ment of time and resources into rigorous validation of bio-
markers and molecular-level profiling of tumors might be-
come more valuable than histopathological information for
therapeutic decisions and drug approval in the future [25].
This review discusses current standard and emerging ap-
proaches in the space of liquid biopsy. We categorize cancer
biomarkers by omics layers (Fig. 2) and for each omics, we
first evaluate the scientific rationale for its relevance in cancer.
Second, we review progress and challenges associated with
established or commercially exploited emerging technologies.
And lastly, we examine and highlight some of the recent suc-
cess stories and challenges in the clinical translation of cancer
biomarkers. Some of the recently developed technologies still
far from producing evidence of clinical validity are outside of




The onset and progression of cancer is dependent of alterations
to DNA sequence of the genomes of cancer cells. The
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illumination of these alterations and their functional conse-
quences can help improve clinical management of cancer pa-
tients. The investigation of genetic underpinnings of cancer led
to the discovery of genetic and genomic cancer risk factors and
biomarkers, some of which are well established in cancer
research and clinical use. A classic example of genetic risk
assessments is based on identifying inherited alleles of
BRCA1 and BRCA2 genes associated with increased risk for
breast cancer [26]. Genotyping cancer biopsy samples by
PCR, Sanger, and next-generation sequencing is becoming
Fig. 2 Liquid biopsy and
biomarkers for precision
medicine. Liquid biopsy is used to
collect body fluid samples from
individual patients. Samples
typically contain multiple sources
of biomarkers, which can in turn
be analyzed using modern high-
throughput omics technologies.
High dimensional and heteroge-
neous data can be integrated into
biological networks with
interacting biochemical circuits
and pathways. This complex
multi-dimensional data can be
analyzed and reduced using sta-
tistical and machine learning al-
gorithms, with the end goal of
producing robust and accurate
classifiers for diagnosis, predic-
tion of response to treatment and
prognosis. Finally, the same
scheme can be used for longitu-
dinal monitoring of patients, ob-
viating the need for repeated in-
vasive biopsies
Fig. 1 Cancer biomarker studies reported in PubMed. Grey bars show the
percentage of biomarker articles among all journal articles and letters
indexed in PubMed in English (articles with substance name
“Biomarkers, Tumor” MeSH term “Humans,” excluding MeSH terms
“Tumor Cells, Cultured, and Cell Line”). The orange bars show the
percentage of PubMed articles on circulating biomarkers (biomarker
articles and letters with MeSH terms “blood”, “plasma”, “serum”,
“urine”, or “saliva”). Cyan bars show the subset of all biomarker
articles and letters from the trial, multicenter, validation, clinical, or
evaluation studies
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standard clinical practice [27], a trend that is likely to continue
as the whole genome sequencing (WGS) costs approach $1,000
per genome [28] (however, see refs [29, 30] for a critical eval-
uation of costs for NGS in clinical practice). Unfortunately,
sample collection for tissue genotyping requires invasive pro-
cedures and returns only static information about a disease
which is ultimately spatiotemporally dynamic. Thus, circulating
DNA [31–33] is being investigated extensively as an emerging
biomarker for personalized medicine.
Circulating or cell free DNA (cfDNA) is released from
healthy as well as cancer tissues. cfDNA probably originates
from apoptotic and necrotic cells, but the exact origin and
mechanism of release are still a topic of investigation [34,
35]. Primary tumors, circulating tumor cells, occult and overt
metastases can release DNA, increasing concentrations of
cell-free DNA (cfDNA) in bodily fluids of cancer patients,
compared to healthy people [31, 36]. Circulating tumor
DNA (ctDNA) has been found in blood, urine, stool, and
saliva. In people with cancer, about 1% of circulating DNA
is ctDNA [35, 37], but this percentage can vary substantially
between patients and is affected by stage and tumor volume
[34]. Because ctDNA displays mutations characteristic of the
progenitor tumor, it can serve as a biomarker for diagnosis,
prognosis, and prediction.
The half-life of ctDNA is short (2–5 h in blood and urine
[33, 34, 38]) and concentrations can decrease rapidly in re-
sponse to treatment [33]. ctDNA levels are therefore useful as
a monitoring biomarker [33] for estimating cancer burden in
patients and assessing treatment responses.
Current and Emerging Technologies
Current and upcoming genomics technologies to detect and
quantify ctDNA range from targeted to unbiased genome-
wide methods and vary dramatically in their analytical sensi-
tivity, specificity, costs, and throughput. Despite the techno-
logical progress of the field, reliable detection of low ctDNA
amounts and variants with low mutant allele frequencies
(MAF) can be challenging. Because ctDNA typically makes
up only a small fraction of cfDNA, detection of rare tumor
alleles might require large amounts of input materials and
prohibitive sample volumes. Genomics technologies and their
limitations have been a topic of a recent comprehensive re-
view [34] and we will only cover them briefly in the following
paragraphs.
Detection and quantification of predetermined alleles from
ctDNA by Sanger sequencing, single and multi-locus PCRs
[39], and qPCR [40, 41] is established in clinical oncology
(e.g., cobas assay [40, 42, 43]). However, these methods are
typically limited to detecting MAFs well above 1% [34, 44,
45], which would leave many cancers smaller than 10 cm3
undetected because their expected plasma MAFs can be
0.1% or lower [17, 46]. Advances such as digital droplet
PCR (ddPCR) [47] and BEAMing [48, 49] allow absolute
quantification of allele frequencies as low as 0.01%.
Next-generation sequencing (NGS) methods can be used
for both targeted and unbiased (the whole genome (WGS)
approach) identification of patient-specific structural aberra-
tions [50], copy number variations, and SNPs. However, NGS
approaches are limited by the low abundance of ctDNA frac-
tion in total cfDNA, short ctDNA fragment length, as well as
by high error rates that preclude reliable detection of rare
variants. The sensitivity of targeted NGS methods can be
boosted by identifying cancer-specific mutations (from
patient-specific tumor tissue samples or known cancer-
related alleles), and then applying this information as a selec-
tor in liquid biopsy samples. This approach is exemplified by
tagged amplicon deep sequencing (TAm-Seq) [51], and en-
richment by hybrid capture and molecular barcoding methods
such as Safe-Seq [52] and CAPP-Seq [53] to detect MAF as
low as 0.00025%. The record analytical sensitivity of detect-
ing 4 in 105 cfDNA molecules was achieved by combining
CAPP-Seq with molecular barcoding and in silico digital error
suppression [54]. Sensitivity of unbiased methods can be im-
proved by using methods such as whole genome amplification
(WGA) [55].
Whole exome sequencing (WES) from liquid biopsy sam-
ples offers the ability to longitudinally follow cancer patients
under treatment and monitor the appearance of resistance-
conferring mutations. For example, in a proof-of-principle
study,WES from plasma has been used to monitor six patients
with metastatic breast, ovarian, and lung cancers for up to 2
years, revealing resistance-conferring mutations evolving in
response to treatment [56]. However, such unbiased ap-
proaches have low sensitivity and can only be used on patients
with advanced cancer.
Short-read massively parallel sequencing is now being in-
creasingly used in the biomarker discovery and routine clini-
cal applications. However, the aforementioned short read
technologies suffer from GC bias, difficulty resolving com-
plex and repeating sequences and phasing alleles. Genotyping
liquid biopsy samples using long read single molecule se-
quencing offers a new approach that mitigates some of these
limitations. There are currently two commercially available
single molecule sequencing platforms with long reads com-
mercialized by Pacific Biosciences and Oxford Nanopore
Technologies. These two sequencing platforms enable phas-
ing of nucleotide variants [57], sequencing of complex repet-
itive regions, and structural rearrangements [58], and epige-
netic modifications [59, 60]. Furthermore, they allow rapid
sequencing runs, which is desirable in diagnostic settings [61].
Single molecule real-time sequencing (SMRT) [62] plat-
form by Pacific Biosciences is the more mature of the two
platforms. SMRT technology derives sequence data from real
time recording of incorporation of fluorescent nucleotides by
polymerases immobilized on solid phase [62]. The polymerase
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reads the circularized template, resulting in long reads (> 10 kb
on average, > 80 kb maximal read length [63]), albeit with a
relatively high error rate (~ 13%) [63].Where shorter (< 10 kb)
reads suffice, templates can be read multiple times, allowing
computation of highly accurate circular consensus sequences
(CCS) from individual single passes (subreads). CCS-based
sequencing has already been used to detect mutations at fre-
quencies below 0.5% in the stool of CRC patients [64].
The long-read platform commercialized by Oxford
Nanopore Technologies (ONT) [65] is a relative newcomer
to the market. Nanopore sequencing platform derives se-
quence information from nucleotide-specific ionic current
changes observed as ssDNA passes through a membrane-
bound nanopore [66]. Standard ONT protocols result in
DNA fragments of ~ 8 kb; however, there is no technical
limitation to read length, apart from the length of DNA tem-
plates in the sample [63]. The biggest drawback of the ONT
platform is its high error rate (~ 15%) [67], with no possibility
of sequencing the same strand multiple times. The accuracy
can be improved through 2D nanopore sequencing, where the
two strands of a dsDNA template are linked by a hairpin and
sequenced consecutively as ssDNA, allowing a consensus se-
quence to be computed.
The potential of SMRT and ONT platforms for advancing
liquid biopsy is big, but long read technologies suffer from
several drawbacks that currently limit more widespread use
and implementation into routine clinical settings. Notably,
per-base costs are considerably higher than for short read se-
quencing and currently available bioinformatics algorithms
are less mature than for short read sequence analysis [68].
However, recent developments in base-calling software [69,
70] and future improvements in sequencing chemistries are
expected to facilitate adoption of long read sequencing plat-
forms into biomarker development and clinical use.
Translational Status
Molecular profiling of tumor tissues by genomics techniques
has a critical role in advancing cancer research and is gradu-
ally becoming standard clinical practice. Given the wealth of
knowledge these approaches accumulated about cancer mo-
lecular biology and technical advances in sequencing, it is not
surprising that ctDNA from liquid biopsies are already yield-
ing biomarkers validated in clinical trials. Furthermore, some
of the assays have already been FDA-approved and are mov-
ing into clinical practice.
The first FDA-approved liquid biopsy test on the market is
cobas EGFR Mutation Test v2 (Roche Diagnostics Inc) [42,
43]. The assay relies on detecting cancer-specific mutations in
cfDNA and is used as a companion diagnostic test for detec-
tion of mutations in the epidermal growth factor receptor
(EGFR) gene to identify patients with metastatic non-small
cell lung cancer (NSCLC) eligible for treatment with erlotinib.
One of the standing problems in clinical practice is identi-
fying patients with high risk of recurrence after surgery. The
fact that plasma ctDNA can correlate with minimal residual
disease, cancer-specific MAFs can serve as proxies for recur-
rence risk. Patient-specific cancer alleles can be specified by
analyzing the cancer tissue at loci known to be recurrently
mutated in cancer. The locus with the highest MAF can be
chosen, and its abundance in plasma ctDNA can be used as a
prognostic biomarker [71]. This approach was used to identify
high-risk colon cancer patients. Specifically, quantification of
patient-specific mutated alleles in ctDNA by dPCR in post-
operative samples showed that ctDNA-positive patients were
at a higher risk for recurrence in a prospective multicenter
cohort of patients with resected stage II colon cancer (HR =
18; N = 230) [71].
In addition to revealing cancer-specific SNPs, ctDNA re-
flects other tumor-specific changes, such as chromosomal re-
arrangements. The potential of combining patient-specific so-
matic mutations and structural variants (first identified in tu-
mor samples by SNP [72] arrays and WGS [72, 73], and then
assayed in ctDNA by ddPCR) to estimate the risk of recur-
rence has been tested in two studies on patients with colorectal
cancer [72, 73]. The first study investigated the ability of
ctDNA to predict recurrence in retrospectively selected six
relapsing and five non-relapsing patients following colorectal
surgery [72]. Somatic structural variants in ctDNA were
shown to be valuable prognostic biomarkers in terms of de-
tecting post-surgery relapse with 100% sensitivity and 100%
specificity. Importantly, relapse was detected on average 10
months earlier than when using conventional follow-up. The
second study [73] was a part of a single-site prospective ob-
servational cohort with colorectal cancer patients undergoing
surgical treatment, split into two cohorts. The investigation
off the first cohort (N = 27 retrospectively selected with 1:1
ratio of relapsing and non-relapsing patients) showed that
patients treated with curative intent for localized disease
who were ctDNA-positive within 3 months of surgery
had a very high risk (100%) of relapsing (HR 37.7). The
ctDNA analysis of an independent validation cohort (ret-
rospectively selected 18 CRC patients with liver metasta-
ses) showed that ctDNA within the first 3 months was
associated with a high relapse risk (HR 4.9). These esti-
mates should be interpreted with caution given the relative-
ly low sample size. Indeed, patients are being recruited for
a multi-site prospective observational cohort (N = 1800,
NCT03637686) to validate the ctDNA as a biomarker for
detection of subclinical residual disease and precisely esti-
mate the risk of recurrence from colorectal cancer.
In a single-center retrospective study of patients with non-
metastatic breast cancer, the abundance of rearrangements in
ctDNAwas used to identify patients who will eventually de-
velop metastases [74]. Authors first carried out whole genome
sequencing of primary tumors to identify patient-specific
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chromosomal rearrangements. Next, they analyzed plasma
ctDNA from follow-up blood samples and quantified tumor-
specific rearrangements using ddPCR. The assay could dis-
criminate patients with eventual metastasis from those with
long-term disease-free survival with 93% sensitivity and
100% specificity (AUC = 0.98, N = 20) [74]. This exploratory
study shows the potential of ctDNA to detect occult metasta-
ses. SAGA Diagnostics is deploying two ultrasensitive
ddPCR assays (IBSAFE and KROMA) based on these results.
A similar approach has been successfully implemented for
personalized cancer profiling by deep sequencing (CAPP-
Seq) in NSCLC patients (5 healthy controls and 13 patients
undergoing treatment for newly diagnosed or recurrent
NSCLC) [53]. The development of a personalized profile is
a multistep process. The first step is the identification of re-
currently mutated cancer-specific regions in The Cancer
Genome Atlas (TCGA) [75]. The next step is to design a
library of biotinylated DNA oligonucleotides (CAPP-Seq “se-
lector” library) that can selectively enrich identified targets in
the sample. CAPP-Seq library is then used to identify patient-
specific aberrations in tumor tissue samples. In the last step,
CAPP-Seq is applied to plasma cfDNA to enrich and quantify
ctDNA [75]. The assay had a maximal sensitivity 85% and
maximal specificity of 96% to discriminate between NSCLC
patients and healthy controls. CAPP-Seq has been adopted by
Roche in AVENIO ctDNA NGS liquid biopsy kit.
Signatera RUO (Natera) is a multiplex-PCR NGS ctDNA
test for monitoring and minimal residual disease assessment in
NSCLC patients. The Signatera RUO technology is being
validated in an observational prospective cohort trial called
TRACERx (Tracking Non-Small-Cell Lung Cancer
Evolution Through Therapy (Rx)) study (NCT01888601)
with the goal of defining the relationship between intratumor
heterogeneity over 5 years and clinical outcome following
surgery and adjuvant therapy. The analysis of ctDNA samples
of the first 96 participants with NSCLC [46] shows evidence
of adjuvant chemotherapy resistance. Furthermore, the assay
was able to identify patients with recurrence with sensitivity
of 93% and specificity of 90% in the sub-group of 24 patients
from the TRACERx cohort (retrospectively selected 10 con-
trol cases and 14 confirmed relapses).
Similar efforts have been undertaken by other compa-
nies. For example, Guardant Health has just completed a
trial comparing a liquid cfDNA assay Guardant360 to
tissue biopsy for detecting predictive and prognostic ge-
netic markers in NSCLC patients (NCT03615443).
Similarly, Foundation Medicine has established a com-
panion diagnostics test called FoundationOne Liquid
based on profiling more than 70 genes and genomic bio-
markers for microsatellite instability.
The aforementioned approaches are applied once the can-
cer has been diagnosed and treatment initiated. However, most
cancers present symptomatically and are only diagnosed at
difficult to treat stages. Arguably, pre-symptomatic population
wide screening for early cancer detection is one of the most
attractive applications of liquid biopsies and could in principle
improve clinical outcomes [3]. However, this application
comes with a unique set of challenges that will need to be
addressed before clinical adoption. First and foremost, in a
setting with asymptomatic individuals, liquid biopsy bio-
markers are likely to be the only source of diagnostic infor-
mation. Second, already present tumors will tend to be small
in size and at early stages, which means that the concentration
of cancer biomarkers might be close to the methods’ limit of
detection. Third, mutational analysis will need to account for
non-tumor somatic mutations. Finally, establishing true clini-
cal sensitivity and specificity of the assay will be of utmost
importance, which will require large cohorts of healthy indi-
viduals with longitudinal follow-up.
The genomics company GRAIL is setting out to tackle
these challenges, by leveraging cfDNA sequencing for early
detection in one of the largest genomics medicine studies to
date. Currently, GRAIL is conducting two clinical studies.
The first, called STRIVE (NCT03085888), is a prospective
observational cohort study with enrollment of approximately
100,000 women undergoing mammography. Participants will
be followed for five years to record clinical outcome data, with
the ultimate goal of validating GRAIL’s blood-based assay for
ear ly breast cancer detect ion. The second study
(NCT02889978), called the Circulating Cell-Free Genome
Atlas (CCGA), is a prospective observational case-control
study at the recruitment stage. CCGA is enrolling more than
10,000 subjects to characterize the landscape of cfDNA found
in the blood of cancer patients and healthy individuals. During
2019, GRAIL also plans to deploy a clinical study (SUMMIT)
to evaluate the blood assay and sequence cfDNA in 50,000
participants with no cancer diagnosis at the time of enrolment.
This study will follow up patients for 3 years, and then track
them through medical registries for additional five to evaluate
clinical outcomes. Planned sample sizes will be sufficient for
showing clinical validity of the screening approach. However,
adoption of population-wide screening will require evidence
for clinical utility, which might require additional large co-
horts with long follow-ups.
Circulating Tumor Cells
Scientific Rationale
Circulating tumor cells (CTCs) were first discovered in 1869
[76]. CTCs have reemerged as a topic of interest in the last
couple of decades because of their role in tumor biology and
potential to serve as biomarkers for liquid biopsy. CTCs are
cells that enter the circulatory system from the primary tumor
site during the growth and metastasis [77, 78]. The biology of
CTC release into the bloodstream involves at least two
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independent mechanisms. The first mechanism requires
epithelial-mesenchymal transition (EMT), where tumor cells
lose their epithelial phenotype and acquire mesenchymal traits
[79, 80]. The second mechanism does not require EMT and
could depend on external forces, such as surgery [79, 81].
How these two mechanisms of CTCs release contribute to
metastatic spread of cancer is still a topic of intensive
investigation.
The potential of CTCs for liquid biopsy is manifold. CTC
enumeration has to this point been most intensively investi-
gated as a biomarker. Typically, CTCs are low in abundance
(fewer than 10 cells per milliliter of blood [79, 82, 83]), and
the abundance of CTCs correlates with reduced progression-
free and overall survival [84], and can therefore be used as
liquid biopsy biomarker for determining the cancer burden.
CTCs can retain some of the markers of the tissue of origin,
allowing localization of the tumor of origin [85]. Furthermore,
the advent of microfluidic and single-cell omics methodolo-
gies [86] allows the analysis of CTCs by technologies that
were earlier limited to bulk tissue samples [87]. However,
the effective use CTCs in clinical practice is mainly hampered
by methodological and standardization challenges related to
enrichment and selection of CTCs, as outlined below.
Current and Emerging Technologies
The main technological challenge for analysis of CTCs
for basic research and clinical use is their low abundance in
blood. Therefore, the first step in any detection and analysis
procedure is enrichment and selection. Enrichment methods
(reviewed in [79, 88]) take advantage of CTCs biological
properties (expression of surface cell proteins [89, 90]) or
physical properties (size/shape [91, 92], electric charge [93,
94]). Once enriched, CTCs can be separated from normal cells
on the basis of cell-surface antigen expression.
To complicate things further, CTCs exist as either apoptotic
or viable populations, each in turn harboring subpopulations
with different phenotypical characteristics [79, 95]. Thus, dif-
ferent enrichment procedures bias the enriched CTC pool to-
wards specific subpopulations. Depending on the intended use
of CTCs for liquid biopsy, this methodological challenge will
need to be addressed differently [79]. For example, the early
detection of cancer requires extreme sensitivity to the lowly
abundant CTCs. Prognostic use of CTCs requires comprehen-
sive enrichment of all CTC subpopulations, such that all the
relevant tumor heterogeneity can be captured. Using CTCs as
predictive and monitoring biomarkers requires enrichment of
all living CTCs as well as their characterization to determine the
tumor’s sensitivity or resistance to therapeutic interventions.
Despite this challenge, there are many attempts to use
CTCs for liquid biopsy. To date, most progress has been made
using CTC enumeration as biomarker prognostic biomarker in
patients treated for metastatic breast [96], colorectal (CRC)
[97], or prostate cancer (PCa) [98].
In addition to CTC enumeration, single-cell omics method-
ologies are being leveraged to characterize tumors and extract
clinically meaningful information. Whole genome amplifica-
tion (WGA) can be used to facilitate the genomic analysis of
CTCs [99–101]. Multi-gene panel sequencing of CTCs from
patients with stage IV CRC uncovered genotypes that were
subsequently identified at subclonal levels in primary tumors
and metastases of the same patients [102]. Whole genome
sequencing of CTCs has been used in patients with metastatic
breast cancer [103]. The long-read technology enabled identi-
fication of driver mutations as well as the primary tissue of
origin. A similar study based on the whole exome sequencing
for metastatic prostate cancer [104] uncovered concordance
between mutations found in CTCs genomes and tumor tissues
(primary and metastatic), demonstrating that CTC genomics
profiling could be a valuable diagnostic and prognostic tool
[103, 104].
Genome-wide epigenomic analysis of DNA from liquid
biopsy samples might not be possible at the moment, but there
are already attempts to probe the methylation status of targeted
genes [105] and promoters in CTCs [106]. Single cell RNA
sequencing has already been used to investigate CTC
transcriptomes in hepatocellular [87] cancer, melanoma
[107], pancreatic [108], and breast cancer [109]. Established
CTCs protein analysis includes identification of CTCs via
antibody staining [96]. However, higher throughput and cov-
erage will advance through recent improvements in
microfluidics [110]. Microfluidics devices are already en-
abling the analysis of proteomics [111] and secretomics
[112], as well as metabolic [113] biomarkers from CTCs.
Translational Status
Despite the promise of CTC omics assays for personalized
oncology, more clinical trials are needed to establish clinical
validity and utility. As we mentioned earlier, the field is still
hampered by technical and reproducibility issues related to
CTC enrichment.
To date, the only FDA-approved CTC assay on the market
is CellSearch (Menarini Silicon Biosystems, Inc, acquired
from Janssen Diagnostics LLC/Veridex LLC). The assay ex-
ploits the epithelial cell adhesion molecule (EpCAM),
expressed by many carcinoma cells to isolate CTC cells [82,
114]. Because EpCAM expression is linked to poor survival,
CellSearch enumeration of EpCAM positive CTCs can serve
as a prognostic biomarker in combination with other clinical
information. In a pivotal prospective, double-blind, multi-
center clinical trial a total of 177 patients with metastatic
breast cancer were recruited to investigate CTC counts as
predictors of progression-free survival and overall survival
[96]. The results show that patients with higher CTC counts
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(≥ 5 CTC/mL) had significantly shorter OS and PFS. Later
three prospective multi-center cohort studies showed similar
results for metastatic breast, colorectal, and prostate cancer
[115].
The aforementioned trials demonstrate the clinical va-
lidity of the CellSearch-based CTC enumeration as predic-
tive and prognostic biomarker. However, the utility of CTC
liquid biopsy in specific clinical contexts is still unclear
and a subject of ongoing clinical trials (reviewed in ref
[116]). For example, HER2 status of CTC cells enriched
by CellSearch in patients with metastatic breast cancer
showed potential as a prognostic and predictive biomarker
for clinical response to therapies targeting HER2 [117,
118]. One therapy for HER2-positive metastatic breast can-
cer is trastuzumab emtansine (trastuzumab-DM1 or T-
DM1), a conjugate of a tumor-activated prodrug and hu-
manized anti-HER2 monoclonal antibody [119]. An inter-
ventional multi-site trial (NCT01975142) was carried out
to test if patients with metastatic HER2-negative breast
cancer but with HER2-positive CTC cells respond to treat-
ment with T-DM1. The study found that HER2-positive
CTCs can be detected in a subpopulation of HER2-
negative metastatic breast cancer, but there was an overall
low response to anti-HER2 therapy [120].
CellMaxLife is currently conducting clinical trials on using
an automated liquid biopsy platform CellMax CTC (CMx)
[85, 121] for early detection of colorectal (NCT03476122),
prostate (NCT03488706), and breast cancer (NCT03511859).
In addition to CTC enumeration, omics profiling is also
being investigated in clinical trials. Oncotype DX AR-V7 is
an assay that detects AT-V7 proteins in nuclei of CTCs. The
assay has shown efficacy in identifying metastatic prostate
cancer patients who will not respond to androgen receptor
(AR)-targeted therapies. Clinical studies show that Oncotype
DX AR-V7 can be used to guiding the choice of treatment
between taxanes and androgen receptor signaling inhibitors
[122–124]. In a cross-sectional single-site cohort study of his-
tologically confirmed mCRPC undergoing a change in thera-
py, it was investigated if pretherapy nuclear AR-V7 in CTCs is
a treatment-specific marker. The results showed that taxanes
result in improved OS compared to ARS inhibitors in patients
with AR-V7-positive CTCs (HR 0.24) [122]. These findings
were later validated in an independent, multi-site, blinded,
cross-sectional cohort (N = 225) [124].
Epigenome
Scientific Rationale
Epigenetic modifications, such as DNA and histone methyla-
tion, play a critical role in regulating core cellular processes,
such as transcription, DNA repair, and replication. Because
dysregulation of DNA-templated processes is a crucial step
in neoplastic progression, proteins and complexes involved
in epigenetic modifications are often found mutated across
different cancer types [125]. Changes in epigenomic regula-
tors during tumorigenesis in turn lead to changes in methyla-
tion patterns compared to normal cells [125, 126].
Exactly how epigenomics changes modulate cellular pro-
cesses in normal and cancer cells is a field of intense research.
This research has established a causal relationship between
epigenetic changes and some of the hallmarks of cancer
[125, 126]. DNA methylation is the most widely researched
epigenetic modification. Repression of tumor suppressor
genes can be readily achieved through epigenetic changes
[127, 128]. Specifically, methylation patterns at CpG sites in
promoter regions can regulate expression of downstream
genes. Tumor suppressor specific hypermethylation is a pro-
cess where cancer cells methylate CpG islands in promoters of
tumor suppressor genes, thus downregulating their expres-
sion. Furthermore, genome-wide hypomethylation has also
been observed in cancer [129, 130]. Hypomethylation of pro-
moters that are methylated in normal cells can dysregulate
gene expression, which can promote tumorigenesis when tar-
gets of dysregulation are proto-oncogenes. In combination
with hypomethylation of repetitive sequences [131], this can
elevate mutation rates, cause genomic instability, and promote
tumor formation [126, 132]. Because these processes are cru-
cial for cancer progress, key players are being investigated as
therapeutic targets [125, 133–135] (reviewed recently in ref
[136])
The epigenomic aberrations characteristic of cancer cells
can readily distinguish healthy from cancer tissues with high
accuracy [137]. Therefore, epigenomics changes such as
DNA methylation patterns have been recognized as potential
diagnostic, prognostic, and predictive biomarkers.
Furthermore, there is evidence of concordance between epi-
genetic changes found in ctDNA and its tissue of origin
[138–140], making epigenomic biomarkers promising candi-
dates for liquid biopsy.
DNA methylation patters are highly tissue-specific [141],
enabling detection of tissue of origin for ctDNA [142]. A
recently published atlas of human cfDNA methylation pat-
terns [143] could bolster efforts for early cancer detection
and help pinpoint the tissue of origin.
Current and Emerging Technology and Biomarkers
Epigenomic biomarkers can be assessed in cfDNA, exosomes
and CTCs. It is possible to approach epigenomic biomarkers
by looking at specific changes at predetermined loci (for ex-
ample at recurring cancer-specific epigenetic changes or at
patient-specific methylation patterns), or to probe genome-
wide epigenomic patterns characteristic of cancer.
5-Methylcytosine (5mC) is the most extensively studied
DNA methylation in epigenomics [125]. Epigenomics
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techniques to assess the methylation patterns of DNA rely on
bisulfite treatment, which converts unmethylated cytosine to
uracil, but leaves 5mC unaffected. Bisulfite-treated DNA is
then subject to different methods that attempt to distinguish
uracil from cytosine in the template [126, 144–146].
Bisulfite PCR methods to assess methylation in liquid bi-
opsy biomarkers include single [147] or multiplex [144, 148]
quantitative real-time PCR, bisulfite dPCR (methyl-
BEAMing) [146], and methylation-specific PCR [145].
While it is possible to make diagnostic decisions by assaying
the methylation status of one marker or small gene panels
[144], the accurate identification of individual epigenomic
biomarkers is typically problematic because of low sensitivity
due to background plasma DNA noise [149]. Furthermore,
DNA methylation profiles are strongly influenced by gender,
ethnicity, and individual differences and spatial heterogeneity
within tumors [149, 150], necessitating the use of large bio-
marker panels to increase accuracy, as well as large and di-
verse cohorts to validate clinical utility of epigenomics bio-
markers for liquid biopsy.
Aforementioned approaches rely of quantifying changes in
methylation at one or more predetermined loci. An alternative
is to assay methylation patterns in cfDNA in a highly parallel
manner, for example, by using methylation microarrays [151].
Similarly, massively parallel bisulfite sequencing offers an
unbiased way to assay genome-wide methylation patterns
[129] in circulating DNA. A recent study shows that an unbi-
ased DNA methylome can predict the outcome in patients
with juvenile myelomonocytic leukemia in small discovery
and validation cohorts [152]. A modification of the general
method, involving methylated CpG tandems amplification
and sequencing (MCTA-Seq) [153] can allow detection of
methylated alleles at frequencies as low as 0.25%.
The major limitation of bisulfite-based approaches is that
the initial step of bisulfite conversion degrades most of the
input DNA [154]. To address this issue, a new bisulfite-free
method for epigenomic profiling was developed [155]. This
cell-free methylated DNA immunoprecipitation and high-
throughput sequencing (cfMeDIP-seq) is an unbiased method
that captures and enriches methylated cfDNA fragments to
assess genome-widemethylation patterns from lowly abundant
DNA samples, albeit at a lower resolution (100–300 bp) [156].
A n o t h e r t y p e o f DNA m e t h y l a t i o n i s 5 -
hydroxymethylcytosine (5-hmC). The regulation of 5-hmC
is known to be affected in some human cancer types, making
5-hmC a potential biomarker for cancer [157–159]. A recently
developed bisulfite-free method targeting 5-hmC takes advan-
tage of the fact that the hydroxymethyl group in 5-hmC can be
selectively chemically labeled [160]. This reduces the back-
ground noise and allows higher analytical sensitivity in sam-
ples with low input DNA [160].
Given that dramatic changes in epigenomes are universal to
all cancers, it might be possible to go beyond cancer type-
specific biomarkers and develop pan-cancer methylation bio-
markers in the future. An innovative approach along these
lines investigates how the methylation landscape
(“Methylscape” [161]) affects physicochemical properties of
DNA. Specifically, authors exploited changes in solvation and
gold affinity of plasma cfDNA caused by cancer-specific
methylation, and developed an innovative and rapid electro-
chemical and colorimetric assays for the presence of breast
and colorectal cancer (case-control study with 45 healthy in-
dividuals and combined 100 breast and CRC cancer patients,
AUC = 0.887 for discrimination of healthy vs cancer patients)
[161].
In general, epigenomics biomarkers have a lot of potential
for liquid biopsy. However, major technological limitations
are low sensitivity, high costs, and the required expert knowl-
edge. Furthermore, different protocol for isolating cfDNA
show significant variation in the amount of recovered DNA,
necessitating analytical validation and standardization of new
methods before clinical implementation.
Translational Status
Despite being a field in its infancy, epigenomics is already
yielding biomarkers and assays for liquid biopsy in clinical
practice. Assays based on even a single epigenetic marker can
serve as powerful diagnostic tools. The first FDA-approved
blood test for CRC diagnosis, Epi proColon (Epigenomics,
Inc), uses qualitative real-time PCR to detect methylated
Septin 9 DNA in plasma. Epi proColon has shown similarly
sensitivity to the fecal immunochemical test (FIT), albeit at a
lower specificity in a multicenter observational case control
study (NCT01580540) [147]. The study with the primary goal
of establishing non-inferiority of Epi proColon compared to
FITwas conducted on two cohorts: the first had subjects with
diagnosed CRC (N = 102) and the second had subjects sched-
uled to undergo colonoscopy (N = 199). Sensitivity to dis-
criminate between CRC and non-CRC was 73%, and speci-
ficity was 82%. Interestingly, a randomized controlled two-
site trial with average-risk adults overdue for screening
(NCT02251782) showed that Epi proColon boasts better pa-
tient adherence to screening than FIT (N = 413, 99.5% vs
88.1%) [162].
Another FDA-approved assay for liquid biopsy is
Cologuard assay (Exact Sciences). Cologuard is multitargeted
stool DNA test that can detect colorectal cancer. Aberrant
methylation patterns in NDRG4 and BMP3 are detected
through allele-specific real-time PCR and employed as diag-
nostic biomarkers in combination with hemoglobin and the
allelic status of KRAS gene [148]. The sensitivity and speci-
ficity of the assay were determined in a large observational
case-only prospective study involving asymptomatic persons
at average risk for colorectal cancer scheduled to undergo
screening colonoscopy (N = 9989). The sensitivity was
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92.3% (versus 73.8% for the FIT assay) for discriminating
between CRC and non-CRC patients, including those with
negative findings on colonoscopy, precancerous lesions, and
non-advanced adenomas. Cologuard had a lower specificity
than FIT (89.8% for Cologuard vs 96.4% for FIT) for patients
with negative results on colonoscopy [148].
Nucleix has recently published a study detailing the clinical
performance of their Bladder EpiCheck. The test assays meth-
ylation patterns in a urine panel of 15 DNA methylation bio-
markers [163] for follow-up of patients with non-muscle-
invasive bladder cancer (blinded, single-arm, prospective
multicenter study, N = 353, AUC = 0.82 for cancers including
and AUC = 0.94 for excluding LG Ta tumors). With a high
NPV (99.3%), EpiCheck could be used in follow-up to reduce
the burden of repeated cystoscopies, which is the standard of
care to diagnose bladder cancer progression.
Transcriptome
Scientific Rationale
The pool of all expressed RNA species is collectively called
the transcriptome. The transcriptome plays a pivotal role in
cellular processes. The human genome encodes approximate-
ly 20,000 genes that are transcribed into mRNA, rRNA, and
tRNA. The importance of these RNA species for regulation
and protein synthesis has been recognized since the inception
of molecular biology. The non-coding RNAs (ncRNA) have
been discovered in the last couple of decades, expanding the
concept of transcriptome to include microRNA (miRNA)
[164], piRNA [165], tiRNA [166], snoRNA [167], Y RNA
[168], PASR [169], TSS-RNA [170], snRNA [171], and
lncRNA [169, 172, 173].
While DNA content is mostly identical in different cells of
an organism, transcriptional profiles can vary dramatically
across cell types, space, and time. Therefore, changes in the
transcriptome offer an opportunity to associate cellular pheno-
types to underlying molecular mechanisms and potential ge-
notypic changes. The experimental methods, algorithms, and
the underlying domain knowledge have been developing
more than four decades [174]. With the advent of RNA-Seq,
transcriptomics has arguably become the most mature omics
approach in the functional genomics toolset.
The role of transcriptional changes in healthy and diseased
states, carcinogenesis in particular, have been the focus of
intense investigation. Notably, aberrant mRNA expression
levels are associated with dysregulation in cancer.
Comprehensive profiling of gene expression patterns across
many tissues and cancers have yielded molecular classifica-
tions of cancer (sub)types [75, 175]. Furthermore, unbiased
sequencing of transcripts has enabled detection of cancer- and
patient-specific somatic mutations [176, 177] and fusions/
rearrangements, spearheading the discovery of novel mRNA
biomarkers [178].
Methodological advances in transcriptomics have also
helped uncover the role of non-coding RNAs in health and
disease. Small ncRNAs have been implicated in the regulation
of transcription, post-transcriptional processing pathways,
gene silencing, epigenetic processes, translation, and protein
activity [179, 180]. The most widely studied class of ncRNAs
in cancer are miRNAs, known to regulate tumor suppressors
and oncogenes [181]. Aberrant miRNA expression has been
implicated in the occurrence and progression of tumors [182].
More importantly, miRNA expression patterns are cancer-
specific and can accurately identify tissue of origin in meta-
static cancer [183]. Because miRNAs are dysregulated in all
stages of cancer, they can be used as biomarkers for early
detection, prognosis, or treatment selection. Similarly,
lncRNA have a wide range of regulatory functions in cancer
and normal cells [174, 184]. The functions of other ncRNAs
in carcinogenesis are still poorly understood.
The existence of the circulating transcriptome as a liquid
biopsy biomarker was first recognized when cell free RNA
(cfRNA) from Epstein-Barr virus was discovered in the blood
of nasopharyngeal carcinoma patients [185] and circulating
miRNAs were found in the serum of B-cell lymphoma pa-
tients [186]. cfRNAs can be released into body fluids passive-
ly through processes such as cell death, or actively secreted in
exosomes or in complexes with proteins [187].
miRNAs are remarkably stable and abundant in fluids like
blood, making them most widely investigated transcriptomics
biomarkers for liquid biopsy [187, 188]. The major impedi-
ment for discovery and clinical use of other cfRNA bio-
markers, mRNA specifically, is their poor stability in body
fluids, mostly due to degradation by RNase [187]. Recent
studies uncovered that longer circulating RNA species can
be found in exosomes or complexes with (lipo)proteins, both
of which increase the stability and the resistance to RNase
[184, 188].
Current and Emerging Technology and Biomarkers
Quantification methods include qRT-PCR, dPCR, microar-
rays, and RNA-Seq (for both miRNA and lncRNA). PCR-
based methods tend to be quick, sensitive, and easy to inter-
pret, but they lack throughput and can only analyze a small
panel of predetermined RNAs [189]. Microarrays have the
advantage of analyzing many biomarkers in parallel [190,
191]. However, they are characterized by lower analytical
sensitivity and specificity [192]. RNA-Seq allows detection
of high-throughput analysis, the capacity to identify novel
fusions, but at a cost of higher complexity of analysis and
the larger amount of sample input.
There are a number of studies exploring the potential of
circulating RNAs as diagnostic, predictive, and prognostic
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biomarkers. Plasma [193, 194] and serum [195] miRNAs
have shown potential as biomarkers for early detection of
NSCLC. Furthermore, patterns of miRNA and their precur-
sors (pri-miRNA) can be used to detect NSCLC and enable
discrimination between squamous cell carcinoma and adeno-
carcinoma NSCLC subtypes [196]. Similarly, circulating
miRNA have been proposed as markers for guiding therapy
by identifying triple negative breast cancer [197]. Finally,
miRNA species in blood show potential as metastatic bio-
markers in osteosarcoma [198], bladder cancer [199], and
ovarian cancer [200]. However, one of the major drawbacks
of miRNA as cancer biomarkers is that most species exist in
both healthy and cancer patients, and their expression differ-
ences can be rather small [187].
The number of studies investigating potential miRNAs bio-
markers is high, but there are recent examples that show the
potential of using other RNA species. For example, different
mRNAs from liquid biopsies can be potential biomarkers for
predicting sensitivity to chemotherapy in gastric cancer
[201–203]. Currently, one of the most promising mRNA bio-
markers is telomerase reverse transcriptase (TERT), showing
potential as a diagnostic, prognostic, and predictive biomarker
in gastric [204], prostate [205], hepatocellular cancer [206],
CRC [207], and breast cancer [208].
A recent study [188] looked at combined patterns of altered
expression of different RNA classes, using a combination of
NGS and validation by qPCR and ddPCR. The study uncov-
ered a number of novel microRNA, mRNA, and YRNA in
plasma of melanoma patients compared to healthy control.
However, these novel biomarkers will need to be validated
in larger studies [188].
The choice of RNA quantification technology needs to be
accompanied by other analytical considerations. The first step
in any transcriptomics protocol is the isolation and purifica-
tion or RNA. Extraction from body fluids often results in
samples with low RNA quality and quantity. Furthermore,
the use of different isolation protocols can affect purity and
quality of isolated cfRNA [184]. To complicate matters fur-
ther, cfRNA concentrations and fractions can vary drastically
between different body fluids [184], tissues, organs, and indi-
viduals [184]. In addition to these technical challenges, data
analysis procedures protocols are not standardized [209, 210].
Translational Status
The published results on transcriptomics-based liquid biopsy
highlight an abundance of potential (mostly miRNA) bio-
markers. However, many proposed circulating RNA bio-
markers were validated only in underpowered retrospective
single-center studies with small cohorts [187], often leading
to contradictory results [211]. Nevertheless, RNA-based as-
says are being validated in clinical trials, and there are already
tests ready for commercial and clinical use.
A large validation study was conducted to validate miR-
Test, a screening blood assay based on signatures of 13 serum
miRNAs quantified by microarrays [212]. Specifically, high-
risk individuals enrolled in a single-center non-randomized
lung cancer screening trial (COSMOS study) [213] were se-
lected, split into four cohorts, and screened with the miR-Test
[212]. The first, calibration cohort (N = 24) was screened
using an extended panel of 34 miRNAs. The initial miRNA
set was then reduced to the most informative 13 miRNAs,
whose discriminatory power was validated in a second cohort
(N = 1008 from the COSMOS trial, where 36 patients had
low-dose computed tomography (LDCT)-detected lung can-
cer). miR-Test showed the sensitivity of 77.8% to detect all
tumors and the specificity of 74.8%. In the third cohort, the
miR-Test was assayed for the ability to discriminate non-
malignant frommalignant diseases (N = 83 patients who never
developed cancer during a 5-year follow-up), showing speci-
ficity of 86.7%. The fourth cohort was a clinical validation set
(N = 74 patients diagnosed with stage I-III lung cancer outside
of the COSMOS study) where sensitivity to detect cancer was
70.3%, with similar performance across different stages [212].
A similar result was obtained in a randomized multi-center
prospective trial (N = 939) carried out to test the clinical utility
of qRT-PCR-based miRNA signatures in plasma [214]. The
test showed good diagnostic performance with NPV = 99%,
as well as the ability to identify malignancy and the aggres-
siveness by predicting death as a result of the disease with
sensi t iv i ty of 95% and an NPV of 100% [214] .
Cumulatively, these two examples show that miRNA-based
liquid biopsy assays could be used as biomarkers for early
detection of lung cancers with similar sensitivity and specific-
ity to low-dose computed tomography (LDCT), and could
potentially be used to reduce false positive rates associated
with LDCT screening alone [212, 214].
Another example is Progensa PCA3 [215] (Gen-Probe), a
prostate-specific lncRNA overexpressed in primary and met-
astatic prostate adenocarcinoma [216]. A urine-based test spe-
cific for PCA3 [217] has shown good analytical [218] and
clinical performance in a number of clinical studies, a greater
specificity but lower sensitivity than the classical PSA bio-
marker [216]. In a multicenter prospective cohort of men
scheduled for repeat prostate biopsy, the assay showed
77.5% sensitivity and 57.1% specificity for repeat biopsy out-
come (N = 441) [215]. The PCA3 test has been approved by
FDA for clinical decisions about repeat biopsy of prostate
cancer [217].
SelectMDx (MDxHealth, Inc) is a liquid biopsy test based
on detecting HOXC6 and DLX1 mRNA levels in urine for
prediction of clinically significant prostate cancer prior to
prostate biopsy. The performance of the test has been investi-
gated in a trial with two multicenter cohorts, a discovery co-
hort (N = 519), and validation cohort (N = 386). The results
show that the test performs with AUC = 0.90 for a classifier
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that combines mRNA levels with PSA levels and clinical risk
factors, excluding DRE results [219]. The clinical use of
SelectMDx has shown potential to increase health outcomes
and reduce overall treatment costs through elimination of un-
necessary biopsies in two simulations of cost-effectiveness
[220, 221].
Cxbladder is a urine-based multiplex RNA test for detect-
ing, monitoring, and stratification in bladder cancer [222,
223]. The test derives its score from increased expression
levels of five genes, MDK, HOXA13, CDC2, IGFBP5, and
CXCR2. In a multi-center study with prospectively recruited
patients with hematuria, Cxbladder detected 82% cases (at
specificity of 85%) of urothelial carcinoma from urine sam-
ples taken prior to cystoscopy, outperforming other tests and
cytology (N = 485) [224]. Furthermore, it distinguished be-
tween low-grade Ta tumors and other detected urothelial car-
cinoma with a sensitivity of 91% and a specificity of 90% in
the same cohort [224].
Proteome
Scientific Rationale
The proteome is the entire set of proteins expressed in a cell,
tissue, or an organism. Unlike the genome, the composition of
the proteome can change with time and in response to varying
intracellular and extracellular conditions. Furthermore, be-
cause expression of a single gene can involve alternative splic-
ing, recoding events, and a wide range of post-translational
modifications, the number of expressed proteins and
proteoforms vastly outnumbers the number of genes. The
identification and quantification of expressed proteoforms
can illuminate molecular pathways, interactions, and events
underlying cellular phenotypes in healthy and disease
contexts.
Oncoproteomics investigates proteins involved in the car-
cinogenic processes with the aim of understanding the under-
lying molecular mechanisms, deriving novel targets for ther-
apy, and identifying proteins that can serve as diagnostic,
prognostic, and predictive biomarkers. Historically, the prote-
ome has been the major source of circulating biomarkers for
clinical use. Due to analytical and clinical limitations of these
early markers, the field of oncoproteomics has been focused
on discovering new protein molecules and signatures that can
inform clinical decisions.
The advancement in proteomics methods and instrumenta-
tion, paired with other omics methodologies, raised hopes for
the development of protocols to aid the rapid discovery of
novel biomarkers and to implement personalized approaches
in clinical practice. The promise of proteomics to advance
basic biology and cancer research has culminated in projects
to elucidate the maps of the human (tissue) proteome
[225–228] and the cancer proteome [229]. However, despite
the advances in methods and the accumulation of domain
knowledge, much of the current oncoproteomics research for
biomarkers remains in the discovery phase. The introduction
of novel protein biomarkers and proteomic technologies in the
clinic is still hampered by technical challenges, poor analytical
performance, reproducibility issues, a lack of standards, and
the lack of validation in large and rigorously designed clinical
studies. The careful analysis of past success and failures has
been critical for shaping the guidelines and regulations for
advancing the field of biomarker discovery and for bringing
new biomarkers into standard clinical practice [20, 21,
230–233].
Current and Emerging Technology and Biomarkers
Of all the sources of biomolecular information that can be
used to diagnose and characterize cancers through liquid bi-
opsy, protein biomarkers have the longest standing tradition in
clinical practice. These circulating protein biomarkers include
CEA [234], PSA [235], β-hGC [236], AFP [237, 238], FDP
[239, 240], HE4 [241], ALT/AST [242], LDH [243, 244], CA
125 [245, 246], CA 15-3 [247], CA 19-9 [248], CA 27.29
[247] (reviewed in [230, 249–252]). Standard clinical protein
biomarker assays typically target a single or a small number of
prespecified tumor-associated antigens using immune-based
methods [253]. These methods have a high analytical sensi-
tivity and assays can easily be automated using liquid han-
dling robots [254]. The limitation is that antibodies can detect
multiple proteoforms [255] and non-specifically interact with
interfering compounds generating false positives [256, 257].
Limited dynamic range is another technical issue affecting
immunoassays [254].
High-throughput proteomics techniques have emerged as a
viable alternative to address some of these issues. Importantly,
newer proteomics methods can go beyond detecting
predetermined panels of biomarkers, complementing genomic
and transcriptomic approaches in probing the molecular sig-
nature of the underlying cancer. Furthermore, proteomics can
provide additional information about concentrations of
expressed proteins and their post-translational modifications,
offering unique approaches to analyze and stratify cancer
types.
The most widely used proteomics approach is mass-
spectrometry (MS) [254]. Mass-spectrometry is an umbrella
term that describes a wide array of methods that ionize
analytes and then detect and analyze ions in the gas phase.
Different ionization methods (electrospray ionization (ESI)
[258] or matrix-assisted laser desorption/ionization
(MALDI) [259], surface-enhanced laser desorption/
ionization (SELDI) [259, 260], etc.) can be coupled with dif-
ferent analyzers (quadrupoles, time-of-flight, orbitrap ana-
lyzers, etc.) to achieve different analytical characteristics
[254]. Furthermore, MS instruments can be combined in
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tandem (MS/MS) to afford structural information on analyzed
ions. This setup can allow implementation of selected and
multiple reaction monitoring (SRM [261] and MRM [262],
respectively) in order to detect and quantify pre-specified ions.
This mode of analysis is highly specific and can be used to
multiplex quantification of approximately 200 proteins [263,
264]. In general, MS-based proteomic methods can yield large
targeted or unbiased datasets with high precision and resolu-
tion [265]. In clinical laboratory, they offer lower routine
costs, higher specificity and throughput, as well as the possi-
bility to multiplex assays. Limitations of MS-based proteo-
mics include reproducibility issues, analytical sensitivity to
proteoforms with low abundance, method validation and stan-
dardization, instrument cost, and the need for expert
interpretation.
An emerging platform for proteomics biomarker discovery
is the protein array technology [266]. Protein (micro)arrays or
chips are solid surfaces that immobilize up to thousands of
purified or synthesized proteins at high densities [266–269].
Protein arrays are used to quantify large predetermined panels
of proteins by capturing a wide range of protein binding ac-
tivities [270]. The technology is characterized by high-
throughput, high sensitivity, and robustness. The discovery
of protein biomarkers for liquid biopsy is an important appli-
cation of protein arrays. Arrays with immobilized antibodies
are a low-cost method to profile the expression of many pro-
teins in parallel [269], but they rely on using pre-existing
antibodies for targets of interest. Functional protein arrays
[271] contain complements of purified protein and can be
used for unbiased assays of the entire circulating proteome.
While it is difficult and costly to fabricate functional protein
arrays, there are commercial variants available on the market
[266]. An interesting variation of the technology are reverse-
phase lysate microarrays, which allow lysates (e.g., from liq-
uid biopsy) to be printed on a micro-array and quantified by
immunochemical methods in a massively parallel fashion
[272, 273]. These arrays are typically cheaper than functional
ones but are limited by the availability of antibodies.
Another high-throughput proteomics technology with po-
tential use in biomarker discovery is an aptamer-based plat-
form called SOMAscan (Somalogic Inc.) [274]. SOMAscan is
a multiplex quantitative affinity-based assay where
immobilized aptamers bind to proteins with high specificity
and affinity [274].
Proteomics technologies for liquid biopsy are being im-
proved at a rapid rate, and some of the technical challenges
are being addressed. Further improvements in this field will
benefit from organized and institutionalized efforts to charac-
terize cancers by integrating proteogenomic technologies and
to establish standards for translation of the research in cancer
biology. An example of such effort is the National Cancer
Institute’s Clinical Proteomic Tumor Analysis Consortium
(CPTAC), which is advancing integrated proteogenomic
analysis for illumination of molecular bases of colorectal,
breast and ovarian cancer [275–277]. The CPTAC initiative
led to the creation of two additional programs, The Applied
Proteogenomics OrganizationaL Learning and Outcomes
(APOLLO) [278] network and the International Cancer
Proteogenome Consortium (ICPC) [279]. These two networks
are advancing the translation of proteogenomic research into
routine clinical practice and enhancement of precision oncol-
ogy through international data sharing.
Translational status
Assays for classic circulating protein biomarkers have been in
clinical use for a couple of decades. Systematic reviews call in
question the indiscriminate use of some of these biomarkers
for population-wide screening [280–283], with the major lim-
itation being a lack of specificity to a single cancer type, and
high false positive rates associated with non-cancerous condi-
tions [284]. These issues can translate into unnecessary treat-
ments that harm patients and increase healthcare costs.
Despite the general issues with classical protein bio-
markers, they show utility in appropriately defined clinical
settings, especially when used in combination with other clin-
ical variables. CEA has limited specificity and sensitivity for
routine follow-up of early-stage CRC patients [285], but in
combination with clinical, radiological, and histological find-
ings, it can predict recurrence of CRC after resection [286,
287]. Likewise, PSA-based screening is associated with false
positive rates and overdiagnosis [288, 289], but it was shown
to reduce mortality from PCa when screening high-risk pa-
tients between 55 and 69 years of age in conjunction with
digital rectal examination [288], it can detect PCa recurrence
after resection, as well as predict response to treatment [290].
Similarly, while LDH is unsuitable as a biomarker for diagno-
sis of early-stage melanoma, it is a validated prognostic bio-
marker in metastatic melanoma (and currently the only sero-
logic marker for melanoma) [244, 291].
New proteomics technologies have been used extensively
in biomarker discovery in the last two decades. However,
these methods are not easily translated into routine clinical
use due to technical complexity, low throughput, and low
reproducibility [292]. There are efforts to address these issues
in a systematic fashion. A multi-site study has been imple-
mented to standardize protocols and limit variability and irre-
producibility in multiple reaction monitoring for plasma pro-
teomics [293]. Attempts to translate proteomics-based bio-
markers into clinical trials can be improved by following fit-
for-purpose recommendations for designing analytical valida-
tion experiments and reporting findings [294].
Poorly designed and underpowered trials have hampered
the translation of proteomic biomarkers into the clinic [20].
Some of the known examples of biomarker failures include
the use of exoprotease-generated peptidome patterns in serum
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for detection of various cancer types [295]. In the original
study, MALDI-TOF MS analysis of peptidomic patterns
yielded a panel of biomarkers for accurate discrimination of
three cancer types form healthy controls [295]. However, sub-
sequent reanalysis of the study design revealed a number of
flaws in the study design, namely improper case-control
matching (age and sex brackets different in case and control
patients) and inappropriately selected patient population (co-
hort including mostly patients with late-stage cancer, where
intended purpose was early cancer detection) [20]. Later val-
idation study found no evidence that serum peptidomic pat-
terns can be used as cancer biomarkers [296]. Another exam-
ple of a flawed design is a study that suggested a four bio-
marker panel yielding 95% sensitivity and 95% specificity,
thus outperforming the standard CA125 biomarker for detec-
tion of ovarian cancer [297]. A subsequent study found that
expanding the biomarker panel to six analytes could further
improve specificity (99%) to OvCa [298]. However, an inde-
pendent, blinded attempt to validate these findings showed
that none of the biomarkers outperformed CA125 in sensitiv-
ity and specificity to OvCa [20, 299]. Reanalysis of the orig-
inal study design revealed that authors used partially overlap-
ping training and validation cohorts, causing overfitting [300].
Furthermore, cases and control patients came from different
sources, where sample collection procedure was not standard-
ized, introducing potential biases into the analysis [300].
Similar study design flaws prevented OvaCheck, an MS-
based serum test to identify ovarian cancer patients [301], to
be marketed for public use. Namely, differential handling of
samples from different sources created batch effects that con-
founded the signal [302–304].
To address aforementioned study design issues, recom-
mendations have been put in place for the phased design in
biomarker discovery [305] aimed at better evaluation of clas-
sification accuracy in the intended clinical context. A novel
candidate protein biomarker for pancreatic ductal adenocarci-
noma (PDAC) has been put forth using the recommended
study design [306, 307]. Authors first carried out an experi-
ment where they reprogrammed human PDAC cells into an
induced pluripotent stem cell-like line (10-22 cell line) [308].
A proteomic analysis of media from 10-22 cell-derived pre-
cursor pancreatic intraepithelial neoplasia cultured as
organoids revealed 107 candidate proteins. Authors cross-
referenced this candidate set against human plasma proteins
[308] and focused on proteins with low abundance in healthy
human plasma [306, 309]. They further reduced the set to
three candidates, matrix metalloproteinase 2 (MMP2),
MMP10, and thrombospondin-2 (THBS2), and assayed these
in human plasma samples from a biospecimen repository (N =
10 cancer cases and N = 10 controls). MMP2 and MMP10
were uninformative, but THBS2 could discriminate pancreatic
cancer from healthy controls (AUC = 0.76), and resectable
and locally advanced PDAC against healthy controls (AUC
= 0.886) in this small discovery cohort. A combined panel
with THBS2 and CA19-9 performed well across all stages
on PDAC in a larger validation cohort (AUC = 0.970, N =
161, 81 cancer and 80 healthy controls). The authors then
validated the two-marker panel in an independent cohort (N
= 337) and found that it can discriminate between cancer and
healthy subjects with AUC = 0.97 [306].
In 2009, FDA has approved OVA1, the first in vitro
Diagnostic Multivariate Index Assay (IVDMIA) for Ovarian
Cancer [231]. OVA1 combines results of assays for CA-125
II, prealbumin, apolipoprotein A-1, β2-microglobulin, and
transferrin into a single score that can distinguish malignant
ovarian tumors from non-malignant forms that do not warrant
referral to surgery. The assay was initially developed as a
SELDI-TOF assay, but due to reproducibility issues, it was
finally implemented as an immunoassay [310]. The OVA1 test
was first validated in combination with physician assessment
to predict malignancy in a prospective multicenter cohort of
women scheduled for surgery of an ovarian tumor (N = 516,
sensitivity 96%, specificity 35%) [311]. In a second study, the
assay was validated in the context of its intended use, for risk
stratification of ovarian malignancy after enrollment by non-
gynecologic oncology providers. This prospective multicenter
trial assayed pre-operative serum of 494 women and correlat-
ed the results with surgical pathology results. In combination
with clinical variables, the assay could distinguish malignant
from benign adnexal masses with the sensitivity of 95.7% and
specificity 50.7% [312]. A recent improvement of the assay,
OVA2, showed increased specificity (69%) to OvCa in a
multi-site prospective cohort (N = 493) [313].
Another successful example of a commercialized liquid
biopsy test is Veristrat (Biodesix). Veristrat classifies
NSCLC patients as “Good” or “Poor” based on a multivariate
MALDI-TOF proteomics blood test via detection of inflam-
matory states associated with aggressive lung cancer [314,
315]. Veristrat was used for patient stratification in a random-
ized phase III multi-center clinical trial with the goal of mea-
suring survival and response to EGFR-TK inhibitor (erlotinib)
or chemotherapy [316]. In this cohort of 285 confirmed, sec-
ond-line, stage IIIB or IV NSCLC patients [316], those with a
Veristrat classification of “Poor” had shorter overall survival
on erlotinib than on chemotherapy (3 vs 6.4 months, HR =
1.72). Biodesix has now partnered withMRMProteomics Inc.
in an effort to implement the iMALDI platform for proteomic
biomarkers to further enhance diagnosis and prognosis for
lung cancer.
In 2018, Integrated Diagnostics announced the results of its
multi-site prospective PANOPTIC (Pulmonary Nodule
Plasma Proteomic Classifier) Trial [317] (NCT01752114).
PANOPTICwas designed to validate Xpresys Lung 2, a liquid
biopsy assay that integrates clinical data and MRM quantifi-
cation of two plasma proteins, LG3BP and C163A, to distin-
guish benign frommalignant lung nodules. The assay showed
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high sensitivity (97%), specificity of 44%, NPV of 98% and
could in principle reduce procedures carried out on benign
nodules by 40% (N = 392 patients with pulmonary nodules)
[317].
Array-based proteomics technologies are also showing
their potential for translation. IMMray™ PanCan-d
(Immunovia) is a blood test based on machine learning to
derive a diagnostic classifier from antibody microarray data.
The test could classify samples from pancreatic cancer pa-
tients or healthy controls accurately with AUC > 0.95 in six
retrospective cohorts to date [318–322]. IMMray™ PanCan-d
is currently undergoing a clinical trial to investigate its diag-
nostic accuracy for detection of pancreatic cancer in high-risk
groups (NCT03693378). The antibodymicroarray technology
has potential to be used in diagnostics of other types of cancer
and has already been tested to longitudinally monitor sera of
patients with breast cancer [323] and to classify patients based
on risk for developing prostate cancer [324].
The potential of SOMAscan assay to bridge biomarker
discovery and validation phases was tested in three multi-
site prospectively designed case/control studies. These studies
used archived samples to discover and validate protein bio-
markers for NSCLC detection in high-risk patient populations
[325]. The first cohort (N = 363) was used to discover a robust
panel of protein NSCLC biomarkers from 1033 SOMAscan
analytes. The analysis resulted in a 7-marker panel with an
AUC of 0.85 for all cases of NSCLC vs benign nodule con-
trols. The histopathological sensitivity of the 7-protein panel
was validated in a second cohort and showed similar discrim-
ination between cancer and healthy subjects (AUC= 0.81,N =
138), and AUC = 0.89 for squamous cell carcinoma. Authors
performed an additional validation study on an EDRN multi-
center reference set for validating biomarkers for detection of
lung cancer (N = 135). In this cohort, they found that the
biomarker panel could detect NSCLC vs healthy samples with




Cancer metabolism dramatically differs from that of a normal
tissue. This phenomenon, dubbed metabolic reprogramming,
is recognized as one of the hallmarks of cancer [326]. The first
known example of metabolic reprogramming in cancer cells,
the Warburg effect, was discovered 90 years ago [327]. The
Warburg effect describes a metabolic phenotype where cancer
cells display higher glycolytic flux and produce lactate at a
higher rate than normal cells despite oxygen availability.
The acquisition and maintenance of neoplastic processes
such as abnormal cellular proliferation and metastasis generally
increases the demand for energy and biosynthetic building
blocks, and changes the redox balance [328, 329].
Consequently, the cellular metabolism changes to accommo-
date those requirements and increase the fitness of cancer cells.
The exact mechanisms of metabolic reprogramming and how
they contribute to malignant phenotypes are active topics of
investigation.
Oncometabolites are small molecules whose abundance is
drastically increased as a consequence of cancer-associated
metabolic reprogramming or because of somatic mutations
in specific enzymes [328]. The most commonly known
oncometabolite is D-2-hydroxyglutarate (D2HG), a reduced
form α-ketoglutarate. The abundance of D2HG is low in nor-
mal tissues but increases in tumors harboring mutations in
isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) [328, 330,
331].
The discovery of oncometabolites prompted the search for
metabolomic biomarkers. However, looking for a single
oncometabolite to serve as an accurate diagnostic, prognostic,
or predictive biomarker for complex diseases like cancer
might prove to be futile. A more promising perspective might
be to rely on metabolite panels or signatures. This better re-
flects the reality of dysregulated pathways, as well as im-
proves statistical robustness of the biomarker-informed deci-
sion-making.
Discovery in cancer metabolism can proceed with two dif-
ferent pathways, either by quantifying metabolites
(metabolomics) or by measuring activities of metabolic path-
ways (e.g., by metabolic flux analysis) [332, 333]. These two
approaches are not interchangeable and provide complemen-
tary information. A combination of both can yield important
insights into metabolic phenotypes in cancer and uncover
oncometabolite biomarkers for precision medicine.
Current and Emerging Technology and Biomarkers
Metabolomic experiments typically use analytical platforms
such as nuclear magnetic resonance (NMR) [334], liquid-
chromatography mass spectrometry (LC-MS) [335, 336],
gas chromatography mass spectrometry (GC-MS) [335], and
capillary electrophoresis mass spectrometry (CE-MS) [335,
337] to analyze and quantify metabolites in a sample [338].
These experiments could be targeted to a specific metabolite, a
class of metabolites, or attempt to comprehensively assess all
metabolites in an unbiasedmanner. Targeted approaches focus
on up to a hundred metabolites, while untargeted analyses can
cover hundreds or even thousands in a single experiment.
Different platforms are suitable for different applications or
the analysis of different metabolites. GC-MS is typically used
to assay metabolites smaller than 1,000 Da that are volatile or
can be made volatiles via chemical derivatization [338]. In a
single acquisition, GC-MS can resolve a couple of hundred
metabolites with different properties (such as sugars and their
derivates, amino and organic acids, amines, sterols and fatty
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acids) [339]. The advantage of GC-MS is reproducibility
across different platforms, the existence of comprehensive
spectral libraries, robustness, and relatively low costs. LC-
MS is mostly used for larger metabolites that are non-
volatile [339]. LC-MS can generally resolve a larger number
of molecular species than GC-MS. CE-MS is ideal for the
analysis of polar and ionic compounds, especially from low
volumes. However, the sensitivity is generally lower, and var-
iability is higher than that of GC-MS and LC-MS [338]. NMR
has an advantage over MS methods by being a non-
destructive analytical technique. Furthermore, in addition to
quantification, NMR can be used to unambiguously resolve
structures of unknown metabolites. Results of a 1H-NMR
analyses are highly reproducible, but they typically have low-
er sensitivity than MS-based approaches [338].
Targeted approaches are empowered by known changes in
cancer metabolism. In some cases, it might be possible to
associate cancer-specific genetic alterations to changes in me-
tabolite concentration and devise a scheme to discriminate
between different types of cancer. For example, a mutation
in isocitrate dehydrogenase (IDH) is a driver event in malig-
nant gliomas [330]. The accumulation of 2-hydroxyglutarate
(2HG) is observed in glioma cells with IDH1 mutation [340].
Plasma and urine levels of 2-hydroxyglutarate can be used to
predict response to treatment [341].
Targeted metabolomics can also focus on oncometabolite
concentration changes caused by dysregulation in metabolic
pathways. Known examples are changes to concentrations of
prostaglandins resulting from reprogramming of the eicosa-
noid pathway, which was shown to promote tumor growth
[342]. These changes can in turn create distinct metabolic
signatures in urine, which can be detected by targeted methods
such as SRM. This approach showed the potential of using
urine prostaglandins as biomarkers for detecting patients with
high risk of developing pancreatic cancer [343]. Similar stud-
ies highlighted prostaglandins as biomarkers for identifying
patients at high risk of breast cancer [344] and for prognosis
of lung metastases in breast cancer patients [345]. Another
example looks at polyamines as circulating biomarkers.
Dysregulation of intracellular polyamine metabolism is a hall-
mark of most cancers [346] and a potential target for therapy.
Furthermore, urine and plasma polyamine content in cancer
patients can mirror intracellular levels of these metabolites,
presenting an opportunity to use them as liquid biopsy bio-
markers. The biomarker potential of polyamines was recently
investigated using targeted analysis with LC MS/MS in colo-
rectal [347, 348], ovarian [349], and prostate cancer [350].
The second approach uses untargeted/unbiased analysis of
circulating metabolites to find differences between cancer pa-
tients and healthy individuals. Unsurprisingly, the findings of
these untargeted approaches can sometimes recapitulate
known cancer-related metabolic changes. For example, dys-
regulation of the citric acid cycle can alter plasma and urine
concentration of pathway intermediates, such as succinate and
fumarate [328]. The potential of these two biomarkers for
diagnosing and staging renal cell carcinomawas demonstrated
using untargeted 1H-NMR and GC-MS [351]. Similarly, ex-
tracellular protein breakdown is a hallmark of pancreatic can-
cer [352] and leads to release of branched-chain amino acids
(BCAA). A recent study relied on LC-MS metabolic profiling
of individuals from four prospective cohorts uncovered that
three BCAAs (isoleucine, leucine, and valine) whose elevated
levels in plasma can indicate twofold increased risk of PDAC
future diagnosis [353].
An innovative unbiased metabolomic approach bypassing
urine and plasma sampling relies on analyzing volatile organic
compounds (VOC) from breath and breath condensate. The
analytical platform can be MS or a proprietary Field
Asymmetric Ion Mobility Spectrometry (FAIMS) technology
(Owlstone Inc). This approach is being investigated to uncov-
er novel metabolic biomarkers of lung cancer [354, 355]. A
systematic review of VOC studies for early detection of lung
cancer found that 2-butanone and 1-propanol are commonly
reported as best discriminators between healthy and lung can-
cer subjects [356].
Different metabolites can differ drastically in their size and
physicochemical properties. Because no single method can be
used to separate, detect, and quantify a wide range of molec-
ular species, multiple sample preparation and analytical
methods can be used to capture the metabolome. Using
multiplatform metabolomic approaches is a powerful strategy
to identify biomarkers signatures. For example, combined
metabolomics and lipidomics approaches using 1H-NMR,
GC-MS, and LC-MS have uncovered potential biomarkers
originating from alterations in lipid metabolism that could
help identifying breast cancer [357]. Similarly, a panel of
Fourier transform ion cyclotron resonance mass spectrometry
(FTICR-MS), liquid chromatography (LC) MS/MS, and
NMR was used for discovery of a set of biomarkers from
altered lipid metabolism with the potential for early detection
of colorectal cancer [358].
One of the examples of discovering cancer-specific
metabolomic signatures by first computationally identifying dys-
regulated pathways, and then confirming these predictions using
metabolomics comes from our group. We explored the integra-
tion of multiomics data with genome-scale metabolic models
and showed that genetic alterations in clear cell renal cell carci-
noma (ccRCC) were associated to ccRCC-specific metabolic
reprogramming [359, 360]. The detailed computational analysis
of ccRCC metabolism showed altered regulation of glycosami-
noglycan (GAG) biosynthesis [360]. CE-based plasma and urine
analysis of samples from ccRCC patients showed that a GAG
panel (19 metabolic species) can be used to derive a GAG sig-
nature with diagnostic and prognostic potential [360–362].
Studies cited above demonstrate that advancements in
instrumentation and computational methods are adequate to
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allow metabolomics biomarker discovery. However, the field
is still hindered by different analytical challenges. Most im-
portantly, experimental procedures and materials, as well as
data handling and statistical analyses will need to be stan-
dardized to ensure analytical validation of biomarkers.
Translational Status
Arguably, the translational efforts in oncometabolomics are still
in its infancy. There are currently no FDA-approved
metabolomic liquid biopsy tests on the market. There are many
challenges that will need to be addressed before metabolic bio-
markers in the discovery phase can be validated and translated
into clinical practice. Typically, only a small number of samples
is collected during clinical trials, making the subsequent iden-
tification and validation of discovered metabolites challenging.
Another challenge is found in the difficulty of measuring small
differences in metabolites between healthy and cancer patients,
masked by high inter-individual variation due to genetic and
environmental factors [363]. Some of these challenges can par-
tially be addressed by the advent of the Human Metabolome
Database (HMDB) [364]. The database contains information
on ranges of specific metabolites in human populations and
their link to cancer pathways and disease phenotypes.
However, like with other classes of biomarkers, the conclusive
evidence of biomarker’s validity can only be established
through clinical trials with large and diverse cohorts.
Some of the mentioned issued with metabolomic bio-
markers are exemplified by sarcosine. Plasma sarcosine has
shown promise as a biomarker for prostate cancer [365].
However, its validity and utility as a viable biomarker were
questioned when it failed in later validation trials [366–368],
and then resurfaced as a biomarker in a recent study [369].
The definite decision about the clinical utility will require
large and rigorously designed validation trials.
The sensitivity of circulating metabolites to external factors
means that biomarker validation studies need to account for
ethnographic and dietary habits. Aminoindex Cancer
Screening (AICS, Ajinomoto Co., Inc.) system is a blood test
based on multivariate analysis of plasma-free amino-acids
(PFAA) [370, 371]. The AICS assay has been validated in a
series of clinical trials covering approximately 2,500 patients
with 7 different types of cancer and 15,000 healthy controls
[372–374]. The AICS test is currently being used to screen for
early detection of lung cancer in Japan [372, 375]. Ajinomoto
is sponsoring a single-site observational prospective case-
control study to investigate performance characteristics of
the AICS test for gynecological cancers in the US population
(NCT02178462).
Our group has completed a number of prospective and
retrospective studies to establish clinical validity of a GAGs
as biomarkers for liquid biopsy in ccRCC. We found that
plasma and urine GAG scores readily distinguish cancer
patients from healthy controls (100% specificity and 100%
sensitivity in a discovery cohort with 34 mccRCC patients
and 16 healthy individuals, and a validation cohort with 18
mccRCC and 9 healthy subjects) [360]. Furthermore, the di-
agnostic and prognostic value of GAGwas investigated in two
additional studies [361, 362]. The first study explored the
association between urine and plasma GAG scores with pro-
gression free and overall survival in a prospective cohort of 31
patients diagnosed with ccRCC [361]. The results show that
urine GAG score was a predictor of PFS and OS (hazard ratio
(HR) 4.62 and HR 10.13, respectively). The second study
[362] investigated plasma GAG score as a biomarker for
pre-operative detection of early-stage RCC and prediction of
recurrence and death after RCC surgery. This retrospective
case-control study consisted of a consecutive series of surgi-
cally treated 175 RCC patients and 19 healthy controls [362].
We found that the GAG score could correctly classify RCC
from healthy subjects with AUC = 0.999 in the discovery part
of the cohort (N = 67). In the validation set (N = 108), the
GAG score achieved an AUC of 0.991, and achieved 93.5%
sensitivity at the predetermined cutoff [362]. This test will be
validated in the multicenter prospective clinical study
AURORAX-087A for detection of post-surgical recurrence
in ccRCC (NCT04006405).
A systematic review of VOC studies for early detection of
lung cancer found that 2-butanone and 1-propanol are com-
monly reported as best discriminators between healthy and
lung cancer subjects [356]. However, there is some discor-
dance between relevant VOCs, as one study points to n-
dodecane as having the highest discriminatory power between
patients with histologically proven lung cancer and healthy
controls (sensitivity 76%, specificity of 100%, when using a
decision tree based on n-dodecane and 9 other peaks; N = 50
cancer patients and N = 39 healthy subjects) [354]. Instead of
relying on identification of individual VOC, entire VOC sig-
natures have potential for lung cancer detection. For example,
one pilot study compared VOC patterns of 32 patients with
cytological or histological diagnosis of lung cancer and 54
healthy controls. Combinations of VOC peaks could discrim-
inate cancer from healthy subjects with leave-on-out cross-
validation accuracy of 100% [355]. Owlstone Ltd. is currently
sponsoring a multi-center case-control study on patients
suspected to have lung cancer aimed at evaluating VOC anal-
ysis using their breath biopsy technology for early detection of
lung cancer (NCT02612532).
‘Breathomics’ are not limited to lung cancer detection. An
observational cohort trial on patients referred to CRC surgery or
for diagnostic colonoscopy was completed (NCT02332213),
where breath biopsy samples were collected prior to surgery
or colonoscopy. The GC-MS analysis of VOC revealed that
acetone and ethyl acetate were elevated in CRC patients, com-
pared to healthy controls. A discriminant function analysis of
breath VOC patterns could discriminate CRC vs healthy
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controls with 85% sensitivity and a 94% specificity (N = 209)
[376]. Two recently published studies shown that VOCs have
the potential to discriminate esophagogastric cancer patients
from heathy controls [377, 378]. Another study shows that
VOCs can be used for early detection of pancreatic cancer
[379]. Owlstone Ltd. is currently recruiting patients for a pan-
cancer prospective cross-sectional observational case-control
study to evaluate if breath biopsy can differentiate between
healthy subjects and patients with gastric, esophageal, pancre-
atic, renal, prostate, and bladder cancer from matched controls
(NCT03756597). Breath biopsies are a promising source of
biomarkers for precision medicine. The ongoing trials will help
address some of the challenges in the field, such as low repro-
ducibility and lowVOC concordance between different studies.
Exosomes
Scientific Rationale
Exosomes are bioactive nanovesicles (30–150 nm in size)
enclosed in lipid bilayer membranes [380–382]. Exosomes
are released from endosomes of almost all cell types. The
molecular cargo of exosomes includes diverse classes of bio-
molecules (proteins, DNA, various RNA species, lipids, and
other metabolites). The exact composition of exosomes can be
very heterogeneous, and likely reflects the composition and
the phenotypic state of the cell of origin. The exact mecha-
nisms of exosome biogenesis and function are still under in-
vestigation, but there is evidence showing that exosomes have
an important role in inter-cellular communication, both in
healthy and diseased states [383].
Exosomes are being investigated as important factors in
carcinogenesis, with potential to both promote tumor growth
and restrain it [384]. Studies show that tumor-derived
exosomes can modulate tumor progression, angiogenesis,
and metastasis [385]. Given their role in cancer biology,
exosomes are being studied as targets for anticancer-therapy
[386], potential drug delivery vectors [387], and as biomarkers
[383].
Exosomes are rich in biomolecules that reflect the state and
the composition of progenitor cells; they are a rich source of
biomarkers [383]. In fact, genomics [388], transcriptomics
[388], proteomics [389], and metabolomics [390] analyses
can be applied to exosome-derived biomarkers. Importantly,
because exosomes can be readily isolated from blood, plasma,
saliva, urine, breast milk, semen, ascites fluid, amniotic fluid,
and cerebrospinal fluid, they are an ideal target for liquid
biopsy. Finally, exosomes can obviate the need for repeated
tumor biopsies. Because exosome heterogeneity can be asso-
ciated with intra-tumor heterogeneity, the entire phenotypic
and genotypic tumor landscape can be captured with a single
liquid biopsy.
Current and Emerging Technologies and Biomarkers
To fully exploit exosomes as a source of robust and accurate
biomarkers, it is important to carefully consider methods for
sample handling, isolation, and enrichment. The main
methods for isolation of exosomes are differential ultracentri-
fugation [391, 392], density-gradient ultracentrifugation [391,
392], polymer-facilitated precipitation [393, 394], immunoaf-
finity capture [391, 395], and size-exclusion chromatography
[396]. The most commonly used method is differential centri-
fugation [392]. However, the method can cause vesicle aggre-
gation and co-isolation of protein contaminants [397].
Density-gradient ultracentrifugation can produce samples of
higher purity, but it is laborious and lengthy, making it unsuit-
able for clinical applications. Size exclusion chromatography
can produce similarly pure samples, and minimally affect
exosome characteristics [398]. Exosome purification using
commercial polymer-facilitated precipitation is rapid and easy
to implement, but results can be poor [399]. Isolation using
immunoaffinity can be used to enrich specific subpopulations
of exosomes based on surface antigens [391].
One of the major challenges in the field of exosome biolo-
gy is the lack of standardization of protocols used for exosome
enrichment and characterization. Biased isolation of exosome
components can introduce variability in results [400].
Differences in experimental procedures can affect results
across different studies. As a way of tackling this issue and
establishing experimental guidelines, a crowdsourcing
knowledgebase resource called EV-TRACK has been
established [401]. Once exosomes are isolated, they can be
used as starting materials for further characterization.
Exosomes can be characterized by electron and atomic force
microscopy methods [402–405], but here we focus on molec-
ular characterization drawing on omics technologies described
earlier.
Exosomal nucleic acid content represents the genetic vari-
ants of the originating cancer, as could therefore be used to
tailor therapeutic decisions and monitor response to therapy.
Given the high abundance and the stability of exosomes, com-
pared to cfDNA and CTCs in patients who have undergone
therapy, exosome-derived DNA (exoDNA) is a robust source
of genetic biomarkers to guide therapy. Indeed, driver muta-
tions such as BRAFV600E mutation in melanoma and EGFR
L858R and T790M mutations in lung cancer have been read-
ily detected in exoDNA [406]. On the other hand, results of
exosomal liquid biopsies in population-wide screening should
be carefully interpreted, because driver mutations, such as
KRAS and TP53, can be found in exosomes of healthy indi-
viduals [407, 408].
In addition to DNA, exosomes are a rich source of variety
of RNA species [184, 409]. Of all exosomal RNA (exoRNA),
miRNAs have been the main focus of exosomal biomarker
discovery [410]. On the other hand, long RNAs, such as
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lncRNA [411] and mRNA [412], are also informative and can
be used to identify somatic mutations and changes in gene
expression characteristic of cancers. Exosomal hTERT
mRNA can be detected in exosomes of patients with different
malignancies [412]. The utility of this potential pan-cancer
marker will need to be validated in larger cohorts.
Exosomes are significantly more abundant than CTCs in
body fluids. This means that exosomally derived proteins are
more amenable to proteomics analyses. Exosome proteomes
can be probed for biomarkers in an unbiased way, using
untargeted MS-proteomics approaches [413, 414], or using
affinity-based approaches, such as binding to aptamer-based
SOMAscan arrays [415]. Indeed, studies have shown that sin-
gle protein biomarkers and protein panels from exosomes
have the potential to be used as diagnostic and prognostic
biomarkers in pancreatic cancer [416, 417], melanoma
[418], lung cancer [389], and colorectal cancer [419].
Combining multiple omics approaches can yield more ro-
bust biomarkers than relying on a single method. For example,
exoDNA and exoRNA can be investigated in tandem to detect
oncogenic fusion transcripts [420]. This approach can be very
useful for combined genomics and transcriptomics profiling
of cancers that are not amenable to solid tissue biopsies [420].
Similarly, improvements in sensitivity and specificity can be
achieved by simultaneous investigation of protein and
miRNA panels derived from exosomes [421].
Recent developments in the field use various strategies to
bypass purification steps. In one such strategy, called
ExoScreen, authors used two types of antibodies and
photosensitizer-beads to directly capture and detect cancer-
derived circulating EVs [422]. ExoScreen uses antibodies
against CD9 and CD147 antigens to capture CD9/CD147
double-positive EVs which were enriched in the serum of
stage I colorectal cancer patients [422]. Similarly, protein mi-
croarrays with cocktails of antibodies against exosome-
specific tetraspanins can be used to ensure specific capture
of all exosomes. This approach called Extracellular Vesicle
Array (EV Array) [423] enabled the detection of exosomes
from a crude biofluid sample in a high-throughput manner.
Microfluidics platforms [424–426] are a new avenue to-
wards integrated isolation, detection, and multi-omics charac-
terization of exosomes for liquid biopsies. Microfluidic de-
vices obviate the need for lengthy and laborious protocols,
enable working with smaller sample volumes, and offer higher
throughput. Clinical validity of microfluidic devices is an ac-
tive area of research, but early efforts have showed promise
for liquid biopsies. Microfluidic devices like ExoChip [424]
can offer integrated quantification of exosome levels in
biofluids. ExoChip relies on immuno-isolation of exosomes
by CD63 [424, 427], followed by fluorescence staining and
detection/quantification using a standard plate readers. A sim-
ilar platform, ExoSearch [426], uses continuous flow to isolate
CD9-positive exosomes, which are then stained with
fluorescently labeled antibodies against exosomal tumor
markers (CA125, EpCAM, and CD24), followed bymultiplex
fluorescence imaging. Another innovative method for
exosome capture and characterization, called nano-
plasmonic exosome (nPLEX) sensor, uses an array of periodic
nanoholes embedded in a gold film [419]. nPLEX arrays are
functionalized with exosome-specific affinity ligands, where
exosome capture causes changes in the local refractive index
proportional to the target protein levels. Importantly, captured
exosomes can be released, facilitating analysis of mRNA car-
go by qRT-PCR [419]. Microfluidic exosome isolation can
also be carried out via size selection. An example of this ap-
proach is Exodisc lab-on-a-chip [428]. Exodisc uses tandem
nano-filters to enrich exosome subpopulations in the range of
20–600 nm. An integrated immunoassay can then be used to
quantify and characterize isolated exosomes.
These emerging technologies have a higher throughput and
require much lower volume than standard methods for
exosome isolation. Whether this will promote wider adoption
of exosome-derived biomarkers for clinical decision-making
will remain to be seen after some of the methods are validated
in independent prospective clinical trials.
Translational Status
The clinical use of exosome-based biomarkers is fraught with
challenges. Exosomes can vary in size and concentrations in
different biological samples [429]. Moreover, external factors
such as physical activities undertaken prior to sampling or the
time of sampling can influence the composition of exosomes
in liquid biopsy samples [397]. Once samples are taken, it is
critical to consider rapid sample processing and storage be-
cause circulating cells inside the sample can continue produc-
ing exosomes [397]. Additionally, any downstream biomarker
analysis is reliant on costly specialized instrumentation and
kits for exosome isolation [430]. Moreover, isolation tech-
niques are often matrix-specific and lack standardization nec-
essary for clinical use. Future improvements in standardiza-
tion, scalability, and turnover time for exosome isolation will
pave way for routine use of this important source of bio-
markers in the clinic.
Despite these challenges, exosome-based liquid biopsy
tests might make it to the clinic in the near future. Exosome
Diagnostics has two assays on the market. ExoDx Prostate
(IntelliScore) is a urine-based liquid biopsy test that uses
exosomal RNA to quantify expression of three genes and
predict the aggressiveness of prostate cancer [431]. A multi-
site prospective cohort study of patients undergoing prostate
biopsy was used to validate the ExoDx assay for discrimina-
tion between aggressive (Gleason grade 7 and higher) versus
Gleason grade 6 or benign prostate cancer. In a training cohort
(N = 255), the exosome assay score in combination with PSA
and clinical variables could detect GS7 or higher prostate
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cancer with AUC = 0.77 [431]. In the validation cohort (N =
519), the performance was similar, with AUC = 0.73 to detect
GS7 cancer or higher, outperforming the PSA-based standard
of care test (AUC = 0.63) [431]. The test is available for
clinical use and Exosome Diagnostics is currently conducting
a trial to investigate its utility and evaluate its potential to
reduce the number of in i t i a l p ros ta t e b iops ies
(NCT03235687). Their second test, ExoDx Lung (ALK), cur-
rently available for research only, is a qPCR test that detects
EML4-ALK fusion transcripts in plasma exosomes to inform
therapy selection for lung cancer. ExoDx Lung (ALK) was
tested for longitudinal monitoring in response to treatment in
a prospective cohort of ALK-positive patients (N = 52, total
144 longitudinal samples) [432]. The assay detected exoRNA
ALK-fusions in 50% of patients at baseline. Furthermore,
98% of samples from patients who showed objective response
or stable disease were tested negative, showing that ExoDx




The biology of cancer is characterized by complex phenotypes
such as genomic instability, metabolic reprogramming, chang-
es in proliferative signaling, evasion of apoptosis and immune
response, induction of angiogenesis, invasion and metastasis,
collectively known as cancer hallmarks [433]. To understand,
identify, and target these neoplastic processes, we need
systems-level integration and understanding of information
from multiple layers of biological activity (Fig. 2).
The first application of systems biology for precision on-
cology is the discovery of new (multiomics) biomarkers.
Systems biology provides a framework to investigate complex
cancer phenotypes in terms of pathways and networks. The
state-of-the-art statistical and computational algorithms can be
applied to the accumulated multi-layered biological data and
integrated with known cancer-related biochemical pathways
to guide the discovery of new biomarker panels [434]. The
biomarker candidates can then be analytically and clinically
validated in clinical trials.
The second application addresses the problem of intra- and
inter-patient cancer heterogeneity. Despite general common-
alities [433], cancers are defined by distinct background ge-
notypes and molecular signatures. To implement successful
personalized treatment protocols, we need to account for ge-
netic and environmental differences between individuals, as
well as temporal and spatial heterogeneity of cancer cells
within patients. Multiomics patient data collection and assays
for known biomarkers can be combined with machine learn-
ing approaches [435] for precise patient stratification. The
complexity and costs associatedwith these approaches are still
a barrier to implementing systems biology into clinical oncol-
ogy. However, as the costs of omics analyses keeps declining,
and as analysis tools become more powerful and easier to use,
multiomics strategies might approach routine use in the next
decade.
Current and Emerging Technology
The main drivers of systems biology are big data sets gener-
ated through omics technologies described in previous sec-
tions. Comprehensive multiomics profiling over thousands
of cancer patients has resulted in large databases of cancer-
related biological data. Arguably, the most important publicly
available resource for cancer systems biology is The Cancer
Genome Atlas (TCGA) [75]. TCGA contains petabytes of
data from (epi)genomics, transcriptomics, and proteomics ex-
periments and clinicopathologic annotation data describing 33
cancer types from 11,160 patients and has been instrumental
for translational cancer research [436]. Another similar re-
source is The International Cancer Genome Consortium
(ICGC) cancer data portal that contains multiomics data from
84 cancer projects and more than 20,000 patients worldwide
[437].
The availability of big multiomics dataset is not enough to
produce biological or clinical insight on its own. In fact, our
ability to generate big data sets is vastly greater than the ability
to analyze and integrate them [438]. Combining the results of
biological assays with imaging, biopsy, and clinical data is
used routinely in clinical practice. Extracting useful informa-
tion from high-dimensional and heterogeneous biological data
sets requires a different approach. The data can be used in
combination with models of cellular processes and pathways
[18] to reduce the dimensionality and generate candidate list
of features. Another approach is to directly combine biological
information from different omics platforms (multianalyte ap-
proach) to derive classifiers and diagnostic scores uses sophis-
ticated computational methods [435]. These methods include
various network topology analyses, dimensionality reduction
methods, anomaly detection, supervised and unsupervised
machine learning algorithms, as well as summarization and
visualization techniques for complex high-dimensional data
[439]. These methods have been used for feature selection
on big data sets directly [440, 441].
The sensitivity, specificity, and confidence of clinical
decision-making can be boosted by leveraging orthogonal
multianalyte panels. However, using multi-layered informa-
tion and multiple markers runs the risk of over-fitting predic-
tive models [439]. The importance of identified multiomics
biomarkers (genes, transcripts, proteins, and metabolites from
the candidate list) needs to be investigated by targeted assays
and omics experiments and be validated in retrospective clin-
ical studies. Robust statistical methods can then be used to
remove biomarkers with the minimal impact on accuracy,
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to identify meaningful correlations, and devise predictive
models [439]. The final set of biomarkers, in combination
with appropriate statistical methods, can then be validated in
larger cohorts [439].
Multi-omics technologies and their integration with diverse
clinical data will become even more important for robust pa-
tient stratification and cancer diagnostics with the advent of
artificial intelligence and deep learning (DL) algorithms [442].
Deep learning is a subclass of machine learning algorithms
that use neural networks, multi-layered data processing net-
works capable of feature extraction and pattern recognition in
large and diverse data sets [443]. While the successful appli-
cations of DL algorithms in medicine are mostly focused on
automated classification of medical imaging data [444, 445],
there are promising examples of applications to (multi)-omics
in precision medicine. In one study, authors used an artificial
neural network (ANN) to distinguish multiple myeloma pa-
tients from healthy subjects with 95% sensitivity at 95% spec-
ificity (N = 84, case-control study) based onMALDI TOFMS
low mass spectral fingerprint/metabolomic analysis of periph-
eral plasma samples [446]. In another study, miRNA sequence
data from serum samples of epithelial ovarian cancer (EOC)
patients was used to train a neural network, resulting in a
diagnostic algorithm that outperformed CA125 in
distinguishing cancer patients from healthy controls and be-
nign tumors (AUC = 0.9,N = 179, case-control studies) [447].
The authors then reduced the set of diagnostic miRNAs to
only seven that could be detected via qPCR, adapted the neu-
ral network to the reduced set, and validated the classifier on
51 pre-operative clinical samples to achieve an AUC = 0.85
[447].
The power of deep learning is that it can readily integrate
disparate data, such as multi-omics data, medical images, and
clinical information to enhance prediction accuracy [443].
However, further progress is limited by small data sets. The
full realization of DL potential will have to wait on the avail-
ability of sufficiently large, matched, and carefully annotated
datasets. However, even with perfect datasets of sufficient
size, validation and assurance of proper use might require
interpretability of predictions before DL is adopted into rou-
tine clinical use [448, 449].
Translational Status
Translational use of systems biology and multi-analyte bio-
markers is a relatively new addition to the field. However,
there have been some notable studies yielding new biomarker
panels for liquid biopsy. Some of these biomarkers show
promise in early clinical trials and await validation in larger
cohorts, while others are on their way to being commercial-
ized and used in clinical practice.
CancerSEEK is a promising multianalyte blood test, with
potential for pan-cancer diagnosis [450]. The initial case-
control study (N = 1005) on patients with clinically detected
stage I-III cancers shows that the test could detect a median of
70% over eight common cancer types by quantifying levels of
protein markers in plasma and cancer-specific mutations in
cfDNA. Importantly, CancerSEEK protein markers were use-
ful in detecting the candidate tissue of origin, which is a crit-
ical feature in a population-wide screens for early pan-cancer
detection. However, the specificity needs to be assessed and
validated on large prospective cohorts [450].
Large biomarker panels can in some cases be replaced by
only a few biomarkers. For example, combining digital drop-
let PCR to determine KRAS mutant allele fraction (MAF) in
cfDNA and exoDNA can help devise a classifier to predict
liver cancer. This classifier was tested for clinical utility in a
longitudinal prospective cohort of 194 patients undergoing
treatment for clinically and histologically confirmed localized
or metastatic pancreatic adenocarcinoma [32]. The baseline
multianalyte analysis of the cohort showed that the ctDNA
and exoDNA MAFs ≥ 5% to be a significant predictor of
OS (HR, 7.73). Furthermore, longitudinal multianalyte moni-
toring of exoDNA showed that MAF peak above 1% is asso-
ciated with radiologic progression (sensitivity 79% and spec-
ificity 100%) [32]. This study shows that longitudinal moni-
toring of circulating nucleic acids can provide useful predic-
tive and prognostic information.
A larger multianalyte test has been investigated for predic-
tion of pancreatic cancer in a population with risk for familial
pancreatic cancer [451]. The panel used multiple analytes
across different sample matrices: tissue (miRNA: miR-
196b), serum (snRNA: RNU2-1f; protein: LCN2, TIMP1,
Glypican-1, and CA 19-9), duodenal juice exosomes (protein:
Glypican-1), and duodenal cfDNA (KRAS mutations). The
validation in a small cohort showed that the entire panel could
be reduced to the three plasma analytes (miR-196b, TIMP1,
and LCN2), and distinguish stage I PDAC (N = 5) from
healthy individuals (N = 20) with an AUC = 1, and sensitivity,
and specificity at 100% [451]. Validating the specificity of this
multi-analyte panel towards early stage PDAC is necessary.
However, it might be challenging to do so, because clinically
validated stage I PDAC samples are extremely rare [451].
A successful case of a multianalyte test that also incorpo-
rates clinical data is the Stockholm 3 model (STHLM3). This
test combines plasma protein biomarkers (PSA, free PSA,
intact PSA, hK2,MSMB,MIC1), 232 genetic polymorphisms
associated with prostate cancer in earlier studies, and clinical
variables to identify high risk prostate cancer at biopsy [324].
STHLM3 was validated in an independent multi-center com-
munity cohort of 533 patients scheduled for prostate biopsy
[452]. Blood samples drawn prior to biopsy and analyzed to
compare STHL3 to PSA-based diagnosis of clinically signif-
icant prostate cancer (ISUP Grade Group (GG) 2 or higher).
STHLM3 showed better diagnostic performance than PSA
alone (AUC = 0.859 vs 0.642 for PSA and 0.748 for PSA
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density) for detection of Gleason grade group ≥ 2 vs benign
and Gleason grade group = 1 PCa, with the potential to reduce
the total number of biopsies by 38% [452]. The Stockholm3
test is now entering clinical use in Sweden, Norway, and
Finland.
An upcoming AI Genomics start-up Freenome is recruiting
patients for an observational study focused on colorectal can-
cer screening. Their approach will be to analyze all cfDNA
(most of which originates from immune cells [453]), cfRNA
and circulating protein as potential circulating biomarkers.
Their first report, on sequencing cfDNA for early CRC detec-
tion, was available as a preprint at the time of writing this
review [454]. The study was performed on retrospectively
collected 871 plasma samples from international institutions
and commercial biobanks (from 546 predominantly early
stage CRC cases, and 271 non-cancer controls). The authors
estimated ctDNA fraction in plasma cfDNA from copy num-
ber variation and used machine learning (logistic regression
and support vector machine) to discriminate between healthy
and CRC samples. Using k-fold cross validation, the proce-
dure showed sensitivity of 85% at 85% specificity for CRC
versus healthy subjects.
Conclusions and Future Directions
Themolecular characterization of tumor tissue biopsy samples
is currently the gold standard of precision and personalized
medicine. However, the invasiveness of (repeated) biopsies is
one of the main drivers of research on liquid biopsy bio-
markers for clinical decision making. Moreover, liquid biop-
sies can offer insights into biological phenomena and clinical-
ly important information about spatiotemporal heterogeneity
of tumors that is not readily accessible through tissue biopsy.
Towards Best Practices for Discovery and Validation
of Biomarkers
The accumulation of understanding of cancer biology and
advances in omics technologies have already yielded many
potential circulating biomarkers. The declining costs of high-
throughput assays and propagation of efficient computational
methods have enabled both targeted and unbiased genome-
wide studies on biomarkers for clinical applications. The
emerging liquid biopsy tests are increasingly focused on
multiparametric assays, involving multiple analytes from a
single layer of biological information or multi-omics analytes.
These kinds of studies are propelled by advances in statistical
and machine learning methods for analyzing big data.
However, while current research highlights the promise of
liquid biopsy biomarkers for precision oncology, the majority
of studies are still in an early proof-of-concept phase.
There are many challenges that will need to be overcome
before many of the new omics biomarkers can enter into stan-
dard clinical practice. One of the reasons for the discrepancy
between the number of biomarkers in the primary literature
and clinical practice is the gulf between the experimental ev-
idence needed to establish a finding in basic science and the
requirements for a robust diagnostic assay [230]. Moreover,
even when analytical validity is established, assays need to be
clinically validated in well-designed trials. Currently, there are
many biomarkers that show promise in retrospective and case-
control pilot studies, but there is a general lack of large pro-
spective studies demonstrating—at the very least—clinical
validity. For example, a recent systematic assessment of clin-
ical proteomics literature [455] revealed that only 10–20%
studies mention potential clinical application, while the rest
focus mainly on development of technical aspects of an assay
or sample preparation. Furthermore, even where reviewed
studies included clinical validation, it was found to be under-
powered for the specific context of use (low sample size), the
potential biomarker was not tested against current methods,
the studywas not performed on the population of interest (e.g.,
screening biomarker tested in a case-control study with differ-
ent prevalence than in reality), or tested in the intended context
of use [455]. Moreover, the evidence of clinical utility is lack-
ing for the majority of liquid biopsy biomarkers.
Demonstrating clinical validity and utility is perhaps even
more challenging for circulating biomarkers that would enable
population-wide screening and early detection of tumors.
While the early data may show promising diagnostic perfor-
mance, caution is necessary because of large numbers of false
positives even when clinical specificity is high (> 99%).
Because the incidence and the mortality from any specific
cancer is low, clinical utility studies need to be long and cover
a sufficiently large population.
The weight of evidence and the scope of clinical trials
needed to successfully complete a phased biomarker research
for screening applications is well outside of reach for most
research groups. In fact, multidisciplinary collaborations are
often needed to successfully complete the process of biomark-
er discovery and validation through multiple phases that re-
quire a diverse and orthogonal sets of expertise: biological,
analytical, statistical, clinical, ethical, and regulatory [456].
Inadequate attention to one ormore of these facets of biomark-
er development has led to failures in validation studies.
Specifically, past biomarker failures have been linked to poor
selection of patients, low-quality sample acquisition, process-
ing and storage, insufficient statistical power, lacking stan-
dards for biomarker profiling, and problems with reporting
and analysis [20, 21, 456, 457].
To address common problems in biomarker development,
various authors and organizations have devised sets of standards
and guidelines for study design and reporting. Some of the im-
portant resources that provide guidelines for phased biomarker
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development, study design, and reporting standards for proto-
cols and results include: guidelines for phased development of
biomarkers for early detection of cancer [307], guidelines for
case-control study design [305], validation steps for omics bio-
markers [304], the Biospecimen Reporting for Improved Study
Quality (BRISQ) [458], PRospective-specimen-collection,
retrospective-Blinded-Evaluation (PRoBE) [305], design strate-
gies for identification of predictive biomarkers [459], REporting
recommendations for tumor MARKer prognostic studies
(REMARK) [460], Consolidated Standards of Reporting Trials
(CONSORT) [461], and standards for reporting of diagnostic
accuracy (STARD) [462]. The National Biomarker
Development Alliance (NBDA) set forth to establish standards
and point out phases of the systems-based, end-to-end biomark-
er development that still need to be standardized [463]. Some
critical points along the biomarker development trajectory are
addressed below.
Many research and clinical ambiguities can be avoided by
establishing the clinical question early at the inception of the
biomarker research program [464]. This should be done by
consulting with clinicians and taking unmet clinical needs into
account (see the following subsection). Prespecifying the con-
text of use enables early and productive engagement with
regulatory bodies. Moreover, predetermined intended use of
the biomarker dictates the details of all downstream phases.
Specifically, it assures that patient selection, sample sources,
quality, and adequate size/number are relevant to the intended
clinical utility [299].
The importance of a large sample size is pronounced where
multi-omics data are analyzed for biomarker discovery—
small N leads to overfitting and false positives [463].
Equally important are independent confirmatory studies,
where independent training and blinded test sets can increase
confidence in the validity of a biomarker. In cases where bio-
markers are being developed for a cancer (sub)type with low
prevalence, it might be necessary to use biobanks and samples
from multiple research centers to reach requisite numbers for
validation. Furthermore, access to all clinical data is necessary
to rule out patient characteristics other than the disease state as
the source of biomarker level variation.
Prior to clinical validation, it is necessary to carry out the
analytical validation of the biomarker assay. The assurance of
the analytical validity of the test assay requires the use refer-
ence standards and can be assessed by measuring different
parameters: accuracy, trueness, precision, reproducibility, ro-
bustness, linearity, analytical sensitivity and specificity, the
limit of detection, and interfering substances. Notably, using
multiomics procedures necessitates adherence to strict quality
control standards [304, 463]. As the last step for ensuring the
validity of the assay, it is important to establish multi-site
assay precision and reproducibility. Adoption of FDA Good
Laboratory Practice [465] and CLIA laboratory proficiency
testing [466] can enhance analytical and statistical rigor.
Protocols for all pre-analytical (processing, handling, trans-
port, and storage), analytical (assay methods and instrumen-
tation) and post-analytical (statistical/computational pipeline
for data analysis and interpretation) procedures need to be
standardized and strictly defined (“locked down”) at this point
in order to mitigate reproducibility issues downstream [463].
Data collection, storage, and analysis algorithms are anoth-
er critical area where special care is necessary [463].
Increasingly complex multi-omics approaches require valida-
tion and application of new analytical and statistical ap-
proaches, the development of analytical standards, and robust
open-source classification algorithms. Collection, storage, and
sharing of high-quality data and metadata is important
throughout the development process. Importantly, data shar-
ing and publication of negative and contradictory results can
simplify investigation of reasons for biomarker failure.
Researchers need to adhere to data quality standards, use
established ontologies, vocabularies, minimum reporting stan-
dards, and utilize accepted exchange formats. FDA and NIH
jointly developed BEST (Biomarkers, EndpointS, and other
Tools) Resource [19] to facilitate this process.
Clinical validation of the biomarker requires careful study
design according to the intended use of the biomarker.
Prospective randomized trials are considered to be a gold
standard for biomarker validation; however, some cancer bio-
markers currently in use were validated using retrospective
analyses of clinical trials [459] (e.g., KRAS [467, 468] and
BRCA mutations [469]). Critically, statistical procedures and
threshold values for evaluating biomarker utility need to be
prespecified. Depending on the intended use, biomarker char-
acteristics will be estimated by receiver operating characteris-
tic (ROC) curve analysis, estimated as clinical sensitivity and
specificity, positive and negative predictive value (PPV and
NPV, respectively).
As the final goal of biomarker development, it is necessary
to establish clinical utility. In this phase, it is necessary to dem-
onstrate the improvement of patient outcomes through the use
of the biomarker (e.g., through overall or progression-free sur-
vival, mortality), show economical utility, and compare it to the
established biomarkers and the standard of care.
Even if the number of aforementioned aspects to take in
consideration for a successful translation of newly discov-
ered biomarkers in the clinic may seem overwhelming and
beyond the capacity of academic research, in our experience,
biomarker validation is an iterative process (Fig. 3). Each
iteration redefines the level of readiness of the liquid biopsy
technology. Through each “cycle” of validation, evidence is
accumulated on the clinical validity/utility of the biomarker,
before the ultimate decision can be made about the commer-
cialization of the assay. Noteworthy, reaching the market
does not mark the end of the process, because biomarker
performance needs to be monitored even after it has been
approved for commercialization [463].
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Towards Unmet Clinical Needs
Despite all the challenges, translational efforts in liquid biopsy
have resulted in validated and commercialized biomarkers,
some of which are already in clinical use (Table 1). In partic-
ular, diagnostic, prognostic, and predictive circulating bio-
marker options exist for lung, breast, colorectal, bladder, ovar-
ian, cervical, and prostate cancer. Additionally, the first chron-
ic myeloid leukemia liquid biopsy assay for monitoring treat-
ment response, QXDx AutoDG ddPCR System (Bio-Rad
Laboratories), received FDA clearance at the time of writing
this review. However, management of patients with solid tu-
mors like gastric, esophageal, liver, pancreatic, endometrial,
brain, thyroid, head and neck, melanoma, and renal cancers
still has no validated and established liquid biopsy
biomarkers.
Gastric (GC) and esophageal cancer are estimated to cause
death inmore than a 1.2 million people worldwide in 2019 [1].
There is an unmet need for diagnostic and prognostic liquid
biopsy biomarkers for these two types of cancer. However, all
available studies have been carried out in basic studies or
retrospective and prospective studies with small cohorts.
Hepatocellular carcinoma is another example of a common
and deadly cancer with an urgent need for liquid biopsy bio-
markers [470]. Many liver cancer patients are diagnosed at
late stage, where curative treatment is no longer an option.
Importantly, sorafenib, a drug used to treat advanced hepato-
cellular carcinoma, currently has no clinically validated bio-
markers for response prediction.
Similarly, pancreatic cancer, one of the most aggressive
tumors, is asymptomatic at an early stage and most diagnosis
are made at late stage where there are limited options for
treatment [471]. The established biomarker for pancreatic can-
cer, CA19-9, is not suitable for screening and diagnosis.
Moreover, pancreatic cancer has four different subtypes with
complex molecular signatures, which are impossible to re-
solve using current diagnostic procedures [471].
Another example is endometrial cancer, typically diag-
nosed at an early stage when it is treatable. However, about
20% of the cases are diagnosed at late stage where 5-year
survival is drastically lower [472]. Late stage endometrial can-
cer is treated with surgery, radiotherapy, and chemotherapy.
However, chemotherapy is less effective than with other can-
cers, and different cancer subtypes require different therapeu-
tic decisions, warranting development and validation of bio-
markers for monitoring recurrence and response to therapy
[472].
Perhaps the most compelling reason for development of
liquid biopsy biomarkers are tumors of the central nervous
system. Clinical decision-making, including monitoring re-
sponse to treatment, is heavily reliant of neuroimaging.
However, chemoradiation and antiangiogenic therapy can al-
ter contrast enhancement and confound imaging results by
affecting the permeability of the blood-brain barrier and the
tumor vasculature [473]. Furthermore, brain tumor tissue bi-
opsy carries significant risk for the patient, creating difficulties
for diagnosis, prediction, and prognosis. Thus, there is an
unmet clinical need for non-invasive liquid biopsy biomarkers
for brain tumors.
Precision and personalized medicine will benefit greatly
when analytical and clinical challenges affecting circulating
biomarker development are addressed. While it might take a
Fig. 3 The process of biomarker validation in practice. Biomarker
validation can be seen as an iterative process where the liquid biopsy
assay at an increasing level of analytical validation is tested for clinical
validity for an intended purpose and on a fit-for-purpose patient popula-
tion. The study design and an endpoint need to be predetermined, and
sample and clinical data collection need to be carried out in accordance
with clinical and biomarker development guidelines. Upon completion of
the study, assay performance characteristics need to be reported to requi-
site regulatory bodies. Upon enhancement of the analytical performance
all protocols need to be locked down and validated again
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long time before clinical validity and utility are demonstrated
for early detection, liquid biopsy biomarkers are becoming
crucial for patient stratification and therapy response predic-
tion. We believe that these trends will continue, and that liquid
biopsy will play an increasingly important role in personalized
cancer patient management in the future.
Acknowledgments The authors wish to acknowledge the following grant
support: Knut and Alice Wallenbergs Foundation (Dnr 2018.0266). The
authors would like to give acknowledgements to Professor Robert Langer
for inspiring our work in the field of cancer biology. His many contribu-
tions in the field of science and engineering, and in particular his demon-
strations on how science can be translated for use in the society, have
served as a great inspiration for us in our work. His mentoring and support
for our work related to cancer biomarkers is deeply appreciated.
Funding Information Open access funding provided by Chalmers
University of Technology.
Compliance with Ethical Standards
Conflict of Interest FG and JN are shareholders in Elypta AB.
Additionally, FG is employed at Elypta AB.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.
Global cancer statistics 2018: GLOBOCAN estimates of inci-
dence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/
caac.21492.
2. Chaffer CL, Weinberg RA. A perspective on cancer cell metasta-
sis. Science. 2011;331(6024):1559–64. https://doi.org/10.1126/
science.1203543.
3. Ahlquist DA. Universal cancer screening: revolutionary, rational,
and realizable. npj Precision Oncol. 2018;2(1). https://doi.org/10.
1038/s41698-018-0066-x.
4. Schiffman JD, Fisher PG, Gibbs P. Early detection of cancer: past,
present, and future. Am Soc Clin Oncol Educ Book. 2015:57–65.
https://doi.org/10.14694/EdBook_AM.2015.35.57.
5. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogene-
ity in the clinic. Nature. 2013;501(7467):355–64. https://doi.org/
10.1038/nature12627.
6. Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C.
Translational implications of tumor heterogeneity. Clin Cancer
Res. 2015;21(6):1258–66. https://doi.org/10.1158/1078-0432.
Ccr-14-1429.
7. Stewart E, McEvoy J, Wang H, Chen X, Honnell V, Ocarz M,
et al. Identification of therapeutic targets in rhabdomyosarcoma
through integrated genomic, epigenomic, and proteomic analyses.
Cancer Cell. 2018;34(3):411–26.e19. https://doi.org/10.1016/j.
ccell.2018.07.012.
8. Yu KH, Snyder M. Omics profiling in precision oncology. Mol
Cell Proteomics. 2016;15(8):2525–36. https://doi.org/10.1074/
mcp.O116.059253.
9. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D,
Gronroos E, et al. Intratumor heterogeneity and branched evolu-
tion revealed by multiregion sequencing. New Engl J Med.
2012;366(10):883–92. https://doi.org/10.1056/NEJMoa1113205.
10. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al.
Acquired resistance and clonal evolution in melanoma during
BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80–93.
https://doi.org/10.1158/2159-8290.CD-13-0642.
11. Johnson BE,Mazor T, Hong C, BarnesM, Aihara K, McLean CY,
et al. Mutational analysis reveals the origin and therapy-driven
evolution of recurrent glioma. Science. 2014;343(6167):189–93.
https://doi.org/10.1126/science.1239947.
12. Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G,
Van Loo P, et al. Subclonal diversification of primary breast cancer
revealed by multiregion sequencing. Nat Med. 2015;21(7):751–9.
https://doi.org/10.1038/nm.3886.
13. Duffy MJ. Role of tumor markers in patients with solid cancers: a
critical review. Eur J Intern Med. 2007;18(3):175–84. https://doi.
org/10.1016/j.ejim.2006.12.001.
14. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid
biopsies into the management of cancer. Nat Rev Clin Oncol.
2017. https://doi.org/10.1038/nrclinonc.2017.14.
15. Bardelli A, Pantel K. Liquid biopsies, what we do not know (Yet).
Cancer Cell. 2017;31(2):172–9. https://doi.org/10.1016/j.ccell.
2017.01.002.
16. Marrugo-Ramirez J, Mir M, Samitier J. Blood-based cancer bio-
markers in liquid biopsy: a promising non-invasive alternative to
tissue biopsy. Int J Mol Sci. 2018;19(10):E2877. https://doi.org/
10.3390/ijms19102877.
17. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and
future perspectives of liquid biopsies in genomics-driven oncolo-
gy. Nat Rev Genet. 2019;20(2):71–88. https://doi.org/10.1038/
s41576-018-0071-5.
18. Nielsen J. Systems biology of metabolism: a driver for developing
personalized and precision medicine. Cell Metab. 2017;25(3):
572–9. https://doi.org/10.1016/j.cmet.2017.02.002.
19. FDA-NIH Biomarker Working Group. BEST (biomarkers, end-
points, and other tools) resource [Internet]. BEST (Biomarkers,
EndpointS, and other Tools) Resource. Silver Spring (MD) 2016.
20. Diamandis EP. Cancer biomarkers: can we turn recent failures into
success? J Natl Cancer I. 2010;102(19):1462–7. https://doi.org/10.
1093/jnci/djq306.
21. Ioannidis JP. Biomarker failures. Clin Chem. 2013;59(1):202–4.
https://doi.org/10.1373/clinchem.2012.185801.
22. Sturgeon C, Hill R, Hortin GL, Thompson D. Taking a new bio-
marker into routine use - a perspective from the routine clinical
biochemistry laboratory. Proteomics Clin Appl. 2010;4(12):892–
903. https://doi.org/10.1002/prca.201000073.
23. Bossuyt PMM. Clinical validity: defining biomarker performance.
Scand J Clin Lab Invest. 2010;70:46–52. https://doi.org/10.3109/
00365513.2010.493383.
24. Pletcher MJ, Pignone M. Evaluating the clinical utility of a bio-
marker a review of methods for estimating health impact.
Circulation. 2011;123(10):1116–U261. https://doi.org/10.1161/
Circulationaha.110.943860.
25. Prasad V, Kaestner V, Mailankody S. Cancer drugs approved
based on biomarkers and not tumor type-FDA approval of
pembrolizumab for mismatch repair-deficient solid cancers.
JAMA Oncol. 2018;4(2):157–8. https://doi.org/10.1001/
jamaoncol.2017.4182.
26. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE,
Hopper JL, et al. Average risks of breast and ovarian cancer asso-
ciated with BRCA1 or BRCA2 mutations detected in case series
Regen. Eng. Transl. Med. (2021) 7:312–352 337
unselected for family history: a combined analysis of 22 studies.
Am J Hum Genet. 2003;72(5):1117–30. https://doi.org/10.1086/
375033.
27. Ross JS, Cronin M. Whole cancer genome sequencing by next-
generation methods. Am J Clin Pathol. 2011;136(4):527–39.
https://doi.org/10.1309/Ajcpr1svt1vhugxw.
28. Hayden EC. Technology: The $1,000 genome. Nature.
2014;507(7492):294–5. https://doi.org/10.1038/507294a.
29. Plothner M, Frank M, von der Schulenburg JG. Cost analysis of
whole genome sequencing in German clinical practice. Eur J
Health Econ. 2017;18(5):623–33. https://doi.org/10.1007/
s10198-016-0815-0.
30. Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-
exome and whole-genome sequencing approaches cost-effective?
A systematic review of the literature. Genet Med. 2018;20(10):
1122–30. https://doi.org/10.1038/gim.2017.247.
31. Aravanis AM, Lee M, Klausner RD. Next-generation sequencing
of circulating tumor DNA for early cancer detection. Cell.
2017;168(4):571–4. https://doi.org/10.1016/j.cell.2017.01.030.
32. Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu
FC, et al. Circulating nucleic acids are associated with outcomes of
patients with pancreatic cancer. Gastroenterology. 2019;156(1):
108–18.e4. https://doi.org/10.1053/j.gastro.2018.09.022.
33. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M,
et al. Circulating mutant DNA to assess tumor dynamics. Nat
Med. 2008;14(9):985–90. https://doi.org/10.1038/nm.1789.
34. Volckmar AL, SultmannH, Riediger A, Fioretos T, Schirmacher P,
Endris V, et al. A field guide for cancer diagnostics using cell-free
DNA: from principles to practice and clinical applications. Genes
Chromosom Cancer. 2018;57(3):123–39. https://doi.org/10.1002/
gcc.22517.
35. Ossandon MR, Agrawal L, Bernhard EJ, Conley BA, Dey SM,
Divi RL, et al. Circulating tumor DNA assays in clinical cancer
research. Jnci-J Natl Cancer I. 2018;110(9):929–34. https://doi.
org/10.1093/jnci/djy105.
36. Bettegowda C, SausenM, Leary RJ, Kinde I,WangY, Agrawal N,
et al. Detection of circulating tumor DNA in early- and late-stage
human malignancies. Sci Transl Med. 2014;6(224):224ra24.
https://doi.org/10.1126/scitranslmed.3007094.
37. Kahlert C, Melo SA, Protopopov A, Tang JB, Seth S, Koch M,
et al. Identification of double-stranded genomic DNA spanning all
chromosomes with mutated KRAS and p53 DNA in the serum
exosomes of patients with pancreatic cancer. J Biol Chem.
2014;289(7):3869–75. https://doi.org/10.1074/jbc.C113.532267.
38. Cheng THT, Jiang PY, Tam JCW, Sun X, Lee WS, Yu SCY, et al.
Genomewide bisulfite sequencing reveals the origin and time-
dependent fragmentation of urinary cfDNA. Clin Biochem.
2017;50(9):496–501. https://doi.org/10.1016/j.clinbiochem.2017.
02.017.
39. Katseli A, Maragos H, Nezos A, Syrigos K, Koutsilieris M.
Multiplex PCR-based detection of circulating tumor cells in lung
cancer patients using CK19, PTHrP, and LUNX specific primers.
Clinical Lung Cancer. 2013;14(5):513–20. https://doi.org/10.
1016/j.cllc.2013.04.007.
40. Jenkins S, Yang JCH, Ramalingam SS, Yu K, Patel S, Weston S,
et al. Plasma ctDNA Analysis for detection of the EGFR T790 M
mutation in patients with advanced non-small cell lung cancer. J
Thorac Oncol. 2017;12(7):1061–70. https://doi.org/10.1016/j.
jtho.2017.04.003.
41. Reck M, Hagiwara K, Han BH, Tjulandin S, Grohe C, Yokoi T,
et al. ctDNA Determination of EGFRmutation status in European
and Japanese patients with advanced NSCLC: the ASSESS study.
J Thorac Oncol. 2016;11(10):1682–9. https://doi.org/10.1016/j.
jtho.2016.05.036.
42. cobas EGFR Mutation Test v2. https://www.fda.gov/Drugs/
InformationOnDrugs/ApprovedDrugs/ucm504540.htm.
Accessed 05 Feb 2019
43. Wu YL, Lee V, Liam CK, Lu S, Park K, Srimuninnimit V, et al.
Clinical utility of a blood-based EGFR mutation test in patients
receiving first-line erlotinib therapy in the ENSURE, FASTACT-
2, andASPIRATION studies. LungCancer. 2018;126:1–8. https://
doi.org/10.1016/j.lungcan.2018.10.004.
44. Fassunke J, Ihle MA, Lenze D, Lehmann A, Hummel M,
Vollbrecht C, et al. EGFR T790 M mutation testing of non-small
cell lung cancer tissue and blood samples artificially spiked with
circulating cell-free tumor DNA: results of a round robin trial.
Virchows Arch. 2017;471(4):509–20. https://doi.org/10.1007/
s00428-017-2226-8.
45. WuYL, Zhou C, LiamCK,WuG, Liu X, Zhong Z, et al. First-line
erlotinib versus gemcitabine/cisplatin in patients with advanced
EGFR mutation-positive non-small-cell lung cancer: analyses
from the phase III, randomized, open-label ENSURE study. Ann
Oncol. 2015;26(9):1883–9. https://doi.org/10.1093/annonc/
mdv270.
46. Abbosh C, Birkbak NJ,Wilson GA, Jamal-Hanjani M, Constantin
T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage
lung cancer evolution. Nature. 2017;545(7655):446–51. https://
doi.org/10.1038/nature22364.
47. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ,
Makarewicz AJ, et al. High-throughput droplet digital PCR sys-
tem for absolute quantitation of DNA copy number. Anal Chem.
2011;83(22):8604–10. https://doi.org/10.1021/ac202028g.
48. Diehl F, Li M, Dressman D, He YP, Shen D, Szabo S, et al.
Detection and quantification of mutations in the plasma of patients
with colorectal tumors. P Natl Acad Sci USA. 2005;102(45):
16368–73. https://doi.org/10.1073/pnas.0507904102.
49. Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN,
Shuber AP, et al. Analysis of mutations in DNA isolated from
plasma and stool of colorectal cancer patients. Gastroenterology.
2008;135(2):489–98. https://doi.org/10.1053/j.gastro.2008.05.
039.
50. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig
D, et al. Detection of chromosomal alterations in the circulation of
cancer patients with whole-genome sequencing. Sci Transl Med.
2012;4(162):162ra154. https://doi.org/10.1126/scitranslmed.
3004742.
51. Forshew T,MurtazaM, Parkinson C, Gale D, Tsui DWY, Kaper F,
et al. Noninvasive identification and monitoring of cancer muta-
tions by targeted deep sequencing of plasma DNA. Sci Transl
Med. 2012;4(136):136ra68. https://doi.org/10.1126/scitranslmed.
3003726.
52. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B.
Detection and quantification of rare mutations with massively
parallel sequencing. P Natl Acad Sci USA. 2011;108(23):9530–
5. https://doi.org/10.1073/pnas.1105422108.
53. Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin
LA, et al. An ultrasensitive method for quantitating circulating
tumor DNA with broad patient coverage. Nat Med. 2014;20(5):
552–8. https://doi.org/10.1038/nm.3519.
54. Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ,
Scherer F, et al. Integrated digital error suppression for improved
detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):
547–55. https://doi.org/10.1038/nbt.3520.
55. Gyanchandani R, Kvam E, Heller R, Finehout E, Smith N, Kota
K, et al. Whole genome amplification of cell-free DNA enables
detection of circulating tumor DNA mutations from fingerstick
capillary blood. Sci Rep. 2018;8:17313. https://doi.org/10.1038/
s41598-018-35470-9.
56. Murtaza M, Dawson SJ, Tsui DWY, Gale D, Forshew T, Piskorz
AM, et al. Non-invasive analysis of acquired resistance to cancer
338 Regen. Eng. Transl. Med. (2021) 7:312–352
therapy by sequencing of plasma DNA. Nature. 2013;497(7447):
108–12. https://doi.org/10.1038/nature12065.
57. Suzuki A, Suzuki M, Mizushima-Sugano J, Frith MC,
Makalowski W, Kohno T, et al. Sequencing and phasing cancer
mutations in lung cancers using a long-read portable sequencer.
DNA Res. 2017;24(6):585–96. https://doi.org/10.1093/dnares/
dsx027.
58. Gong L, Wong CH, Cheng WC, Tjong H, Menghi F, Ngan CY,
et al. Picky comprehensively detects high-resolution structural
variants in nanopore long reads. Nat Methods. 2018;15(6):455–
60. https://doi.org/10.1038/s41592-018-0002-6.
59. Jain M, Olsen HE, Paten B, Akeson M. The Oxford nanopore
MinION: delivery of nanopore sequencing to the genomics com-
munity (vol 17, 239, 2016). Genome Biol. 2016;17:256. https://
doi.org/10.1186/s13059-016-1122-x.
60. Flusberg BA, Webster DR, Lee JH, Travers KJ, Olivares EC,
Clark TA, et al. Direct detection of DNA methylation during sin-
gle-molecule, real-time sequencing. NatMethods. 2010;7(6):461–
U72. https://doi.org/10.1038/Nmeth.1459.
61. Ardui S, Ameur A, Vermeesch JR, Hestand MS. Single molecule
real-time (SMRT) sequencing comes of age: applications and util-
ities for medical diagnostics. Nucleic Acids Res. 2018;46(5):
2159–68. https://doi.org/10.1093/narlgkx066.
62. Eid J, Fehr A, Gray J, Luong K, Lyle J, Otto G, et al. Real-Time
DNA Sequencing from single polymerase molecules. Science.
2009;323(5910):133–8. https://doi.org/10.1126/science.1162986.
63. van Dijk EL, Jaszczyszyn Y, Naquin D, Thermes C. The third
revolution in sequencing technology. Trends Genet. 2018;34(9):
666–81. https://doi.org/10.1016/j.tig.2018.05.008.
64. Russo G, Patrignani A, Poveda L, Hoehn F, Scholtka B,
Schlapbach R, et al. Highly sensitive, non-invasive detection of
colorectal cancer mutations using single molecule, third genera-
tion sequencing. Appl Transl Genom. 2015;7:32–9. https://doi.
org/10.1016/j.atg.2015.08.006.
65. Clarke J, Wu HC, Jayasinghe L, Patel A, Reid S, Bayley H.
Continuous base identification for single-molecule nanopore
DNA sequencing. Nat Nanotechnol. 2009;4(4):265–70. https://
doi.org/10.1038/Nnano.2009.12.
66. Madoui MA, Engelen S, Cruaud C, Belser C, Bertrand L, Alberti
A, et al. Genome assembly using nanopore-guided long and error-
free DNA reads. BMC Genomics. 2015;16:327. https://doi.org/
10.1186/s12864-015-1519-z.
67. Jain M, Tyson JR, Loose M, CLC I, Eccles DA, O’Grady J, et al.
MinION analysis and reference consortium: phase 2 data release
and analysis of R9.0 chemistry. F1000Res. 2017;6:760. https://
doi.org/10.12688/f1000research.11354.1.
68. Mantere T, Kersten S, Hoischen A. Long-read sequencing emerg-
ing in medical genetics. Front Genet. 2019;10:426. https://doi.org/
10.3389/fgene.2019.00426.
69. Teng HT, Cao MD, Hall MB, Duarte T, Wang S, Coin LJM.
Chiron: translating nanopore raw signal directly into nucleotide
sequence using deep learning. Gigascience. 2018;7(5). https://doi.
org/10.1093/gigascience/giy037.
70. Wenger AM, Peluso P, Rowell WJ, Chang P-C, Hall RJ,
Concepcion GT et al. Highly-accurate long-read sequencing im-
proves variant detection and assembly of a human genome.
bioRxiv. 2019:519025. https://doi.org/10.1101/519025.
71. Tie J, Wang YX, Tomasetti C, Li L, Springer S, Kinde I et al.
Circulating tumor DNA analysis detects minimal residual disease
and predicts recurrence in patients with stage II colon cancer. Sci
Transl Med. 2016;8(346). https://doi.org/10.1126/scitranslmed.
aaf6219.
72. Reinert T, Scholer LV, Thomsen R, Tobiasen H, Vang SR,
Nordentoft I, et al. Analysis of circulating tumour DNA to mon-
itor disease burden following colorectal cancer surgery. Gut.
2016;65(4):625–34. https://doi.org/10.1136/gutjnl-2014-308859.
73. Scholer LV, Reinert T, Orntoft MBW, Kassentoft CG, Arnadottir
SS, Vang S, et al. Clinical implications of monitoring circulating
tumor DNA in patients with colorectal cancer. Clin Cancer Res.
2017;23(18):5437–45. https://doi.org/10.1158/1078-0432.Ccr-
17-0510.
74. Olsson E,Winter C, George A, Chen Y, Howlin J, TangMH, et al.
Serial monitoring of circulating tumor DNA in patients with pri-
mary breast cancer for detection of occult metastatic disease.
EMBO Mol Med. 2015;7(8):1034–47. https://doi.org/10.15252/
emmm.201404913.
75. TCGA Research Network. The Cancer Genome Atlas. http://
cancergenome.nih.gov/. Accessed Feb 22 2019
76. Ashworth TR. A case of cancer in which cells similar to those in
the tumors were seen in the blood after death. Australas Med J.
1869;14:146–9.
77. Cima I, Kong SL, Sengupta D, Tan IB, Phyo WM, Lee D, et al.
Tumor-derived circulating endothelial cell clusters in colorectal
cancer. Sci Transl Med. 2016;8(345):345ra89. https://doi.org/10.
1126/scitranslmed.aad7369.
78. Alix-Panabieres C, Pantel K. Clinical applications of circulating
tumor cells and circulating tumor DNA as liquid biopsy. Cancer
Discov. 2016;6(5):479–91. https://doi.org/10.1158/2159-8290.
Cd-15-1483.
79. Chen LC, Bode AM, Dong ZG. Circulating tumor cells: moving
biological insights into detection. Theranostics. 2017;7(10):2606–
19. https://doi.org/10.7150/thno.18588.
80. RhimAD,Mirek ET, Aiello NM,Maitra A, Bailey JM,McAllister
F, et al. EMT and dissemination precede pancreatic tumor forma-
tion. Cell. 2012;148(1-2):349–61. https://doi.org/10.1016/j.cell.
2011.11.025.
81. Camara O, Kavallaris A, Noschel H, Rengsberger M, Jorke C,
Pachmann K. Seeding of epithelial cells into circulation during
surgery for breast cancer: the fate of malignant and benign mobi-
lized cells. World J Surg Oncol. 2006;4:67. https://doi.org/10.
1186/1477-7819-4-67.
82. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao
C, et al. Tumor cells circulate in the peripheral blood of all major
carcinomas but not in healthy subjects or patients with nonmalig-
nant diseases. Clin Cancer Res. 2004;10(20):6897–904. https://
doi.org/10.1158/1078-0432.Ccr-04-0378.
83. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, et al.
Isolation and characterization of circulating tumor cells from pa-
tients with localized and metastatic prostate cancer. Sci Transl
Med. 2010;2(25):25ra23. https://doi.org/10.1126/scitranslmed.
3000403.
84. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller
MC, et al. Circulating tumor cells, disease progression, and sur-
vival in metastatic breast cancer. New Engl J Med. 2004;351(8):
781–91. https://doi.org/10.1056/NEJMoa040766.
85. Lu SH, Tsai WS, Chang YH, Chou TY, Pang ST, Lin PH, et al.
Identifying cancer origin using circulating tumor cells. Cancer
Biol Ther. 2016;17(4):430–8. https://doi.org/10.1080/15384047.
2016.1141839.
86. Hou Y, Guo HH, Cao C, Li XL, Hu BQ, Zhu P, et al. Single-cell
triple omics sequencing reveals genetic, epigenetic, and
transcriptomic heterogeneity in hepatocellular carcinomas. Cell
Res. 2016;26(3):304–19. https://doi.org/10.1038/cr.2016.23.
87. D'Avola D, Villacorta-Martin C, Martins SN, Craig A, Labgaa I,
von Felden J, et al. High-density single cell mRNA sequencing to
characterize circulating tumor cells in hepatocellular carcinoma.
Sci Rep. 2018;8. https://doi.org/10.1038/s41598-018-30047-y.
88. Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell
research. Nat Rev Cancer. 2014;14(9):623–31. https://doi.org/10.
1038/nrc3820.
89. Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii
H, et al. Plastin3 Is a novel marker for circulating tumor cells
Regen. Eng. Transl. Med. (2021) 7:312–352 339
undergoing the epithelial-mesenchymal transition and is associat-
ed with colorectal cancer prognosis. Cancer Res. 2013;73(7):
2059–69. https://doi.org/10.1158/0008-5472.Can-12-0326.
90. Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-
Miller J, et al. A novel platform for detection of CK+ and CK-
CTCs. Cancer Discov. 2011;1(7):580–6. https://doi.org/10.1158/
2159-8290.Cd-11-0215.
91. Vona G, Sabile A, LouhaM, Sitruk V, Romana S, Schutze K, et al.
Isolation by size of epithelial tumor cells - a new method for the
immunomorphological and molecular characterization of circulat-
ing tumor cells. Am J Pathol. 2000;156(1):57–63. https://doi.org/
10.1016/S0002-9440(10)64706-2.
92. Sollier E, Go DE, Che J, Gossett DR, O'Byrne S, Weaver WM,
et al. Size-selective collection of circulating tumor cells using
Vortex technology. Lab Chip. 2014;14(1):63–77. https://doi.org/
10.1039/c3lc50689d.
93. Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A,
et al. Molecular profiling of single circulating tumor cells with
diagnostic intention. Embo Mol Med. 2014;6(11):1371–86.
https://doi.org/10.15252/emmm.201404033.
94. Shim S, Stemke-Hale K, Tsimberidou AM, Noshari J, Anderson
TE, Gascoyne PRC. Antibody-independent isolation of circulat-
ing tumor cells by continuous-flow dielectrophoresis.
Biomicrofluidics. 2013;7(1):011807. https://doi.org/10.1063/1.
4774304.
95. Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, et al.
Subclassification of prostate cancer circulating tumor cells by nu-
clear size reveals very small nuclear circulating tumor cells in
patients with visceral metastases. Cancer. 2015;121(18):3240–
51. https://doi.org/10.1002/cncr.29455.
96. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller
MC, et al. Circulating tumor cells at each follow-up time point
during therapy of metastatic breast cancer patients predict
progression-free and overall survival. Clin Cancer Res.
2006;12(14):4218–24. https://doi.org/10.1158/1078-0432.Ccr-
05-2821.
97. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD,
Gabrail NY, et al. Relationship of circulating tumor cells to tumor
response, progression-free survival, and overall survival in pa-
tients with metastatic colorectal cancer. J Clin Oncol.
2008;26(19):3213–21. https://doi.org/10.1200/Jco.2007.15.8923.
98. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand
A, Tanaka E, et al. Circulating tumor cell number and prognosis in
progressive castration-resistant prostate cancer. Clin Cancer Res.
2007;13(23):7053–8. https://doi.org/10.1158/1078-0432.CCR-
07-1506.
99. Liu HE, Triboulet M, Zia A, Vuppalapaty M, Kidess-Sigal E,
Coller J, et al. Workflow optimization of whole genome amplifi-
cation and targeted panel sequencing for CTC mutation detection.
Npj GenomMed. 2017;2:34. https://doi.org/10.1038/s41525-017-
0034-3.
100. Zhu ZY, Qiu S, Shao K, Hou Y. Progress and challenges of se-
quencing and analyzing circulating tumor cells. Cell Biol Toxicol.
2018;34(5):405–15. https://doi.org/10.1007/s10565-017-9418-5.
101. Ni XH, Zhuo ML, Su Z, Duan JC, Gao Y, Wang ZJ, et al.
Reproducible copy number variation patterns among single circu-
lating tumor cells of lung cancer patients. P Natl Acad Sci USA.
2013;110(52):21083–8. https://doi.org/10.1073/pnas.
1320659110.
102. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM,
et al. Complex tumor genomes inferred from single circulating
tumor cells by array-CGH and next-generation sequencing.
Cancer Res. 2013;73(10):2965–75. https://doi.org/10.1158/0008-
5472.Can-12-4140.
103. Gulbahce N, Magbanua MJM, Chin R, Agarwal MR, Luo XH,
Liu J, et al. Quantitative whole genome sequencing of circulating
tumor cells enables personalized combination therapy of metasta-
tic cancer. Cancer Res. 2017;77(16):4530–41. https://doi.org/10.
1158/0008-5472.Can-17-0688.
104. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD,
Rosenberg M, Cruz-Gordillo P, et al. Whole-exome sequencing
of circulating tumor cells provides a window into metastatic pros-
tate cancer. Nat Biotechnol. 2014;32(5):479–84. https://doi.org/
10.1038/nbt.2892.
105. Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E,
Voutsina A, et al. ESR1 methylation: a liquid biopsy-based epige-
netic assay for the follow-up of patients with metastatic breast
cancer receiving endocrine treatment. Clin Cancer Res.
2018;24(6):1500–10. https://doi.org/10.1158/1078-0432.Ccr-17-
1181.
106. Pixberg CF, RabaK,Muller F, Behrens B, Honisch E, Niederacher
D, et al. Analysis of DNA methylation in single circulating tumor
cells. Oncogene. 2017;36(23):3223–31. https://doi.org/10.1038/
onc.2016.480.
107. Ramskold D, Luo SJ, Wang YC, Li R, Deng QL, Faridani OR,
et al. Full-length mRNA-Seq from single-cell levels of RNA and
individual circulating tumor cells. Nat Biotechnol. 2012;30(8):
777–82. https://doi.org/10.1038/nbt.2282.
108. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, et al.
RNA sequencing of pancreatic circulating tumour cells implicates
WNT signalling in metastasis. Nature. 2012;487(7408):510–
U130. https://doi.org/10.1038/nature11217.
109. Lang JE, RingA, Porras T, Kaur P, Forte V, TripathyD, et al. RNA
Seq of circulating tumor cells in stage II-III breast cancer. Ann
Surg Oncol. 2018;25(8):2261–70.
110. Hughes AJ, Herr AE. Microfluidic Western blotting. P Natl Acad
Sci USA. 2012;109(52):21450–5. https://doi.org/10.1073/pnas.
1207754110.
111. Sinkala E, Sollier-Christen E, Renier C, Rosas-Canyelles E, Che J,
Heirich K, et al. Profiling protein expression in circulating tumour
cells using microfluidic western blotting. Nat Commun. 2017;8:
14622. https://doi.org/10.1038/ncomms14622.
112. Deng YL, Zhang Y, Sun S, Wang ZH,WangMJ, Yu BQ, et al. An
integrated microfluidic chip system for single-cell secretion pro-
filing of rare circulating tumor cells. Sci Rep. 2014;4. https://doi.
org/10.1038/srep07499.
113. Zhang Y, Tang Y, Sun S, Wang ZH, Wu WJ, Zhao XD, et al.
Single-cell codetection of metabolic activity, intracellular func-
tional proteins, and genetic mutations from rare circulating tumor
cells. Anal Chem. 2015;87(19):9761–8. https://doi.org/10.1021/
acs.analchem.5b01901.
114. de Wit S, van Dalum G, Lenferink ATM, Tibbe AGJ, Hiltermann
TJN, Groen HJM, et al. The detection of EpCAM(+) and
EpCAM(-) circulating tumor cells. Sci Rep. 2015;5:12270.
https://doi.org/10.1038/srep12270.
115. Miller MC, Doyle GV, Terstappen LW. Significance of circulating
tumor cells detected by the cellsearch system in patients with met-
astatic breast colorectal and prostate cancer. J Oncol. 2010;2010:
617421. https://doi.org/10.1155/2010/617421.
116. Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY,
et al. Circulating tumor cells: clinical validity and utility. Int J Clin
Oncol. 2017;22(3):421–30. https://doi.org/10.1007/s10147-017-
1105-2.
117. Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E,
et al. HER2 status of circulating tumor cells in patients with met-
astatic breast cancer: a prospective, multicenter trial. Breast Cancer
Res Tr. 2010;124(2):403–12. https://doi.org/10.1007/s10549-010-
1163-x.
118. Helissey C, Berger F, Cottu P, Dieras V, Mignot L, Servois V, et al.
Circulating tumor cell thresholds and survival scores in advanced
metastatic breast cancer: the observational step of the CirCe01
340 Regen. Eng. Transl. Med. (2021) 7:312–352
phase III trial. Cancer Lett. 2015;360(2):213–8. https://doi.org/10.
1016/j.canlet.2015.02.010.
119. Niculescu-Duvaz I. Trastuzumab emtansine, an antibody-drug
conjugate for the treatment of HER2 + metastatic breast cancer.
Curr Opin Mol Ther. 2010;12(3):350–60.
120. Berger F, Bidard FC, Pierga JY, Sablin MP, Cottu P, Neffati S et al.
117PAnti-HER2 therapy efficacy in HER2-negative metastatic
breast cancer with HER2-amplified circulating tumor cells: results
of the CirCe T-DM1 trial. Annals of Oncology. 2017;28(suppl_5).
https://doi.org/10.1093/annonc/mdx363.033.
121. Tsai WS, Chen JS, Shao HJ, Wu JC, Lai JM, Lu SH, et al.
Circulating tumor cell count correlates with colorectal neoplasm
progression and is a prognostic marker for distant metastasis in
non-metastatic patients. Sci Rep. 2016;6:24517. https://doi.org/
10.1038/srep24517.
122. Scher HI, Lu D, Schreiber NA. Association of AR-V7 on circu-
lating tumor cells as a treatment-specific biomarker with outcomes
and survival in castration-resistant prostate cancer. Jama
Oncology. 2016;2(11):1441–9.
123. Scher HI, Graf RP, Schreiber NA, McLaughlin B, Lu D, Louw J,
et al. Nuclear-specific AR-V7 protein localization is necessary to
guide treatment selection in metastatic castration-resistant prostate
cancer. Eur Urol. 2017;71(6):874–82. https://doi.org/10.1016/j.
eururo.2016.11.024.
124. Scher HI, Graf RP, Schreiber NA, Winquist E, McLaughlin B, Lu
D, et al. Validation of nuclear-localized AR-V7 on circulating
tumor cells (CTC) as a treatment-selection biomarker for manag-
ingmetastatic castration-resistant prostate cancer (mCRPC). J Clin
Oncol. 2018;36(6):273. https://doi.org/10.1200/JCO.2018.36.6_
suppl.273.
125. Dawson MA. The cancer epigenome: concepts, challenges, and
therapeutic opportunities. Science. 2017;355(6330):1147–52.
https://doi.org/10.1126/science.aam7304.
126. Ushijima T. Innovation - Detection and interpretation of altered
methylation patterns in cancer cells. Nat Rev Cancer. 2005;5(3):
223–31. https://doi.org/10.1038/nrc1571.
127. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD,
Chen WD, et al. Epigenetic inactivation of SFRP genes allows
constitutive WNT signaling in colorectal cancer. Nat Genet.
2004;36(4):417–22. https://doi.org/10.1038/ng1330.
128. Chen WY, Zeng XB, Carter MG, Morrell CN, Yen RWC, Esteller
M, et al. Heterozygous disruption of Hic1 predisposes mice to a
gender-dependent spectrum of malignant tumors. Nat Genet.
2003;33(2):197–202. https://doi.org/10.1038/ng1077.
129. Chan KCA, Jiang PY, Chan CWM, Sun K, Wong J, Hui EP, et al.
Noninvasive detection of cancer-associated genome-wide hypo-
methylation and copy number aberrations by plasma DNA bisul-
fite sequencing. P Natl Acad Sci USA. 2013;110(47):18761–8.
https://doi.org/10.1073/pnas.1313995110.
130. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes
of some human cancers from their normal counterparts. Nature.
1983;301(5895):89–92. https://doi.org/10.1038/301089a0.
131. Ross JP, Rand KN, Molloy PL. Hypomethylation of repeated
DNA sequences in cancer. Epigenomics. 2010;2(2):245–69.
https://doi.org/10.2217/Epi.10.2.
132. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal insta-
bility and tumors promoted by DNA hypomethylation. Science.
2003;300(5618):455. https://doi.org/10.1126/science.1083557.
133. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C,
Giagounidis A, et al. Efficacy of azacitidine compared with that of
conventional care regimens in the treatment of higher-risk
myelodysplastic syndromes: a randomised, open-label, phase III
study. Lancet Oncol. 2009;10(3):223–32. https://doi.org/10.1016/
S1470-2045(09)70003-8.
134. Lubbert M, Suciu S, Hagemeijer A, Ruter B, Platzbecker U,
Giagounidis A, et al. Decitabine improves progression-free
survival in older high-risk MDS patients with multiple autosomal
monosomies: results of a subgroup analysis of the randomized
phase III study 06011 of the EORTC Leukemia Cooperative
Group and German MDS Study Group. Ann Hematol.
2016;95(2):191–9. https://doi.org/10.1007/s00277-015-2547-0.
135. San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos
MA, Elghandour A, et al. Panobinostat plus bortezomib and dexa-
methasone versus placebo plus bortezomib and dexamethasone in
patients with relapsed or relapsed and refractory multiple myelo-
ma: a multicentre, randomised, double-blind phase 3 trial. Lancet
Oncol. 2014;15(11):1195–206. https://doi.org/10.1016/S1470-
2045(14)70440-1.
136. Fardi M, Solali S, Hagh MF. Epigenetic mechanisms as a new
approach in cancer treatment: an updated review. Genes Dis.
2018;5(4):304–11. https://doi.org/10.1016/j.gendis.2018.06.003.
137. Hao XK, Luo HY, KrawczykM,WeiW,WangWQ,Wang J, et al.
DNA methylation markers for diagnosis and prognosis of com-
mon cancers. P Natl Acad Sci USA. 2017;114(28):7414–9. https://
doi.org/10.1073/pnas.1703577114.
138. Wong IHN, LoYMD, Zhang J, Liew CT, NgMHL,WongN, et al.
Detection of aberrant p16 methylation in the plasma and serum of
liver cancer patients. Cancer Res. 1999;59(1):71–3.
139. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA
in plasma or serum as biomarker of carcinogenesis: practical as-
pects and biological significance. Mutat Res-Rev Mutat.
2007;635(2-3):105–17. https://doi.org/10.1016/j.mrrev.2006.11.
002.
140. Zhai RH, Zhao Y, Su L, Cassidy L, Liu G, Christiani DC.
Genome-wide DNA methylation profiling of cell-free serum
DNA in esophageal adenocarcinoma and Barrett esophagus.
Neoplasia. 2012;14(1):29–U39. https://doi.org/10.1593/neo.
111626.
141. Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-
Moussavi A, et al. Integrative analysis of 111 reference human
epigenomes. Nature. 2015;518(7539):317–30. https://doi.org/10.
1038/nature14248.
142. Sun K, Jiang PY, Chan KCA, Wong J, Cheng YKY, Liang RHS,
et al. Plasma DNA tissue mapping by genome-wide methylation
sequencing for noninvasive prenatal, cancer, and transplantation
assessments. P Natl Acad Sci USA. 2015;112(40):E5503–E12.
https://doi.org/10.1073/pnas.1508736112.
143. Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach
A, et al. Comprehensive human cell-type methylation atlas reveals
origins of circulating cell-free DNA in health and disease. Nat
Commun. 2018;9(1):5068. https://doi.org/10.1038/s41467-018-
07466-6.
144. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E,
Van Criekinge W, et al. Quantitative methylation-specific poly-
merase chain reaction gene patterns in urine sediment distinguish
prostate cancer patients from control subjects. J Clin Oncol.
2005;23(27):6569–75. https://doi.org/10.1200/Jco.2005.07.009.
145. Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou
ES. SOX17 Promoter methylation in circulating tumor cells and
matched cell-free DNA isolated from plasma of patients with
breast cancer. Clin Chem. 2013;59(1):270–9. https://doi.org/10.
1373/clinchem.2012.191551.
146. Barault L, AmatuA, Bleeker FE,Moutinho C, Falcomata C, Fiano
V, et al. Digital PCR quantification of MGMT methylation refines
prediction of clinical benefit from alkylating agents in glioblasto-
ma and metastatic colorectal cancer. Ann Oncol. 2015;26(9):
1994–9. https://doi.org/10.1093/annonc/mdv272.
147. Johnson DA, Barclay RL, Mergener K,Weiss G, Konig T, Beck J,
et al. Plasma septin9 versus fecal immunochemical testing for
colorectal cancer screening: a prospective multicenter study.
PLoS One. 2014;9(6):e98238. https://doi.org/10.1371/journal.
pone.0098238.
Regen. Eng. Transl. Med. (2021) 7:312–352 341
148. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P,
Lidgard GP, et al. Multitarget stool DNA testing for colorectal-
cancer screening. New Engl J Med. 2014;370(14):1287–97.
https://doi.org/10.1056/NEJMoa1311194.
149. Gai WX, Sun K. Epigenetic biomarkers in cell-free DNA and
applications in liquid biopsy. Genes-Basel. 2019;10(1):E32.
https://doi.org/10.3390/genes10010032.
150. Mazor T, Pankov A, Song JS, Costello JF. Intratumoral heteroge-
neity of the epigenome. Cancer Cell. 2016;29(4):440–51. https://
doi.org/10.1016/j.ccell.2016.03.009.
151. Gordevicius J, Krisciunas A, Groot DE, Yip SM, Susic M, Kwan
A, et al. Cell-Free DNA Modification dynamics in abiraterone
acetate-treated prostate cancer patients. Clin Cancer Res.
2018;24(14):3317–24. https://doi.org/10.1158/1078-0432.Ccr-
18-0101.
152. Stieglitz E, Mazor T, Olshen AB, Geng HM, Gelston LC,
Akutagawa J, et al. Genome-wide DNA methylation is predictive
of outcome in juvenile myelomonocytic leukemia. Nat Commun.
2017;8:2127. https://doi.org/10.1038/s41467-017-02178-9.
153. Wen L, Li JY, Guo HH, Liu XM, Zheng SM, Zhang DF, et al.
Genome-scale detection of hypermethylated CpG islands in circu-
lating cell-free DNA of hepatocellular carcinoma patients (vol 25,
pg 1250, 2015). Cell Res. 2015;25(12):1376. https://doi.org/10.
1038/cr.2015.141.
154. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing:
systematic investigation of critical experimental parameters.
Nucleic Acids Res. 2001;29(13):E65–5.
155. Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl
MHA, Chadwick D, et al. Sensitive tumour detection and classi-
fication using plasma cell-free DNA methylomes. Nature.
2018;563(7732):579–83. https://doi.org/10.1038/s41586-018-
0703-0.
156. Taiwo O, Wilson GA, Morris T, Seisenberger S, Reik W, Pearce
D, et al. Methylome analysis using MeDIP-seq with low DNA
concentrations. Nat Protoc. 2012;7(4):617–36. https://doi.org/10.
1038/nprot.2012.012.
157. Buscarlet M, Tessier A, Provost S, Mollica L, Busque L. Human
blood cell levels of 5-hydroxymethylcytosine (5hmC) declinewith
age, partly related to acquired mutations in TET2. Exp Hematol.
2016;44(11):1072–84. https://doi.org/10.1016/j.exphem.2016.07.
009.
158. Li WS, Zhang X, Lu XY, You L, Song YQ, Luo ZG, et al. 5-
Hydroxymethylcytosine signatures in circulating cell-free DNA
as diagnostic biomarkers for human cancers. Cell Res.
2017;27(10):1243–57. https://doi.org/10.1038/cr.2017.121.
159. Pfeifer GP, Xiong WY, Hahn MA, Jin SG. The role of 5-
hydroxymethylcytosine in human cancer. Cell Tissue Res.
2014;356(3):631–41. https://doi.org/10.1007/s00441-014-1896-
7.
160. Schutsky EK,DeNizio JE, Hu P, LiuMY, Nabel CS, Fabyanic EB,
et al. Nondestructive, base-resolution sequencing of 5-
hydroxymethylcytosine using a DNA deaminase. Nat
Biotechnol. 2018;36(11):1083–90. https://doi.org/10.1038/nbt.
4204.
161. Sina AA, Carrascosa LG, Liang Z, Grewal YS, Wardiana A,
Shiddiky MJA, et al. Epigenetically reprogrammed methylation
landscape drives the DNA self-assembly and serves as a universal
cancer biomarker. Nat Commun. 2018;9(1):4915. https://doi.org/
10.1038/s41467-018-07214-w.
162. Liles EG, Coronado GD, Perrin N, Harte AH, Nungesser R,
Quigley N, et al. Uptake of a colorectal cancer screening blood
test is higher than of a fecal test offered in clinic: a randomized
trial. Cancer Treat Res Commun. 2017;10:27–31. https://doi.org/
10.1016/j.ctarc.2016.12.004.
163. Witjes JA, Morote J, Cornel EB, Gakis G, Valenberg FJPV,
Lozano F, et al. Performance of the Bladder EpiCheck™
methylation test for patients under surveillance for non–muscle-
invasive bladder cancer: results of a multicenter, prospective,
blinded clinical trial. Eur Urol Oncol. 2018;1(4):307–13. https://
doi.org/10.1016/j.euo.2018.06.011.
164. Lee RC, Feinbaum RL, Ambros V. The C-elegans heterochronic
gene Lin-4 encodes small Rnas with antisense complementarity to
Lin-14. Cell. 1993;75(5):843–54. https://doi.org/10.1016/0092-
8674(93)90529-Y.
165. Li XZG, Roy CK, Moore MJ, Zamore PD. Defining piRNA pri-
mary transcripts. Cell Cycle. 2013;12(11):1657–8. https://doi.org/
10.4161/cc.24989.
166. Yamasaki S, Ivanov P, Hu GF, Anderson P. Angiogenin cleaves
tRNA and promotes stress-induced translational repression. J Cell
Biol. 2009;185(1):35–42. https://doi.org/10.1083/jcb.200811106.
167. Tyc K, Steitz JA. U3, U8 and U13 comprise a new class of mam-
malian Snrnps localized in the cell nucleolus. EMBO J.
1989;8(10):3113–9. https://doi.org/10.1002/j.1460-2075.1989.
tb08463.x.
168. Lerner MR, Boyle JA, Hardin JA, Steitz JA. Two novel classes of
small ribonucleoproteins detected by antibodies associated with
lupus erythematosus. Science. 1981;211(4480):400–2. https://
doi.org/10.1126/science.6164096.
169. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R,Willingham
AT, et al. RNA maps reveal new RNA classes and a possible
function for pervasive transcription. Science. 2007;316(5830):
1484–8. https://doi.org/10.1126/science.1138341.
170. Seila AC, Calabrese JM, Levine SS, Yeo GW, Rahl PB, Flynn RA,
et al. Divergent transcription from active promoters. Science.
2008;322(5909):1849–51. https://doi.org/10.1126/science.
1162253.
171. Hadjiolo AA, Venkov PV, Tsanev RG. Ribonucleic acids fraction-
ation by density-gradient centrifugation and by agar gel electro-
phoresis - a comparison. Anal Biochem. 1966;17(2):263–7.
https://doi.org/10.1016/0003-2697(66)90204-1.
172. Clark MB, Choudhary A, Smith MA, Taft RJ, Mattick JS. The
dark matter rises: the expanding world of regulatory RNAs.
Essays Biochem. 2013;54:1–16. https://doi.org/10.1042/
Bse0540001.
173. Morris KV, Mattick JS. The rise of regulatory RNA. Nat Rev
Genet. 2014;15(6):423–37. https://doi.org/10.1038/nrg3722.
174. Cieslik M, Chinnaiyan AM. Cancer transcriptome profiling at the
juncture of clinical translation. Nat Rev Genet. 2018;19(2):93–
109. https://doi.org/10.1038/nrg.2017.96.
175. Lonsdale J, Thomas J, SalvatoreM, Phillips R, Lo E, Shad S, et al.
The genotype-tissue expression (GTEx) project. Nat Genet.
2013;45(6):580–5. https://doi.org/10.1038/ng.2653.
176. Sheng QH, Zhao SL, Li CI, Shyr Y, Guo Y. Practicability of
detecting somatic point mutation from RNA high throughput se-
quencing data. Genomics. 2016;107(5):163–9. https://doi.org/10.
1016/j.ygeno.2016.03.006.
177. Piskol R, Ramaswami G, Li JB. Reliable identification of genomic
variants from RNA-Seq data. Am J Hum Genet. 2013;93(4):641–
51. https://doi.org/10.1016/j.ajhg.2013.08.008.
178. Mertens F, Johansson B, Fioretos T, Mitelman F. The emerging
complexity of gene fusions in cancer. Nat Rev Cancer. 2015;15(6):
371–81. https://doi.org/10.1038/nrc3947.
179. Holoch D, Moazed D. RNA-mediated epigenetic regulation of
gene expression. Nat Rev Genet. 2015;16(2):71–84. https://doi.
org/10.1038/nrg3863.
180. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet.
2011;12(12):861–74. https://doi.org/10.1038/nrg3074.
181. Zhou KC, Liu MX, Cao Y. New insight into microRNA functions
in cancer: oncogene-microRNA-tumor suppressor gene network.
Front Mol Biosci. 2017;4:46. https://doi.org/10.3389/fmolb.2017.
00046.
342 Regen. Eng. Transl. Med. (2021) 7:312–352
182. Calin GA, Croce CM. MicroRNA signatures in human cancers.
Nat Rev Cancer. 2006;6(11):857–66. https://doi.org/10.1038/
nrc1997.
183. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y,
Zepeniuk M, et al. MicroRNAs accurately identify cancer tissue
origin. Nat Biotechnol. 2008;26(4):462–9. https://doi.org/10.
1038/nbt1392.
184. Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of
circulating non-coding RNAs - an update. Nat Rev Clin Oncol.
2018;15(9):541–63. https://doi.org/10.1038/s41571-018-0035-x.
185. Lo KW, Lo YM, Leung SF, Tsang YS, Chan LY, Johnson PJ, et al.
Analysis of cell-free Epstein-Barr virus associated RNA in the
plasma of patients with nasopharyngeal carcinoma. Clin Chem.
1999;45(8 Pt 1):1292–4.
186. Lawrie CH, Gal S, DunlopHM, Pushkaran B, Liggins AP, Pulford
K, et al. Detection of elevated levels of tumour-associated
microRNAs in serum of patients with diffuse large B-cell lympho-
ma. Brit J Haematol. 2008;141(5):672–5. https://doi.org/10.1111/
j.1365-2141.2008.07077.x.
187. Sole C, Arnaiz E, Manterola L, Otaegui D, Lawrie CH. The cir-
culating transcriptome as a source of cancer liquid biopsy bio-
markers. Semin Cancer Biol. 2019. https://doi.org/10.1016/j.
semcancer.2019.01.003.
188. Sole C, Tramonti D, Schramm M, Goicoechea I, Armesto M,
Hernandez LI, et al. The circulating transcriptome as a source of
biomarkers for melanoma. Cancers (Basel). 2019;11(1):E70.
https://doi.org/10.3390/cancers11010070.
189. Fernandez-Mercado M, Manterola L, Larrea E, Goicoechea I,
Arestin M, Armesto M, et al. The circulating transcriptome as a
source of non-invasive cancer biomarkers: concepts and contro-
versies of non-coding and coding RNA in body fluids. J Cell Mol
Med. 2015;19(10):2307–23. https://doi.org/10.1111/jcmm.12625.
190. Shen J, Liu ZL, Todd NW, Zhang H, Liao JP, Yu L, et al.
Diagnosis of lung cancer in individuals with solitary pulmonary
nodules by plasma microRNA biomarkers. BMC Cancer.
2011;11:374. https://doi.org/10.1186/1471-2407-11-374.
191. Baraniskin A, Nopel-Dunnebacke S, Ahrens M, Jensen SG,
Zollner H, Maghnouj A, et al. Circulating U2 small nuclear
RNA fragments as a novel diagnostic biomarker for pancreatic
and colorectal adenocarcinoma. Int J Cancer. 2013;132(2):E48–
57. https://doi.org/10.1002/ijc.27791.
192. Ono S, Lam S, Nagahara M, Hoon DSB. Circulating microRNA
biomarkers as liquid biopsy for cancer patients: pros and cons of
current assays. J Clin Med. 2015;4(10):1890–907. https://doi.org/
10.3390/jcm4101890.
193. Zhang H, Mao F, Shen T, Luo Q, Ding Z, Qian L, et al. Plasma
miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for
screening early-stage non-small cell lung cancer. Oncol Lett.
2017;13(2):669–76. https://doi.org/10.3892/ol.2016.5462.
194. Geng Q, Fan T, Zhang BY, Wang W, Xu Y, Hu H. Five
microRNAs in plasma as novel biomarkers for screening of
early-stage non-small cell lung cancer. Respir Res. 2014;15:149.
https://doi.org/10.1186/s12931-014-0149-3.
195. Zhu WY, Zhou KY, Zha Y, Chen DD, He JY, Ma HJ, et al.
Diagnostic value of serum miR-182, miR-183, miR-210, and
miR-126 levels in patients with early-stage non-small cell lung
cancer. PLoS One. 2016;11(4):e0153046. https://doi.org/10.
1371/journal.pone.0153046.
196. Powrozek T, Kuznar-Kaminska B, Dziedzic M, Mlak R, Batura-
Gabryel H, Sagan D, et al. The diagnostic role of plasma circulat-
ing precursors of miRNA-944 and miRNA-3662 for non-small
cell lung cancer detection. Pathol Res Pract. 2017;213(11):1384–
7. https://doi.org/10.1016/j.prp.2017.09.011.
197. Shin VY, Siu JM, Cheuk I, Ng EKO, Kwong A. Circulating cell-
free miRNAs as biomarker for triple-negative breast cancer. Br J
Cancer. 2015;112(11):1751–9. https://doi.org/10.1038/bjc.2015.
143.
198. Pang PC, Shi XY, Huang WL, Sun K. miR-497 as a potential
serum biomarker for the diagnosis and prognosis of osteosarcoma.
Eur Rev Med Pharmacol Sci. 2016;20(18):3765–9.
199. Fang ZQ, Dai W, Wang XW, Chen W, Shen CX, Ye G, et al.
Circulating miR-205: a promising biomarker for the detection
and prognosis evaluation of bladder cancer. Tumor Biol.
2016;37(6):8075–82. https://doi.org/10.1007/s13277-015-4698-y.
200. Gong L, Wang CJ, Gao Y, Wang J. Decreased expression of
microRNA-148a predicts poor prognosis in ovarian cancer and
associates with tumor growth and metastasis. Biomed
Pharmacother. 2016;83:58–63. https://doi.org/10.1016/j.biopha.
2016.05.049.
201. Shen J, KongWW,Wu YN, Ren HZ, Wei J, Yang Y, et al. Plasma
mRNA as liquid biopsy predicts chemo-sensitivity in advanced
gastric cancer patients. J Cancer. 2017;8(3):434–42. https://doi.
org/10.7150/jca.17369.
202. Shen J,WangH,Wei J, Yu LX, Xie L, Qian XP, et al. Thymidylate
synthase mRNA levels in plasma and tumor as potential predictive
biomarkers for raltitrexed sensitivity in gastric cancer. Int J Cancer.
2012;131(6):E938–E45. https://doi.org/10.1002/ijc.27530.
203. Shen J, Wei J, Guan WX, Wang H, Ding YT, Qian XP, et al.
Plasma mRNA expression levels of BRCA1 and TS as potential
predictive biomarkers for chemotherapy in gastric cancer. J Transl
Med. 2014;12:355. https://doi.org/10.1186/s12967-014-0355-2.
204. Kang Y, Zhang JC, Sun PC, Shang J. Circulating cell-free human
telomerase reverse transcriptase mRNA in plasma and its potential
diagnostic and prognostic value for gastric cancer. Int J Clin
Oncol. 2013;18(3):478–86. https://doi.org/10.1007/s10147-012-
0405-9.
205. March-Villalba JA, Martinez-Jabaloyas JM, Herrero MJ,
Santamaria J, Alino SF, Dasi F. Cell-free circulating plasma
hTERT mRNA is a useful marker for prostate cancer diagnosis
and is associated with poor prognosis tumor characteristics. PLoS
One. 2012;7(8):e43470. https://doi.org/10.1371/journal.pone.
0043470.
206. Miura N, Maeda Y, Kanbe T, Yazama H, Takeda Y, Sato R, et al.
Serum human telomerase reverse transcriptase messenger RNA as
a novel tumor marker for hepatocellular carcinoma. Clin Cancer
Res. 2005;11(9):3205–9. https://doi.org/10.1158/1078-0432.Ccr-
04-1487.
207. Terrin L, Rampazzo E, Pucciarelli S, Agostini M, Bertorelle R,
EspositoG, et al. Relationship between tumor and plasma levels of
hTERT mRNA in patients with colorectal cancer: implications for
monitoring of neoplastic disease. Clin Cancer Res. 2008;14(22):
7444–51. https://doi.org/10.1158/1078-0432.Ccr-08-0478.
208. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C,
Movarekhi S, et al. Telomerase RNA as a detection marker in
the serum of breast cancer patients. Clin Cancer Res.
2000;6(10):3823–6.
209. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji
MM, et al. Blood cell origin of circulating MicroRNAs: a caution-
ary note for cancer biomarker studies. Cancer Prev Res. 2012;5(3):
492–7. https://doi.org/10.1158/1940-6207.Capr-11-0370.
210. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP,
van Zandwijk N, et al. Haemolysis during sample preparation
alters microRNA content of plasma. PLoS One. 2011;6(9):
e24145. https://doi.org/10.1371/journal.pone.0024145.
211. Jarry J, Schadendorf D, Greenwood C, Spatz A, van Kempen LC.
The validity of circulating microRNAs in oncology: five years of
challenges and contradictions. Mol Oncol. 2014;8(4):819–29.
https://doi.org/10.1016/j.molonc.2014.02.009.
212. Montani F, Marzi MJ, Dezi F, Dama E, Carletti RM, Bonizzi G,
et al. miR-Test: a blood test for lung cancer early detection. Jnci-J
Regen. Eng. Transl. Med. (2021) 7:312–352 343
Natl Cancer I. 2015;107(6):djv063. https://doi.org/10.1093/jnci/
djv063.
213. Veronesi G, Bellomi M, Mulshine JL, Pelosi G, Scanagatta P,
Paganelli G, et al. Lung cancer screening with low-dose computed
tomography: a non-invasive diagnostic protocol for baseline lung
nodules. Lung Cancer. 2008;61(3):340–9. https://doi.org/10.1016/
j.lungcan.2008.01.001.
214. Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, et al.
Clinical utility of a plasma-basedmiRNA signature classifier with-
in computed tomography lung cancer screening: a correlative
MILD trial study. J Clin Oncol. 2014;32(8):768–73. https://doi.
org/10.1200/Jco.2013.50.4357.
215. Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I,
Henderson RJ, et al. PCA3 molecular urine test as a predictor of
repeat prostate biopsy outcome in men with previous negative
biopsies: a prospective multicenter clinical study. J Urol.
2013;190(1):64–9. https://doi.org/10.1016/j.juro.2013.02.018.
216. Lee GL, Dobi A, Srivastava S. Prostate cancer: diagnostic perfor-
mance of the PCA3 urine test. Nat Rev Urol. 2011;8(3):123–4.
https://doi.org/10.1038/nrurol.2011.10.
217. Groskopf J, Aubin SMJ, Deras IL, Blase A, Bodrug S, Clark C,
et al. APTIMA PCA3 molecular urine test: development of a
method to aid in the diagnosis of prostate cancer. Clin Chem.
2006;52(6):1089–95. https://doi.org/10.1373/clinchem.2005.
063289.
218. Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL,
et al. A multicenter evaluation of the PCA3 molecular urine test:
pre-analytical effects, analytical performance, and diagnostic ac-
curacy. Clin Chim Acta. 2008;389(1-2):1–6. https://doi.org/10.
1016/j.cca.2007.11.003.
219. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB,
Jannink SA, et al. Detection of high-grade prostate cancer using a
urinary molecular biomarker-based risk score. Eur Urol.
2016;70(5):740–8. https://doi.org/10.1016/j.eururo.2016.04.012.
220. Govers TM, Caba L, Resnick MJ. Cost-effectiveness of urinary
biomarker panel in prostate cancer risk assessment. J Urol.
2018;200(6):1221–6. https://doi.org/10.1016/j.juro.2018.07.034.
221. Hessels D, Govers T, Van Criekinge W, Vlaeminck-Guillem V,
Schmitz-drager B, Stief C, et al. Cost-effectiveness of selectmdx
for prostate cancer in four European countries: a modelling study.
J Urol. 2018;199(4):E614–E5.
222. Holyoake A, O'Sullivan P, Pollock R, Best T, Watanabe J, Kajita
Y, et al. Development of a multiplex RNA urine test for the detec-
tion and stratification of transitional cell carcinoma of the bladder.
Clin Cancer Res. 2008;14(3):742–9. https://doi.org/10.1158/
1078-0432.CCR-07-1672.
223. Darling D, Luxmanan C, O’Sullivan P, Lough T, Suttie J. Clinical
utility of Cxbladder for the diagnosis of urothelial carcinoma. Adv
Ther. 2017;34(5):1087–96. https://doi.org/10.1007/s12325-017-
0518-7.
224. O'Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P,
Cambridge L, et al. A multigene urine test for the detection and
stratification of bladder cancer in patients presenting with hema-
turia. J Urol. 2012;188(3):741–7. https://doi.org/10.1016/j.juro.
2012.05.003.
225. Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS,
Chaerkady R, et al. A draft map of the human proteome.
Nature. 2014;509(7502):575–81. https://doi.org/10.1038/
nature13302.
226. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P,
Mardinoglu A, et al. Tissue-based map of the human proteome.
Science. 2015;347(6220):1260419. https://doi.org/10.1126/
science.1260419.
227. Thul PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Blal
HA, et al. A subcellular map of the human proteome. Science.
2017;356(6340):eaal3321. https://doi.org/10.1126/science.
aal3321.
228. Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M,
Savitski MM, et al. Mass-spectrometry-based draft of the human
proteome. Nature. 2014;509(7502):582–7. https://doi.org/10.
1038/nature13319.
229. Jimenez CR, Zhang H, Kinsinger CR, Nice EC. The cancer pro-
teomic landscape and the HUPO Cancer Proteome Project. Clin
Proteomics. 2018;15:4. https://doi.org/10.1186/s12014-018-9180-
6.
230. Fuzery AK, Levin J, Chan MM, Chan DW. Translation of prote-
omic biomarkers into FDA approved cancer diagnostics: issues
and challenges. Clin Proteomics. 2013;10:13. https://doi.org/10.
1186/1559-0275-10-13.
231. Zhang Z, Chan DW. The road from discovery to clinical diagnos-
tics: lessons learned from the first FDA-cleared in vitro diagnostic
multivariate index assay of proteomic biomarkers. Cancer
Epidemiol Biomark Prev. 2010;19(12):2995–9. https://doi.org/
10.1158/1055-9965.Epi-10-0580.
232. Sawyers CL. The cancer biomarker problem. Nature.
2008;452(7187):548–52. https://doi.org/10.1038/nature06913.
233. Drucker E, Krapfenbauer K. Pitfalls and limitations in translation
from biomarker discovery to clinical utility in predictive and
personalised medicine. EPMA Journal. 2013;4(1):7. https://doi.
org/10.1186/1878-5085-4-7.
234. Gold P, Freedman SO. Specific carcinoembryonic antigens of the
human digestive system. J ExpMed. 1965;122(3):467–81. https://
doi.org/10.1084/jem.122.3.467.
235. WangMC,Valenzuela LA,Murphy GP, Chu TM. Purification of a
human prostate specific antigen. Investig Urol. 1979;17(2):159–
63.
236. Stenman UH, Tiitinen A, Alfthan H, Valmu L. The classification,
functions and clinical use of different isoforms of HCG. Hum
Reprod Update. 2006;12(6):769–84. https://doi.org/10.1093/
humupd/dml029.
237. Tatarinov IS. Content of the embryo-specific alpha-globulin in the
serum of the fetus, newborn infant and adult man with primary
liver cancer. Vopr Med Khim. 1965;11(2):20–4.
238. Bourreille J, Metayer P, Sauger F, Matray F, Fondimare A.
Existence of alpha feto protein during gastric-origin secondary
cancer of the liver. Presse Med. 1970;78(28):1277–8.
239. Rucker P, Antonio SM, Braden B. Elevated fibrinogen-fibrin deg-
radation products (FDP) in serum of colorectal cancer patients.
Anal Lett. 2004;37(14):2965–76. https://doi.org/10.1081/Al-
200035849.
240. Lee S, Huh SJ, Oh SY, Koh MS, Kim SH, Lee JH, et al. Clinical
significance of coagulation factors in operable colorectal cancer.
Oncol Lett. 2017;13(6):4669–74. https://doi.org/10.3892/ol.2017.
6058.
241. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour
marker gene HE4 (WFDC2), is expressed in normal tissues and
undergoes complex alternative splicing to yield multiple protein
isoforms. Oncogene. 2002;21(17):2768–73. https://doi.org/10.
1038/sj/onc/1205363.
242. McGill MR. The past and present of serum aminotransferases and
the future of liver injury biomarkers. EXCLI J. 2016;15:817–28.
https://doi.org/10.17179/excli2016-800.
243. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, AtkinsMB,
Byrd DR, et al. Final version of 2009 AJCC melanoma staging
and classification. J Clin Oncol. 2009;27(36):6199–206. https://
doi.org/10.1200/Jco.2009.23.4799.
244. Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R,
et al. LDH correlation with survival in advanced melanoma from
two large, randomised trials (Oblimersen GM301 and EORTC
18951). Eur J Cancer. 2009;45(10):1807–14. https://doi.org/10.
1016/j.ejca.2009.04.016.
344 Regen. Eng. Transl. Med. (2021) 7:312–352
245. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp
RC. Reactivity of a monoclonal-antibody with human ovarian-
carcinoma. J Clin Investig. 1981;68(5):1331–7. https://doi.org/
10.1172/Jci110380.
246. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB.
Immunopathologic characterization of a monoclonal-antibody
that recognizes common surface-antigens of human ovarian-
tumors of serous, endometrioid, and clear cell-types. Am J Clin
Pathol. 1983;79(1):98–104. https://doi.org/10.1093/ajcp/79.1.98.
247. Frenette PS, Thirlwell MP, Trudeau M, Thomson DMP, Joseph L,
Shuster JS. The diagnostic-value of Ca-27-29, Ca-15-3, Mucin-
like carcinoma antigen, carcinoembryonic antigen and Ca-19-9 in
breast and gastrointestinal malignancies. Tumor Biol. 1994;15(5):
247–54. https://doi.org/10.1159/000217898.
248. Magnani JL, Brockhaus M, Smith DF, Ginsburg V, Blaszczyk M,
Mitchell KF, et al. A monosialoganglioside is a monoclonal
antibody-defined antigen of colon-carcinoma. Science.
1981;212(4490):55–6. https://doi.org/10.1126/science.7209516.
249. Pavlou MP, Diamandis EP, Blasutig IM. The long journey of can-
cer biomarkers from the bench to the clinic. Clin Chem.
2013;59(1):147–57. https://doi.org/10.1373/clinchem.2012.
184614.
250. Borrebaeck CAK. Precision diagnostics: moving towards protein
biomarker signatures of clinical utility in cancer. Nat Rev Cancer.
2017;17(3):199–204. https://doi.org/10.1038/nrc.2016.153.
251. Duffy MJ. Tumor markers in clinical practice: a review focusing
on common solid cancers. Med Princ Pract. 2013;22(1):4–11.
https://doi.org/10.1159/000338393.
252. Mordente A, Meucci E, Martorana GE, Silvestrini A. Cancer bio-
markers discovery and validation: state of the art, problems and
future perspectives. In: Scatena R, editor. Advances in cancer bio-
markers: from biochemistry to clinic for a critical revision.
Advances in Experimental Medicine and Biology, vol. 867.
Dordrecht: Springer Netherlands; 2015. p. 9–26.
253. Anderson NL. The clinical plasma proteome: a survey of clinical
assays for proteins in plasma and serum. Clin Chem. 2010;56(2):
177–85. https://doi.org/10.1373/clinchem.2009.126706.
254. Scherl A. Clinical protein mass spectrometry. Methods. 2015;81:
3–14. https://doi.org/10.1016/j.ymeth.2015.02.015.
255. Smith LM, Kelleher NL. Consortium top down proteomics.
Proteoform: a single term describing protein complexity. Nat
Methods. 2013;10(3):186–7. https://doi.org/10.1038/nmeth.2369.
256. Hoofnagle AN, Wener MH. The fundamental flaws of immuno-
assays and potential solutions using tandem mass spectrometry. J
ImmunolMethods. 2009;347(1-2):3–11. https://doi.org/10.1016/j.
jim.2009.06.003.
257. Morgan BR, Tarter TH. Serum heterophile antibodies interfere
with prostate specific antigen test and result in over treatment in
a patient with prostate cancer. J Urol. 2001;166(6):2311–2. https://
doi.org/10.1016/S0022-5347(05)65565-6.
258. de la Mora JF, Van Berkel GJ, Enke CG, Cole RB, Martinez-
Sanchez M, Fenn JB. Electrochemical processes in electrospray
ionization mass spectrometry - Discussion. J Mass Spectrom.
2000;35(8):939–52.
259. Hillenkamp F, Karas M, Beavis RC, Chait BT. Matrix-assisted
laser desorption ionization mass-spectrometry of biopolymers.
Anal Chem. 1991;63(24):A1193–A202.
260. Tang N, Tornatore P, Weinberger SR. Current developments in
SELDI affinity technology. Mass Spectrom Rev. 2004;23(1):34–
44. https://doi.org/10.1002/mas.10066.
261. MacLean B, Tomazela DM, Abbatiello SE, Zhang SC, Whiteaker
JR, Paulovich AG, et al. Effect of collision energy optimization on
the measurement of peptides by selected reaction monitoring
(SRM) mass spectrometry. Anal Chem. 2010;82(24):10116–24.
https://doi.org/10.1021/ac102179j.
262. Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM.
Multiple reaction monitoring for robust quantitative proteomic
analysis of cellular signaling networks. P Natl Acad Sci USA.
2007;104(14):5860–5. https://doi.org/10.1073/pnas.0608638104.
263. Vidova V, Spacil Z. A review on mass spectrometry-based quan-
titative proteomics: Targeted and data independent acquisition.
Anal Chim Acta. 2017;964:7–23. https://doi.org/10.1016/j.aca.
2017.01.059.
264. Kiyonami R, Schoen A, Prakash A, Peterman S, Zabrouskov V,
Picotti P, et al. Increased selectivity, analytical precision, and
throughput in targeted proteomics. Mol Cell Proteomics.
2011;10(2):M110.002931. https://doi.org/10.1074/mcp.M110.
002931.
265. Aebersold R, Mann M. Mass-spectrometric exploration of prote-
ome structure and function. Nature. 2016;537(7620):347–55.
https://doi.org/10.1038/nature19949.
266. Huang Y, Zhu H. Protein array-based approaches for biomarker
discovery in cancer. Genom Proteom Bioinf. 2017;15(2):73–81.
https://doi.org/10.1016/j.gpb.2017.03.001.
267. Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P,
et al. Global analysis of protein activities using proteome chips.
Science. 2001;293(5537):2101–5. https://doi.org/10.1126/
science.1062191.
268. Haab BB, DunhamMJ, Brown PO. Protein microarrays for highly
parallel detection and quantitation of specific proteins and antibod-
ies in complex solut ions. Genome Biol . 2001;2(2):
RESEARCH0004.
269. Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M.
Identification of differentially expressed proteins in ovarian cancer
using high-density protein microarrays. P Natl Acad Sci USA.
2007;104(44):17494–9. https://doi.org/10.1073/pnas.
0708572104.
270. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T,
Gillespie JW, et al. Reverse phase protein microarrays which cap-
ture disease progression show activation of pro-survival pathways
at the cancer invasion front. Oncogene. 2001;20(16):1981–9.
https://doi.org/10.1038/sj.onc.1204265.
271. Moore CD, Ajala OZ, Zhu H. Applications in high-content func-
tional protein microarrays. Curr Opin Chem Biol. 2016;30:21–7.
https://doi.org/10.1016/j.cbpa.2015.10.013.
272. Spurrier B, Ramalingam S, Nishizuka S. Reverse-phase protein
lysate microarrays for cell signaling analysis. Nat Protoc.
2008;3(11):1796–808. https://doi.org/10.1038/nprot.2008.179.
273. Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A,
Wulfkuhle J, et al. The needle in the haystack: application of
breast fine-needle aspirate samples to quantitative protein micro-
array technology. Cancer Cytopathol. 2007;111(3):173–84.
https://doi.org/10.1002/cncr.22686.
274. Kim CH, Tworoger SS, Stampfer MJ, Dillon ST, Gu XS, Sawyer
SJ, et al. Stability and reproducibility of proteomic profiles mea-
sured with an aptamer-based platform. Sci Rep. 2018;8:8382.
https://doi.org/10.1038/s41598-018-26640-w.
275. ThiagarajanMCPTAC phase II final report. Cancer Res. 2017;77.
https://doi.org/10.1158/1538-7445.Am2017-399.
276. Hannick LI. NCI's CPTAC Phase III, proteogenomic analysis of
additonal cancer types. Cancer Res. 2017;77. https://doi.org/10.
1158/1538-7445.Am2017-400.
277. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR,
Wang P, et al. Proteogenomics connects somatic mutations to sig-
nalling in breast cancer. Nature. 2016;534(7605):55–62. https://
doi.org/10.1038/nature18003.
278. Fiore LD, Rodriguez H, Shriver CD. Collaboration to accelerate
proteogenomics cancer care: The Department of Veterans Affairs,
Department of Defense, and the National Cancer Institute's
Applied Proteogenomics OrganizationaL Learning and
Regen. Eng. Transl. Med. (2021) 7:312–352 345
Outcomes (APOLLO) Network. Clin Pharmacol Ther.
2017;101(5):619–21. https://doi.org/10.1002/cpt.658.
279. Rodriguez H, Pennington SR. Revolutionizing precision oncology
through collaborative proteogenomics and data sharing. Cell.
2018;173(3):533–7. https://doi.org/10.1016/j.cell.2018.04.008.
280. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J,
Djulbegovic B, et al. Screening for prostate cancer: systematic
review and meta-analysis of randomised controlled trials. Bmj-
Brit Med J. 2010;341. https://doi.org/10.1136/bmj.c4543.
281. Henderson JT, Webber EM, Sawaya GF. Screening for ovarian
cancer updated evidence report and systematic review for the US
Preventive Services Task Force. Jama-J Am Med Assoc.
2018;319(6):595–606. https://doi.org/10.1001/jama.2017.21421.
282. Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A,
et al. Prostate cancer screening with prostate-specific antigen
(PSA) test: a systematic review and meta-analysis. BMJ.
2018;362:k3519. https://doi.org/10.1136/bmj.k3519.
283. Sorensen CG, Karlsson WK, Pommergaard HC, Burcharth J,
Rosenberg J. The diagnostic accuracy of carcinoembryonic anti-
gen to detect colorectal cancer recurrence - a systematic review. Int
J Surg. 2016;25:134–44. https://doi.org/10.1016/j.ijsu.2015.11.
065.
284. Yilmaz A, Ece F, Bayramgurler B, Akkaya E, Baran R. The value
of Ca 125 in the evaluation of tuberculosis activity. Respir Med.
2001;95(8):666–9. https://doi.org/10.1053/rmed.2001.1121.
285. Chao M, Gibbs P. Caution is required before recommending rou-
tine carcinoembryonic antigen and imaging follow-up for patients
with early-stage colon cancer. J Clin Oncol. 2009;27(36):e279–
e80. https://doi.org/10.1200/Jco.2009.25.6156.
286. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP.
Diagnostic precision of carcinoembryonic antigen in the detection
of recurrence of colorectal cancer. Surg Oncol. 2009;18(1):15–24.
https://doi.org/10.1016/j.suronc.2008.05.008.
287. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. Serum
carcinoembryonic antigen monitoring after curative resection for
colorectal cancer: clinical significance of the preoperative level.
Ann Surg Oncol. 2009;16(11):3087–93. https://doi.org/10.1245/
s10434-009-0625-z.
288. Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.
Prostate-specific antigen–based screening for prostate cancer.
Jama. 2018;319(18):1914–31. https://doi.org/10.1001/jama.2018.
3712.
289. Stamey TA. Preoperative serum prostate-specific antigen (PSA)
below 10 mu g/L predicts neither the presence of prostate cancer
nor the rate of postoperative PSA failure. Clin Chem. 2001;47(4):
631–4.
290. Adhyam M, Gupta AK. A review on the clinical utility of PSA in
cancer prostate. Indian J Surg Oncol. 2012;3(2):120–9. https://doi.
org/10.1007/s13193-012-0142-6.
291. Palmer SR, Erickson LA, Ichetovkin I, Knauer DJ, Markovic SN.
Circulating serologic and molecular biomarkers in malignant mel-
anoma. Mayo Clin Proc. 2011;86(10):981–90. https://doi.org/10.
4065/mcp.2011.0287.
292. Bell AW, Deutsch EW, Au CE, Kearney RE, Beavis R, Sechi S,
et al. A HUPO test sample study reveals common problems in
mass spectrometry-based proteomics. Nat Methods. 2009;6(6):
423–30. https://doi.org/10.1038/nmeth.1333.
293. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR,
Bunk DM, et al. Multi-site assessment of the precision and repro-
ducibility of multiple reaction monitoring-based measurements of
proteins in plasma. Nat Biotechnol. 2009;27(7):633–U85. https://
doi.org/10.1038/nbt.1546.
294. Carr SA, Abbatiello SE, Ackermann BL, Borchers C, Domon B,
Deutsch EW, et al. Targeted peptide measurements in biology and
medicine: best practices for mass spectrometry- based assay de-
velopment using a fit- for- purpose approach. Mol Cell
Proteomics. 2014;13(3):907–17. https://doi.org/10.1074/mcp.
M113.036095.
295. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-
Bromage H, Olshen AB, et al. Differential exoprotease activities
confer tumor-specific serum peptidome patterns. J Clin Investig.
2006;116(1):271–84. https://doi.org/10.1172/Jci26022.
296. Timms JF, Cramer R, Camuzeaux S, Tiss A, Smith C, Burford B,
et al. Peptides generated ex vivo from serum proteins by tumor-
specific exopeptidases are not useful biomarkers in ovarian cancer.
Clin Chem. 2010;56(2):262–71. https://doi.org/10.1373/
clinchem.2009.133363.
297. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al.
Serum protein markers for early detection of ovarian cancer. P Natl
Acad Sci USA. 2005;102(21):7677–82. https://doi.org/10.1073/
pnas.0502178102.
298. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai YL,
et al. Diagnostic markers for early detection of ovarian cancer. Clin
Cancer Res. 2008;14(4):1065–72. https://doi.org/10.1158/1078-
0432.Ccr-07-1569.
299. Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK,
Hartge P, et al. Ovarian cancer biomarker performance in prostate,
lung, colorectal, and ovarian cancer screening trial specimens.
Cancer Prev Res. 2011;4(3):365–74. https://doi.org/10.1158/
1940-6207.Capr-10-0195.
300. McIntosh M, Anderson G, Drescher C, Hanash S, Urban N,
Brown P, et al. Ovarian cancer early detection claims are biased.
Clin Cancer Res. 2008;14(22):7574. https://doi.org/10.1158/
1078-0432.Ccr-08-0623.
301. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA,
Steinberg SM, et al. Use of proteomic patterns in serum to identify
ovarian cancer. Lancet. 2002;359(9306):572–7. https://doi.org/10.
1016/S0140-6736(02)07746-2.
302. Sorace JM, Zhan M. A data review and re-assessment of ovarian
cancer serum proteomic profiling. Bmc Bioinformatics. 2003;4:
24. https://doi.org/10.1186/1471-2105-4-24.
303. Baggerly KA, Morris JS, Coombes KR. Reproducibility of
SELDI-TOF protein patterns in serum: comparing datasets from
different experiments. Bioinformatics. 2004;20(5):777–U10.
https://doi.org/10.1093/bioinformatics/btg484.
304. Committee on the Review of Omics-Based Tests for Predicting
Patient Outcomes in Clinical Trials. Evolution of translational
omics: lessons learned and the path forward. Washington (DC):
Institute of Medicine of the National Academies; 2012.
305. Pepe MS, Feng ZD, Janes H, Bossuyt PM, Potter JD. Pivotal
evaluation of the accuracy of a biomarker used for classification
or prediction: standards for study design. J Natl Cancer I.
2008;100(20):1432–8. https://doi.org/10.1093/jnci/djn326.
306. Kim J, Bamlet WR, Oberg AL, Chaffee KG, Donahue G, Cao XJ,
et al. Detection of early pancreatic ductal adenocarcinoma with
thrombospondin-2 and CA19-9 blood markers. Sci Transl Med.
2017;9(398):eaah5583. https://doi.org/10.1126/scitranslmed.
aah5583.
307. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML,
Thornquist M, et al. Phases of biomarker development for early
detection of cancer. J Natl Cancer Inst. 2001;93(14):1054–61.
308. Kim J, Hoffman JP, Alpaugh RK, Rhim AD, Reichert M, Stanger
B, et al. An iPSC line from human pancreatic ductal adenocarci-
noma undergoes early to invasive stages of pancreatic cancer pro-
gression. Cell Rep. 2013;3(6):2088–99. https://doi.org/10.1016/j.
celrep.2013.05.036.
309. Nanjappa V, Thomas JK, Marimuthu A, Muthusamy B,
Radhakrishnan A, Sharma R, et al. Plasma Proteome Database
as a resource for proteomics research: 2014 update. Nucleic Acids
Res. 2014;42(D1):D959–D65. https://doi.org/10.1093/nar/
gkt1251.
346 Regen. Eng. Transl. Med. (2021) 7:312–352
310. Fung ET. A recipe for proteomics diagnostic test development: the
OVA1 test, from Biomarker Discovery to FDA Clearance. Clin
Chem. 2010;56(2):327–9. https://doi.org/10.1373/clinchem.2009.
140855.
311. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S,
Podzielinski I, et al. Effectiveness of a multivariate index assay in
the preoperative assessment of ovarian tumors. Obstet Gynecol.
2011;117(6):1289–97. https: / /doi.org/10.1097/AOG.
0b013e31821b5118.
312. Bristow RE, Smith A, Zhang Z, Chan DW, Crutcher G, Fung ET,
et al. Ovarian malignancy risk stratification of the adnexal mass
using a multivariate index assay. Gynecol Oncol. 2013;128(2):
252–9. https://doi.org/10.1016/j.ygyno.2012.11.022.
313. Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC,
Smith A, et al. Validation of a second-generation multivariate in-
dex assay for malignancy risk of adnexal masses. Am J Obstet
Gynecol. 2016;215(1):82.e1–82.e11. https://doi.org/10.1016/j.
ajog.2016.03.003.
314. Fidler MJ, Fhied CL, Roder J, Basu S, Sayidine S, Fughhi I, et al.
The serum-based VeriStrat (R) test is associated with proinflam-
matory reactants and clinical outcome in non-small cell lung can-
cer patients. BMC Cancer. 2018;18:310. https://doi.org/10.1186/
s12885-018-4193-0.
315. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K,
et al. Mass spectrometry to classify non-small-cell lung cancer
patients for clinical outcome after treatment with epidermal
growth factor receptor tyrosine kinase inhibitors: a multicohort
cross-institutional study. J Natl Cancer I. 2007;99(11):838–46.
https://doi.org/10.1093/jnci/djk195.
316. Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni
M, et al. Predictive value of a proteomic signature in patients with
non-small-cell lung cancer treated with second-line erlotinib or
chemotherapy (PROSE): a biomarker-stratified, randomised phase
3 trial. Lancet Oncol. 2014;15(7):713–21. https://doi.org/10.1016/
S1470-2045(14)70162-7.
317. Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP,
Porter A, et al. Assessment of plasma proteomics biomarker’s
ability to distinguish benign from malignant lung nodules results
of the PANOPTIC (Pulmonary Nodule Plasma Proteomic
Classifier) Trial. Chest. 2018;154(3):491–500. https://doi.org/10.
1016/j.chest.2018.02.012.
318. Ingvarsson J, Wingren C, Carlsson A, Ellmark P, Wahren B,
Engstrom G, et al. Detection of pancreatic cancer using antibody
microarray-based serum protein profiling. Proteomics.
2008;8(11):2211–9. https://doi.org/10.1002/pmic.200701167.
319. Wingren C, Sandstrom A, Segersvard R, Carlsson A, Andersson
R, Lohr M, et al. Identification of serum biomarker signatures
associated with pancreatic cancer. Cancer Res. 2012;72(10):
2481–90. https://doi.org/10.1158/0008-5472.Can-11-2883.
320. Gerdtsson AS, Malats N, Sall A, Real FX, Porta M, Skoog P, et al.
A multicenter trial defining a serum protein signature associated
with pancreatic ductal adenocarcinoma. Int J Proteomics.
2015;2015:587250. https://doi.org/10.1155/2015/587250.
321. Gerdtsson AS, Wingren C, Persson H, Delfani P, Nordstrom M,
Ren H, et al. Plasma protein profiling in a stage defined pancreatic
cancer cohort - implications for early diagnosis. Mol Oncol.
2016;10(8):1305–16. https://doi.org/10.1016/j.molonc.2016.07.
001.
322. Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard
BG, Bojesen SE, et al. Serum biomarker signature-based liquid
biopsy for diagnosis of early-stage pancreatic cancer. J Clin Oncol.
2018;36(28):2887–94. https://doi.org/10.1200/Jco.2017.77.6658.
323. Carlsson A, Wingren C, Kristensson M, Rose C, Ferno M, Olsson
H, et al. Molecular serum portraits in patients with primary breast
cancer predict the development of distant metastases. P Natl Acad
Sci USA. 2011;108(34):14252–7. https://doi.org/10.1073/pnas.
1103125108.
324. Nordstrom M, Wingren C, Rose C, Bjartell A, Becker C, Lilja H,
et al. Identification of plasma protein profiles associated with risk
groups of prostate cancer patients. Proteomics Clin Appl.
2014;8(11-12):951–62. https://doi.org/10.1002/prca.201300059.
325. Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld
JL, Wilson DO, et al. Validation of a blood protein signature for
non-small cell lung cancer. Clin Proteomics. 2014;11(1):32.
https://doi.org/10.1186/1559-0275-11-32.
326. Ward PS, Thompson CB. Metabolic reprogramming: a cancer
hallmark even Warburg did not anticipate. Cancer Cell.
2012;21(3):297–308. https://doi.org/10.1016/j.ccr.2012.02.014.
327. Warburg O, Wind F, Negelein E. The metabolism of tumors in the
body. J Gen Physiol. 1927;8(6):519–30. https://doi.org/10.1085/
jgp.8.6.519.
328. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabo-
lism. Sci Adv. 2016;2(5):e1600200. https://doi.org/10.1126/
sciadv.1600200.
329. Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting
cancer cell survival and growth. Nat Cell Biol. 2015;17(4):351–9.
https://doi.org/10.1038/ncb3124.
330. Yan H, Parsons DW, Jin GL, McLendon R, Rasheed BA, Yuan
WS, et al. IDH1 and IDH2mutations in gliomas. NewEngl JMed.
2009;360(8):765–73. https://doi.org/10.1056/NEJMoa0808710.
331. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, et al.
Mutational analysis of IDH1 codon 132 in glioblastomas and other
common cancers. Int J Cancer. 2009;125(2):353–5. https://doi.
org/10.1002/ijc.24379.
332. Oivares O, Dabritz JHM, King A, Gottlieb E, Halsey C. Research
into cancer metabolomics: towards a clinical metamorphosis.
Semin Cell Dev Biol. 2015;43:52–64. https://doi.org/10.1016/j.
semcdb.2015.09.008.
333. Antoniewicz MR. A guide to (13)Cmetabolic flux analysis for the
cancer biologist. Exp Mol Med. 2018;50(4):19. https://doi.org/10.
1038/s12276-018-0060-y.
334. Ranjan R, Sinha N. Nuclear magnetic resonance (NMR)-based
metabolomics for cancer research. NMR Biomed. 2018;32:
e3916. https://doi.org/10.1002/nbm.3916.
335. Dai C, Arceo J, Arnold J, Sreekumar A, Dovichi NJ, Li J, et al.
Metabolomics of oncogene-specific metabolic reprogramming
during breast cancer. Cancer Metab. 2018;6:5. https://doi.org/10.
1186/s40170-018-0175-6.
336. Tolstikov VV, Lommen A, Nakanishi K, Tanaka N, Fiehn O.
Monolithic silica-based capillary reversed-phase liquid
chromatography/electrospray mass spectrometry for plant meta-
bolomics. Anal Chem. 2003;75(23):6737–40. https://doi.org/10.
1021/ac034716z.
337. Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M, Nishioka T.
Quantitative metabolome analysis using capillary electrophoresis
mass spectrometry. J Proteome Res. 2003;2(5):488–94. https://
doi.org/10.1021/pr034020m.
338. Armitage EG, Barbas C. Metabolomics in cancer biomarker dis-
covery: current trends and future perspectives. J Pharmaceut
Biomed. 2014;87:1–11. https://doi.org/10.1016/j.jpba.2013.08.
041.
339. Dias DA,Koal T. Progress inmetabolomics standardisation and its
significance in future clinical laboratory medicine. EJIFCC.
2016;27(4):331–43.
340. Dang L,White DW, Gross S, Bennett BD, BittingerMA, Driggers
EM, et al. Cancer-associated IDH1 mutations produce 2-
hydroxyglutarate. Nature. 2009;462(7274):739–U52. https://doi.
org/10.1038/nature08617.
341. Lombardi G, Corona G, Bellu L, Della Puppa A, Pambuku A,
Fiduccia P, et al. Diagnostic value of plasma and urinary 2-
hydroxyglutarate to identify patients with isocitrate
Regen. Eng. Transl. Med. (2021) 7:312–352 347
dehydrogenase-mutated glioma. Oncologist. 2015;20(5):562–7.
https://doi.org/10.1634/theoncologist.2014-0266.
342. Wang D, DuBois RN. Prostaglandins and cancer. Gut. 2006;55(1):
115–22. https://doi.org/10.1136/gut.2004.047100.
343. Cui Y, Shu XO, Li HL, Yang G, Wen WQ, Gao YT, et al.
Prospective study of urinary prostaglandin E2metabolite and pan-
creatic cancer risk. Int J Cancer. 2017;141(12):2423–9. https://doi.
org/10.1002/ijc.31007.
344. Kim S, Taylor JA, Milne GL, Sandler DP. Association between
urinary prostaglandin E-2 metabolite and breast cancer risk: a
prospective, case-cohort study of postmenopausal women.
Cancer Prev Res. 2013;6(6):511–8. https://doi.org/10.1158/1940-
6207.Capr-13-0040.
345. Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang
CT, et al. Increased levels of urinary PGE-M, a biomarker of
inflammation, occur in association with obesity, aging, and lung
metastases in patients with breast cancer. Cancer Prev Res.
2013;6(5):428–36. https://doi.org/10.1158/1940-6207.Capr-12-
0431.
346. Casero RA, Stewart TM, Pegg AE. Polyamine metabolism and
cancer: treatments, challenges and opportunities. Nat Rev Cancer.
2018;18(11):681–95. https://doi.org/10.1038/s41568-018-0050-3.
347. Nakajima T, Katsumata K, Kuwabara H, Soya R, Enomoto M,
Ishizaki T, et al. Urinary polyamine biomarker panels with
machine-learning differentiated colorectal cancers, benign disease,
and healthy controls. Int J Mol Sci. 2018;19(3):E756. https://doi.
org/10.3390/ijms19030756.
348. Venalainen MK, Roine AN, Hakkinen MR, Vepsalainen JJ,
Kumpulainen PS, KiviniemiMS, et al. Altered polyamine profiles
in colorectal cancer. Anticancer Res. 2018;38(6):3601–7. https://
doi.org/10.21873/anticanres.12634.
349. Niemi RJ, Roine AN, Hakkinen MR, Kumpulainen PS, Keinanen
TA, Vepsalainen JJ, et al. Urinary polyamines as biomarkers for
ovarian cancer. Int J Gynecol Cancer. 2017;27(7):1360–6. https://
doi.org/10.1097/Igc.0000000000001031.
350. Tsoi TH, Chan CF, Chan WL, Chiu KF, Wong WT, Ng CF, et al.
Urinary polyamines: a pilot study on their roles as prostate cancer
detection biomarkers. PLoS One. 2016;11(9):e0162217. https://
doi.org/10.1371/journal.pone.0162217.
351. Falegan OS, Ball MW, Shaykhutdinov RA, Pieroraio PM,
Farshidfar F, Vogel HJ, et al. Urine and serummetabolomics anal-
yses may distinguish between stages of renal cell carcinoma.
Metabol i tes . 2017;7(1) :6 . h t tps : / /do i .org/10.3390/
metabo7010006.
352. Davidson SM, Jonas O, KeiblerMA,HouHW, LuengoA,Mayers
JR, et al. Direct evidence for cancer-cell-autonomous extracellular
protein catabolism in pancreatic tumors. Nat Med. 2017;23(2):
235–41. https://doi.org/10.1038/nm.4256.
353. Mayers JR,WuC, Clish CB, Kraft P, TorrenceME, Fiske BP, et al.
Elevation of circulating branched-chain amino acids is an early
event in human pancreatic adenocarcinoma development. Nat
Med. 2014;20(10):1193–8. https://doi.org/10.1038/nm.3686.
354. Handa H, Usuba A, Maddula S, Baumbach JI, Mineshita M,
Miyazawa T. Exhaled breath analysis for lung cancer detection
using ion mobility spectrometry. PLoS One. 2014;9(12):
e114555. https://doi.org/10.1371/journal.pone.0114555.
355. Westhoff M, Litterst P, Freitag L, Urfer W, Bader S, Baumbach JI.
Ion mobility spectrometry for the detection of volatile organic
compounds in exhaled breath of patients with lung cancer: results
of a pilot study. Thorax. 2009;64(9):744–8. https://doi.org/10.
1136/thx.2008.099465.
356. Saalberg Y, Wolff M. VOC breath biomarkers in lung cancer. Clin
Chim Acta. 2016;459:5–9. https://doi.org/10.1016/j.cca.2016.05.
013.
357. Cala MP, Aldana J, Medina J, Sanchez J, Guio J, Wist J, et al.
Multiplatform plasma metabolic and lipid fingerprinting of breast
cancer: a pilot control-case study in Colombian Hispanic women.
PLoS One. 2018;13(2):e0190958. https://doi.org/10.1371/journal.
pone.0190958.
358. Ritchie SA, Ahiahonu PWK, Jayasinghe D, Heath D, Liu J, Lu
YS, et al. Reduced levels of hydroxylated, polyunsaturated ultra
long-chain fatty acids in the serum of colorectal cancer patients:
implications for early screening and detection. BMCMed. 2010;8:
13. https://doi.org/10.1186/1741-7015-8-13.
359. Gatto F, Nookaew I, Nielsen J. Chromosome 3p loss of heterozy-
gosity is associated with a unique metabolic network in clear cell
renal carcinoma. P Natl Acad Sci USA. 2014;111(9):E866–E75.
https://doi.org/10.1073/pnas.1319196111.
360. Gatto F, Volpi N, Nilsson H, Nookaew I, Maruzzo M, Roma A,
et al. Glycosaminoglycan profiling in patients’ plasma and urine
predicts the occurrence of metastatic clear cell renal cell carcino-
ma. Cell Rep. 2016;15(8):1822–36. https://doi.org/10.1016/j.
celrep.2016.04.056.
361. Gatto F, Maruzzo M, Magro C, Basso U, Nielsen J. Prognostic
value of plasma and urine glycosaminoglycan scores in clear cell
renal cell carcinoma. Front Oncol. 2016;6:253. https://doi.org/10.
3389/fonc.2016.00253.
362. Gatto F, Blum KA, Hosseini SS, Ghanaat M, Kashan M, Maccari
F, et al. Plasma glycosaminoglycans as diagnostic and prognostic
biomarkers in surgically treated renal cell carcinoma. Eur Urol
Oncol. 2018;1(5):364–77. https://doi.org/10.1016/j.euo.2018.04.
015.
363. Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. Xenobiotic
metabolomics: major impact on the metabolome. Annu Rev
Pharmacol. 2012;52:37–56. https://doi.org/10.1146/annurev-
pharmtox-010611-134748.
364. Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, Vazquez-
Fresno R, et al. HMDB 4.0: the human metabolome database for
2018. Nucleic Acids Res. 2018;46(D1):D608–D17. https://doi.
org/10.1093/nar/gkx1089.
365. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu
JD, et al. Metabolomic profiles delineate potential role for
sa rcos ine in pros ta t e cance r p rogress ion . Na tu re .
2009;457(7231):910–4. https://doi.org/10.1038/nature07762.
366. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A,
Kristiansen G, et al. Sarcosine in urine after digital rectal exami-
nation fails as a marker in prostate cancer detection and identifi-
cation of aggressive tumours. Eur Urol. 2010;58(1):12–8. https://
doi.org/10.1016/j.eururo.2010.01.035.
367. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C,
Blankenstein MA. Serum sarcosine is not a marker for prostate
cancer. Ann Clin Biochem. 2010;47(Pt 3):282. https://doi.org/10.
1258/acb.2010.009270.
368. Wu H, Liu TT, Ma CG, Xue RY, Deng CH, Zeng HZ, et al. GC/
MS-based metabolomic approach to validate the role of urinary
sarcosine and target biomarkers for human prostate cancer by
microwave-assisted derivatization. Anal Bioanal Chem.
2011;401(2):635–46. https://doi.org/10.1007/s00216-011-5098-9.
369. WangM, Zou LH, Liang J,Wang X, Zhang DL, Fang Y, et al. The
urinary sarcosine/creatinine ratio is a potential diagnostic and
prognostic marker in prostate cancer. Med Sci Monit. 2018;24:
3034–41. https://doi.org/10.12659/Msm.909949.
370. Noguchi Y, ZhangQW, Sugimoto T, Furuhata Y, Sakai Y,MoriM,
et al. Network analysis of plasma and tissue amino acids and the
generation of an amino index for potential diagnostic use. Am J
Clin Nutr. 2006;83(2):513 s–9 s.
371. Kimura T, Noguchi Y, Shikata N, Takahashi M. Plasma amino
acid analysis for diagnosis and amino acid-based metabolic net-
works. Curr Opin Clin Nutr. 2009;12(1):49–53. https://doi.org/10.
1097/MCO.0b013e3283169242.
372. Anayama T, Higashiyama M, Yamamoto H, Kikuchi S, Ikeda A,
Okami J, et al. Post-operative AICS status in completely resected
348 Regen. Eng. Transl. Med. (2021) 7:312–352
lung cancer patients with pre-operative AICS abnormalities: pre-
dictive significance of disease recurrence. Sci Rep. 2018;8:12378.
https://doi.org/10.1038/s41598-018-30685-2.
373. Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T,
Miura T, et al. Plasma free amino acid profiling of five types of
cancer patients and its application for early detection. PLoS One.
2011;6(9):e24143. https://doi.org/10.1371/journal.pone.0024143.
374. Katayama K, Higuchi A, Yamamoto H, Ikeda A, Kikuchi S,
Shiozawa M. Perioperative dynamics and significance of
plasma-free amino acid profiles in colorectal cancer. BMC Surg.
2018;18:11. https://doi.org/10.1186/s12893-018-0344-0.
375. Okamoto N. Use of AminoIndex technology for cancer screening.
Ningen Dock. 2012;26(6):911–22.
376. Amal H, Leja M, Funka K, Lasina I, Skapars R, Sivins A, et al.
Breath testing as potential colorectal cancer screening tool. Int J
Cancer. 2016;138(1):229–36. https://doi.org/10.1002/ijc.29701.
377. AdamME, Fehervari M, Boshier PR, Chin S-T, Lin G-P, Romano
A, et al. Mass-spectrometry analysis of mixed-breath, isolated-
bronchial-breath, and gastric-endoluminal-air volatile fatty acids
in esophagogastric cancer. Anal Chem. 2019;91(5):3740–6.
https://doi.org/10.1021/acs.analchem.9b00148.
378. Markar SR, Wiggins T, Antonowicz S, Chin ST, Romano A,
Nikolic K, et al. Assessment of a noninvasive exhaled breath test
for the diagnosis of oesophagogastric cancer. Jama Oncol.
2018;4(7):970–6. https://doi.org/10.1001/jamaoncol.2018.0991.
379. Markar SR, Brodie B, Chin ST, Romano A, Spalding D, Hanna
GB. Profile of exhaled-breath volatile organic compounds to di-
agnose pancreatic cancer. Brit J Surg. 2018;105(11):1493–500.
https://doi.org/10.1002/bjs.10909.
380. Tai YL, Chen KC, Hsieh JT, Shen TL. Exosomes in cancer devel-
opment and clinical applications. Cancer Sci. 2018;109(8):2364–
74. https://doi.org/10.1111/cas.13697.
381. Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of
transferrin and recycling of the transferrin receptor in rat reticulo-
cytes. J Cell Biol. 1983;97(2):329–39. https://doi.org/10.1083/jcb.
97.2.329.
382. Pan BT, Johnstone RM. Fate of the transferrin receptor during
maturation of sheep reticulocytes in vitro: selective externalization
of the receptor. Cell. 1983;33(3):967–78. https://doi.org/10.1016/
0092-8674(83)90040-5.
383. Rajagopal C, Harikumar KB. The origin and functions of
exosomes in cancer. Front Oncol. 2018;8:66. https://doi.org/10.
3389/fonc.2018.00066.
384. Kalluri R. The biology and function of exosomes in cancer. J Clin
Investig. 2016;126(4):1208–15. https://doi.org/10.1172/Jci81135.
385. Sun W, Luo JD, Jiang H, Duan DD. Tumor exosomes: a double-
edged sword in cancer therapy. Acta Pharmacol Sin. 2018;39(4):
534–41. https://doi.org/10.1038/aps.2018.17.
386. Gao D, Jiang LL. Exosomes in cancer therapy: a novel experimen-
tal strategy. Am J Cancer Res. 2018;8(11):2165–75.
387. Kibria G, Ramos EK, Wan Y, Gius DR, Liu HP. Exosomes as a
drug delivery system in cancer therapy: potential and challenges.
Mol Pharm. 2018;15(9):3625–33. https://doi.org/10.1021/acs.
molpharmaceut.8b00277.
388. Yang JL, Hagen J, Guntur KV, Allette K, Schuyler S, Ranjan J,
et al. A next generation sequencing based approach to identify
extracellular vesicle mediated mRNA transfers between cells.
BMC Genomics. 2017;18:987. https://doi.org/10.1186/s12864-
017-4359-1.
389. Sun Y, Huo CH, Qao Z, Shang Z, Uzzaman A, Liu S, et al.
Comparative proteomic analysis of exosomes and microvesicles
in human saliva for lung cancer. J Proteome Res. 2018;17(3):
1101–7. https://doi.org/10.1021/acs.jproteome.7b00770.
390. Puhka M, Takatalo M, Nordberg ME, Valkonen S, Nandania J,
Aatonen M, et al. Metabolomic profiling of extracellular vesicles
and alternative normalization methods reveal enriched metabolites
and strategies to study prostate cancer-related changes.
Theranostics. 2017;7(16):3824–41. https://doi.org/10.7150/thno.
19890.
391. Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott
AM, et al. Comparison of ultracentrifugation, density gradient
separation, and immunoaffinity capture methods for isolating hu-
man colon cancer cell line LIM1863-derived exosomes. Methods.
2012;56(2):293–304. https://doi.org/10.1016/j.ymeth.2012.01.
002.
392. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and char-
acterization of exosomes from cell culture supernatants and bio-
logical fluids. Curr Protoc Cell Biol. 2006;Chapter 3:3.22.1–3.9.
https://doi.org/10.1002/0471143030.cb0322s30.
393. Ludwig AK, DeMiroschedji K, Doeppner TR, Borger V, Ruesing
J, RebmannV, et al. Precipitation with polyethylene glycol follow-
ed by washing and pelleting by ultracentrifugation enriches extra-
cellular vesicles from tissue culture supernatants in small and large
scales. J Extracell Vesicles. 2018;7(1):1528109. https://doi.org/10.
1080/20013078.2018.1528109.
394. Martins TS, Catita J, Rosa IM, Silva OABDE, Henriques AG.
Exosome isolation from distinct biofluids using precipitation and
column-based approaches. PLoS One. 2018;13(6):e0198820.
https://doi.org/10.1371/journal.pone.0198820.
395. Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA,
et al. Analysis of antigen presenting cell derived exosomes, based
on immuno-magnetic isolation and flow cytometry. J Immunol
Methods. 2001;247(1-2):163–74. https://doi.org/10.1016/S0022-
1759(00)00321-5.
396. Merchant ML, Powell DW, Wilkey DW, Cummins TD, Deegens
JK, Rood IM, et al. Microfiltration isolation of human urinary
exosomes for characterization by MS. Proteomics Clin Appl.
2010;4(1):84–96. https://doi.org/10.1002/prca.200800093.
397. Lane RE, Korbie D, Hill MM, Trau M. Extracellular vesicles as
circulating cancer biomarkers: opportunities and challenges. Clin
Transl Med. 2018;7. https://doi.org/10.1186/s40169-018-0192-7.
398. Gamez-Valero A, Monguio-Tortajada M, Carreras-Planella L,
Franquesa M, Beyer K, Borras FE. Size-exclusion chromatogra-
phy-based isolation minimally alters extracellular vesicles’ char-
acteristics compared to precipitating agents. Sci Rep. 2016;6:
33641. https://doi.org/10.1038/srep33641.
399. Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K,
Vandesompele J, et al. The impact of disparate isolation methods
for extracellular vesicles on downstream RNA profiling. J
Extracell Vesicles. 2014;3. https://doi.org/10.3402/jev.v3.24858.
400. Rekker K, Saare M, Roost AM, Kubo AL, Zarovni N, Chiesi A,
et al. Comparison of serum exosome isolation methods for
microRNA profiling. Clin Biochem. 2014;47(1-2):135–8. https://
doi.org/10.1016/j.clinbiochem.2013.10.020.
401. Van Deun J, Mestdagh P, Agostinis P, Akay O, Anand S, Anckaert
J, et al. EV-TRACK: transparent reporting and centralizing knowl-
edge in extracellular vesicle research. Nat Methods. 2017;14(3):
228–32. https://doi.org/10.1038/nmeth.4185.
402. Arraud N, Linares R, Tan S, Gounou C, Pasquet JM, Mornet S,
et al. Extracellular vesicles from blood plasma: determination of
their morphology, size, phenotype and concentration. J Thromb
Haemost. 2014;12(5):614–27. https://doi.org/10.1111/jth.12554.
403. Rikkert LG, Nieuwland R, Terstappen LWMM, Coumans FAW.
Quality of extracellular vesicle images by transmission electron
microscopy is operator and protocol dependent. Journal of
Extracellular Vesicles. 2019;8(1):1555419. https://doi.org/10.
1080/20013078.2018.1555419.
404. van der Pol E, Hoekstra AG, Sturk A, Otto C, van Leeuwen TG,
Nieuwland R. Optical and non-optical methods for detection and
characterization of microparticles and exosomes. J Thromb
Haemost. 2010;8(12):2596–607. https://doi.org/10.1111/j.1538-
7836.2010.04074.x.
Regen. Eng. Transl. Med. (2021) 7:312–352 349
405. CabyMP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot
C. Exosomal-like vesicles are present in human blood plasma. Int
Immunol. 2005;17(7):879–87. https://doi.org/10.1093/intimm/
dxh267.
406. Thakur BK, Zhang H, Becker A,Matei I, Huang Y, Costa-Silva B,
et al. Double-stranded DNA in exosomes: a novel biomarker in
cancer detection. Cell Res. 2014;24(6):766–9. https://doi.org/10.
1038/cr.2014.44.
407. Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard
V, et al. High prevalence of mutant KRAS in circulating exosome-
derived DNA from early-stage pancreatic cancer patients. Ann
Oncol. 2017;28(4):741–7. https://doi.org/10.1093/annonc/
mdx004.
408. Yang SJ, Che SPY, Kurywchak P, Tavormina JL, Gansmo LB, de
Sampaio PC, et al. Detection of mutant KRAS and TP53 DNA in
circulating exosomes from healthy individuals and patients with
pancreatic cancer. Cancer Biol Ther. 2017;18(3):158–65. https://
doi.org/10.1080/15384047.2017.1281499.
409. Kim KM,Abdelmohsen K,Mustapic M, Kapogiannis D, Gorospe
M. RNA in extracellular vesicles. Wiley Interdiscip Rev RNA.
2017;8(4). https://doi.org/10.1002/wrna.1413.
410. Bayraktar R, Van Roosbroeck K, Calin GA. Cell-to-cell commu-
nication: microRNAs as hormones. Mol Oncol. 2017;11(12):
1673–86. https://doi.org/10.1002/1878-0261.12144.
411. Srivastava AK, Singh PK, Rath SK, Dalela D, Goel MM, Bhatt
MLB. Appraisal of diagnostic ability of UCA1 as a biomarker of
carcinoma of the urinary bladder. Tumor Biol. 2014;35(11):
11435–42. https://doi.org/10.1007/s13277-014-2474-z.
412. Goldvaser H, Gutkin A, Beery E, Edel Y, Nordenberg J, Wolach
O, et al. Characterisation of blood-derived exosomal hTERT
mRNA secretion in cancer patients: a potential pan-cancer marker.
Br J Cancer. 2017;117(3):353–7. https://doi.org/10.1038/bjc.
2017.166.
413. Ferrari E, De PalmaA,Mauri P. EmergingMS-based platforms for
the characterization of tumor-derived exosomes isolated from hu-
man biofluids: challenges and promises of MudPIT. Expert Rev
Proteomic. 2017;14(9):757–67. https://doi.org/10.1080/
14789450.2017.1364629.
414. Ogawa Y, Miura Y, Harazono A, Kanai-Azuma M, Akimoto Y,
Kawakami H, et al. Proteomic analysis of two types of exosomes
in human whole saliva. Biol Pharm Bull. 2011;34(1):13–23.
https://doi.org/10.1248/bpb.34.13.
415. Webber J, Stone TC, Katilius E, Smith BC, Gordon B, Mason
MD, et al. Proteomics analysis of cancer exosomes using a novel
modified aptamer-based array (SOMAscan(TM)) platform*. Mol
Cell Proteomics. 2014;13(4):1050–64. https://doi.org/10.1074/
mcp.M113.032136.
416. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST,
Kaye J, et al. Glypican-1 identifies cancer exosomes and detects
early pancreatic cancer. Nature. 2015;523(7559):177–U82.
https://doi.org/10.1038/nature14581.
417. Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur
BK, et al. Pancreatic cancer exosomes initiate pre-metastatic niche
formation in the liver. Nat Cell Biol. 2015;17(6):816–26. https://
doi.org/10.1038/ncb3169.
418. Alegre E, Zubiri L, Perez-Gracia JL, Gonzalez-Cao M, Soria L,
Martin-Algarra S, et al. Circulating melanoma exosomes as diag-
nostic and prognosis biomarkers. Clin Chim Acta. 2016;454:28–
32. https://doi.org/10.1016/j.cca.2015.12.031.
419. Im H, Shao HL, Park YI, Peterson VM, Castro CM,Weissleder R,
et al. Label-free detection and molecular profiling of exosomes
with a nano-plasmonic sensor. Nat Biotechnol. 2014;32(5):490–
U219. https://doi.org/10.1038/nbt.2886.
420. San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis
K, et al. Minimally invasive genomic and transcriptomic profiling
of visceral cancers by next-generation sequencing of circulating
exosomes. Ann Oncol. 2016;27(4):635–41. https://doi.org/10.
1093/annonc/mdv604.
421. Madhavan B, Yue SJ, Galli U, Rana S, Gross W, Muller M, et al.
Combined evaluation of a panel of protein and miRNA serum-
exosome biomarkers for pancreatic cancer diagnosis increases
sensitivity and specificity. Int J Cancer. 2015;136(11):2616–27.
https://doi.org/10.1002/ijc.29324.
422. Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda
H, et al. Ultra-sensitive liquid biopsy of circulating extracellular
vesicles using ExoScreen. Nat Commun. 2014;5:3591. https://doi.
org/10.1038/ncomms4591.
423. Jorgensen M, Baek R, Pedersen S, Sondergaard EK, Kristensen
SR, Varming K. Extracellular Vesicle (EV) Array: microarray cap-
turing of exosomes and other extracellular vesicles for multiplexed
phenotyping. J Extracell Vesicles. 2013;2. https://doi.org/10.3402/
jev.v2i0.20920.
424. Kanwar SS, Dunlay CJ, Simeone DM, Nagrath S. Microfluidic
device (ExoChip) for on-chip isolation, quantification and charac-
terization of circulating exosomes. Lab Chip. 2014;14(11):1891–
900. https://doi.org/10.1039/c4lc00136b.
425. Liga A, Vliegenthart ADB, Oosthuyzen W, Dear JW, Kersaudy-
Kerhoas M. Exosome isolation: a microfluidic road-map. Lab
Chip. 2015;15(11):2388–94. https://doi.org/10.1039/c5lc00240k.
426. Zhao Z, Yang Y, Zeng Y, He M. A microfluidic ExoSearch chip
for multiplexed exosome detection towards blood-based ovarian
cancer diagnosis. Lab Chip. 2016;16(3):489–96. https://doi.org/
10.1039/c5lc01117e.
427. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O,
Geuze HJ. Selective enrichment of tetraspan proteins on the inter-
nal vesicles of multivesicular endosomes and on exosomes secret-
ed by human B-lymphocytes. J Biol Chem. 1998;273(32):20121–
7. https://doi.org/10.1074/jbc.273.32.20121.
428. Woo HK, Sunkara V, Park J, Kim TH, Han JR, Kim CJ, et al.
Exodisc for rapid, size-selective, and efficient isolation and anal-
ysis of nanoscale extracellular vesicles from biological samples.
ACS Nano. 2017;11(2):1360–70. https://doi.org/10.1021/
acsnano.6b06131.
429. Ko J, Carpenter E, Issadore D. Detection and isolation of circulat-
ing exosomes and microvesicles for cancer monitoring and diag-
nostics using micro-/nano-based devices. Analyst. 2016;141(2):
450–60. https://doi.org/10.1039/c5an01610j.
430. Li P, Kaslan M, Lee SH, Yao J, Gao ZQ. Progress in exosome
isolation techniques. Theranostics. 2017;7(3):789–804. https://
doi.org/10.7150/thno.18133.
431. McKiernan J, Donovan MJ, O'Neill V, Bentink S, Noerholm M,
Belzer S, et al. A novel urine exosome gene expression assay to
predict high-grade prostate cancer at initial biopsy. Jama
Oncology. 2016;2(7):882–9. https://doi.org/10.1001/jamaoncol.
2016.0097.
432. Brinkmann K, Enderle D, Flinspach C, Meyer L, Skog J,
Noerholm M. Exosome liquid biopsies of NSCLC patients for
longitudinal monitoring of ALK fusions and resistance mutations.
J Clin Oncol. 2018;36(15):e24090. https://doi.org/10.1200/JCO.
2018.36.15_suppl.e24090.
433. Hanahan D, Weinberg RA. Hallmarks of cancer: the next genera-
tion. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.
2011.02.013.
434. Vafaee F, Diakos C, Kirschner MB, Reid G, MichaelMZ, Horvath
LG, et al. A data-driven, knowledge-based approach to biomarker
discovery: application to circulating microRNA markers of colo-
rectal cancer prognosis. NPJ Syst Biol Appl. 2018;4:20. https://
doi.org/10.1038/s41540-018-0056-1.
435. Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis
DI. Machine learning applications in cancer prognosis and predic-
tion. Comput Struct Biotec. 2015;13:8–17. https://doi.org/10.
1016/j.csbj.2014.11.005.
350 Regen. Eng. Transl. Med. (2021) 7:312–352
436. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ,
CherniackAD, et al. An integrated TCGA pan-cancer clinical data
resource to drive high-quality survival outcome analytics. Cell.
2018;173(2):400–16 e11. https://doi.org/10.1016/j.cell.2018.02.
052.
437. Hudson TJ, Anderson W, Aretz A, Barker AD, Bell C, Bernabe
RR, et al. International network of cancer genome projects.
Nature. 2010;464(7291):993–8. https://doi.org/10.1038/
nature08987.
438. Li Y, Chen L. Big biological data: challenges and opportunities.
Genomics Proteomics Bioinformatics. 2014;12(5):187–9. https://
doi.org/10.1016/j.gpb.2014.10.001.
439. Ristevski B, Chen M. Big data analytics in medicine and
healthcare. J Integr Bioinform. 2018;15(3). https://doi.org/10.
1515/jib-2017-0030\.
440. Mohammed A, Biegert G, Adamec J, Helikar T. CancerDiscover:
an integrative pipeline for cancer biomarker and cancer class pre-
diction from high-throughput sequencing data. Oncotarget.
2018;9(2):2565–73. https://doi.org/10.18632/oncotarget.23511.
441. Labuzzetta CJ, Antonio ML, Watson PM, Wilson RC,
Laboissonniere LA, Trimarchi JM, et al. Complementary feature
selection from alternative splicing events and gene expression for
phenotype prediction. Bioinformatics. 2016;32(17):421–9.
https://doi.org/10.1093/bioinformatics/btw430.
442. Azuaje F. Artificial intelligence for precision oncology: beyond
patient stratification. Npj Precis Oncol. 2019;3:6. https://doi.org/
10.1038/s41698-019-0078-1.
443. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M,
Chou K, et al. A guide to deep learning in healthcare. Nat Med.
2019;25(1):24–9. https://doi.org/10.1038/s41591-018-0316-z.
444. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM,
et al. Dermatologist-level classification of skin cancer with deep
neural networks (vol 542, pg 115, 2017). Nature. 2017;546(7660):
686. https://doi.org/10.1038/nature22985.
445. Coudray N, Ocampo PS, Sakellaropoulos T, Narula N, Snuderl M,
Fenyo D, et al. Classification and mutation prediction from non-
small cell lung cancer histopathology images using deep learning.
Nat Med. 2018;24(10):1559–67. https://doi.org/10.1038/s41591-
018-0177-5.
446. Deulofeu M, Kolarova L, Salvado V, Pena-Mendez EM, Almasi
M, Stork M, et al. Rapid discrimination of multiple myeloma
patients by artificial neural networks coupled with mass spectrom-
etry of peripheral blood plasma. Sci Rep. 2019;9:7975. https://doi.
org/10.1038/s41598-019-44215-1.
447. Elias KM, Fendler W, Stawiski K, Fiascone SJ, Vitonis AF,
Berkowitz RS, et al. Diagnostic potential for a serum miRNA
neural network for detection of ovarian cancer. Elife. 2017;6:
e28932. https://doi.org/10.7554/eLife.28932.001.
448. Towards trustable machine learning. Nat Biomed Eng.
2018;2(10):709-10. https://doi.org/10.1038/s41551-018-0315-x.
449. Yu KH, BeamAL, Kohane IS. Artificial intelligence in healthcare.
Nat Biomed Eng. 2018;2(10):719–31. https://doi.org/10.1038/
s41551-018-0305-z.
450. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al.
Detection and localization of surgically resectable cancers with a
multi-analyte blood test. Science. 2018;359(6378):926–30.
https://doi.org/10.1126/science.aar3247.
451. Bartsch DK, Gercke N, Strauch K, Wieboldt R, Matthai E,
Wagner V, et al. The combination of MiRNA-196b, LCN2, and
TIMP1 is a potential set of circulating biomarkers for screening
individuals at risk for familial pancreatic cancer. J Clin Med.
2018;7(10):E295. https://doi.org/10.3390/jcm7100295.
452. Moller A, Olsson H, Gronberg H, EklundM,AlyM, NordstromT.
The Stockholm3 blood-test predicts clinically-significant cancer
on biopsy: independent validation in a multi-center community
cohort. Prostate Cancer Prostatic Dis. 2019;22(1):137–42.
https://doi.org/10.1038/s41391-018-0082-5.
453. Ulz P, Thallinger GG, AuerM, Graf R, Kashofer K, Jahn SW, et al.
Inferring expressed genes by whole-genome sequencing of plasma
DNA. Nat Genet. 2016;48(10):1273–8. https://doi.org/10.1038/
ng.3648.
454. Wan N, Weinberg D, Liu T-Y, Niehaus K, Delubac D, Kannan A
et al. Machine learning enables detection of early-stage colorectal
cancer by whole-genome sequencing of plasma cell-free DNA.
BMC Cancer 2018;19:832. 478065. https://doi.org/10.1101/
478065.
455. Frantzi M, Latosinska A, Kontostathi G, Mischak H. Clinical pro-
teomics: closing the gap from discovery to implementation.
Proteomics. 2018;18(14):1700463. https://doi.org/10.1002/pmic.
201700463.
456. Poste G. Biospecimens, biomarkers, and burgeoning data: the im-
perative for more rigorous research standards. Trends Mol Med.
2012;18(12):717–22. https://doi.org/10.1016/j.molmed.2012.09.
003.
457. Diamandis EP. The failure of protein cancer biomarkers to reach
the clinic: why, and what can be done to address the problem?
BMC Med. 2012;10:87. https://doi.org/10.1186/1741-7015-10-
87.
458. Moore HM, Kelly A, Jewell SD, McShane LM, Clark DP,
Greenspan R, et al. Biospecimen reporting for improved study
quality. Biopreserv Biobank. 2011;9(1):57–70. https://doi.org/
10.1089/bio.2010.0036.
459. Perez-Gracia JL, Sanmamed MF, Bosch A, Patino-Garcia A,
Schalper KA, Segura V, et al. Strategies to design clinical studies
to identify predictive biomarkers in cancer research. Cancer Treat
Rev. 2017;53:79–97. https://doi.org/10.1016/j.ctrv.2016.12.005.
460. Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman
DG. Reporting recommendations for tumor marker prognostic
studies (REMARK): an abridged explanation and elaboration.
Jnci-J Natl Cancer I. 2018;110(8):803–11. djy088. https://doi.
org/10.1093/jnci/djy088.
461. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T,
et al. Consolidated standards of reporting trials (CONSORT) and
the completeness of reporting of randomised controlled trials
(RCTs) published in medical journals. Cochrane Db Syst Rev.
2012;11:MR000030. https://doi.org/10.1002/14651858.
MR000030.pub2.
462. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP,
Irwig LM, et al. The STARD statement for reporting studies of
diagnostic accuracy: explanation and elaboration. Clin Chem.
2003;49(1):7–18. https://doi.org/10.1373/49.1.7.
463. Poste G, Compton CC, Barker AD. The national biomarker devel-
opment alliance: confronting the poor productivity of biomarker
research and development. Expert Rev Mol Diagn. 2015;15(2):
211–8. https://doi.org/10.1586/14737159.2015.974561.
464. Ioannidis JPA, Bossuyt PMM. Waste, leaks, and failures in the
biomarker pipeline. Clin Chem. 2017;63(5):963–72. https://doi.
org/10.1373/clinchem.2016.254649.
465. Food and Drug Administration HHS. Good laboratory practice for
nonclinical laboratory studies (81 FR 58341). 2016. https://
www.federalregister.gov/documents/2016/08/24/2016-19875/
good-laboratory-practice-for-nonclinical-laboratory-studies.
466. CDC. Clinical Laboratory Improvement Amendments (CLIA).
https://www.cdc.gov/clia/law-regulations.html.
467. De Roock W, Piessevaux H, De Schutter J, Janssens M, De
Hertogh G, Personeni N, et al. KRAS wild-type state predicts
survival and is associated to early radiological response in meta-
static colorectal cancer treated with cetuximab. Ann Oncol.
2008;19(3):508–15. https://doi.org/10.1093/annonc/mdm496.
468. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu
D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab
Regen. Eng. Transl. Med. (2021) 7:312–352 351
in advanced colorectal cancer. New Engl J Med. 2008;359(17):
1757–65. https://doi.org/10.1056/NEJMoa0804385.
469. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I,
Rustin G, et al. Olaparib maintenance therapy in patients with
platinum-sensitive relapsed serous ovarian cancer: a preplanned
retrospective analysis of outcomes by BRCA status in a
randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61.
https://doi.org/10.1016/S1470-2045(14)70228-1.
470. Okajima W, Komatsu S, Ichikawa D, Miyamae M, Ohashi T,
Imamura T, et al. Liquid biopsy in patients with hepatocellular
carcinoma: Circulating tumor cells and cell-free nucleic acids.
World J Gastroenterol. 2017;23(31):5650–68. https://doi.org/10.
3748/wjg.v23.i31.5650.
471. Yadav DK, Bai X, Yadav RK, Singh A, Li G, Ma T, et al. Liquid
biopsy in pancreatic cancer: the beginning of a new era.
Oncotarget. 2018;9(42):26900–33. https://doi.org/10.18632/
oncotarget.24809.
472. Muinelo-Romay L, Casas-Arozamena C, Abal M. Liquid biopsy
in endometrial cancer: new opportunities for personalized oncol-
ogy. Int J Mol Sci. 2018;19(8):2311. https://doi.org/10.3390/
ijms19082311.
473. Shankar GM, Balaj L, Stott SL, Nahed B, Carter BS. Liquid bi-
opsy for brain tumors. Expert Rev Mol Diagn. 2017;17(10):943–
7. https://doi.org/10.1080/14737159.2017.1374854.
Publisher’s Note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
352 Regen. Eng. Transl. Med. (2021) 7:312–352
